Close

Form 10-Q MESA LABORATORIES INC For: Dec 31

February 4, 2016 8:05 AM EST


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q

(Mark one)

 

☒     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2015

 

     TRANSITION REPORT PURSUANT TOSECTION 13 OR 15 (d) OF THE SECURITES EXCHANGE ACT OF 1934

 

For the transition period from ___ to ___

 

Commission File No: 0-11740

 


 

MESA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

Colorado

 

84-0872291

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification number)

     

12100 West Sixth Avenue

   

Lakewood, Colorado

 

80228

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (303) 987-8000

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).         Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

 

Large accelerated filer ☐

 

Accelerated filer☒

 

Non-accelerated filer ☐

 

Smaller reporting company ☐

   

(Do not check if a smaller reporting company)

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐     No ☒

 

Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date:

 

There were 3,626,528 shares of the Issuer’s common stock, no par value, outstanding as of January 27, 2016.

 



 

 
 

 

 

Table of Contents

 

 

Part I

   

1.

Financial Statements  

  1
   

Condensed Consolidated Balance Sheets

1

   

Condensed Consolidated Statements of Income

2

   

Condensed Consolidated Statements of Comprehensive Income

3

   

Condensed Consolidated Statements of Cash Flows

4

   

Notes to Condensed Consolidated Financial Statements

5

2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations  

  15

3.

Quantitative and Qualitative Disclosures About Market Risk  

  23

4.

Controls and Procedures  

  23
       

Part II

   

1

Legal Proceedings  

  24

1A.

Risk Factors  

  24

2.

Unregistered Sales of Equity Securities and Use of Proceeds  

  24

6.

Exhibits

  24
       
 

Signatures

  25
       
 

Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)

 
 

Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)

 
 

Certification of Chief Executive Officer Pursuant to Rule 13a-14(b) and 18 U.S.C. Section 1350

 
 

Certification of Chief Financial Officer Pursuant to Rule 13a-14(b) and 18 U.S.C. Section 1350

 

 

 
 

 

 

Part I. Financial Information

 

Item 1. Financial Statements

 

Mesa Laboratories, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

 

 

 

December 31, 2015

(Unaudited)

   

March 31, 2015

 
ASSETS                

Current assets:

               

Cash and cash equivalents

  $ 3,272     $ 2,034  

Accounts receivable, net

    13,283       12,145  

Inventories, net

    14,716       12,420  

Prepaid expenses and other

    1,294       1,334  

Deferred income taxes

    1,682       1,689  

Total current assets

    34,247       29,622  
                 

Property, plant and equipment, net

    15,685       9,598  

Intangibles, net

    41,231       33,231  

Goodwill

    63,953       44,869  
                 

Total assets

  $ 155,116     $ 117,320  
                 

LIABILITIES AND STOCKHOLDERS’ EQUITY

               

Current liabilities:

               

Accounts payable

  $ 3,053     $ 2,503  

Accrued salaries and payroll taxes

    4,340       4,105  

Unearned revenues

    2,809       1,314  

Current portion of contingent consideration

    4,696       1,220  

Other accrued expenses

    2,803       1,307  

Income taxes payable

    201       1,208  

Current portion of long-term debt

    3,000       3,000  

Total current liabilities

    20,902       14,657  
                 

Deferred income taxes

    5,243       5,122  

Long-term debt

    44,000       23,250  

Contingent consideration

    4,327       812  

Total liabilities

    74,472       43,841  
                 
Commitments and Contingencies (Note 7)                

 

               
Stockholders’ equity:                

Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 3,625,003 and 3,561,540 shares, respectively

    21,437       17,751  

Retained earnings

    60,657       55,962  

Accumulated other comprehensive loss

    (1,450 )     (234 )

Total stockholders’ equity

    80,644       73,479  
                 

Total liabilities and stockholders’ equity

  $ 155,116     $ 117,320  

 

See accompanying notes to condensed consolidated financial statements.

 

 
Page 1

 

  

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Income

(Unaudited)

(In thousands except per share data)

 

   

Three Months Ended December 31,

   

Nine Months Ended December 31,

 
   

2015

   

2014

   

2015

   

2014

 
                                 

Revenues

  $ 19,913     $ 17,830     $ 59,847     $ 52,770  

Cost of revenues

    7,704       6,778       23,430       20,890  

Gross profit

    12,209       11,052       36,417       31,880  
                                 

Operating expenses

                               

Selling

    1,517       1,772       5,604       5,177  

General and administrative

    5,885       4,740       17,404       12,581  

Research and development

    975       832       2,929       2,459  

Total operating expenses

    8,377       7,344       25,937       20,217  
                                 

Operating income

    3,832       3,708       10,480       11,663  

Other (expense) income, net

    (381 )     5       (710 )     (314 )
                                 

Earnings before income taxes

    3,451       3,713       9,770       11,349  
                                 

Income taxes

    1,090       1,310       3,351       4,005  
                                 

Net income

  $ 2,361     $ 2,403     $ 6,419     $ 7,344  
                                 

Net income per share:

                               

Basic

  $ 0.65     $ 0.68     $ 1.79     $ 2.09  

Diluted

    0.63       0.66       1.72       2.01  
                                 

Weighted average common shares outstanding:

                         

Basic

    3,614       3,532       3,596       3,513  

Diluted

    3,755       3,654       3,729       3,649  

 

See accompanying notes to condensed consolidated financial statements.

 

 
Page 2

 

 

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)

(In thousands)

 

   

Three Months Ended December 31,

   

Nine Months Ended December 31,

 
   

2015

   

2014

   

2015

   

2014

 
                                 

Net Income

  $ 2,361     $ 2,403     $ 6,419     $ 7,344  
                                 

Other comprehensive loss, net of tax:

                               

Foreign currency translation

    (1,847 )     (250 )     (1,216 )     (250 )
                                 

Total comprehensive income

  $ 514     $ 2,153     $ 5,203     $ 7,094  

 

See accompanying notes to condensed consolidated financial statements.

 

 
Page 3

 

 

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

   

Nine Months Ended December 31,

 
   

2015

   

2014

 

Cash flows from operating activities:

               

Net income

  $ 6,419     $ 7,344  

Depreciation and amortization

    5,207       4,162  

Stock-based compensation

    1,001       776  

Loss on disposition of assets

    --       16  

Deferred income taxes

    128       --  

Foreign currency adjustments

    85       (169 )

Change in assets and liabilities, net of effects of acquisitions

               

Accounts receivable, net

    72       (1,994 )

Inventories, net

    (1,901 )     (3,340 )

Prepaid expenses and other

    40       538  

Accounts payable

    80       747  

Accrued liabilities and taxes payable

    710       (1,439 )

Unearned revenues

    (118 )     (465 )

Contingent consideration

    (1,770 )     --  

Net cash provided by operating activities

    9,953       6,176  
                 
                 

Cash flows from investing activities:

               

Acquisitions

    (23,199 )     (19,050 )

Purchases of property, plant and equipment

    (6,291 )     (2,212 )

Net cash used in investing activities

    (29,490 )     (21,262 )
                 

Cash flows from financing activities:

               

Proceeds from the issuance of debt

    25,000       23,000  

Payments on debt

    (4,250 )     (11,500 )

Dividends

    (1,724 )     (1,618 )

Proceeds from the exercise of stock options

    1,800       1,137  

Net cash provided by financing activities

    20,826       11,019  
                 

Effect of exchange rate changes on cash and cash equivalents

    (51 )     (81 )
                 

Net increase (decrease) in cash and cash equivalents

    1,238       (4,148 )

Cash and cash equivalents at beginning of period

    2,034       5,575  
                 

Cash and cash equivalents at end of period

  $ 3,272     $ 1,427  
                 

Cash paid for:

               

Income taxes

  $ 3,375     $ 2,789  

Interest

    563       354  
                 

Supplemental non-cash activity:

               

Repayment of employee loans for stock options

  $ --     $ 24  

Contingent consideration as part of an acquisition

    9,541       300  

 

See accompanying notes to condensed consolidated financial statements.

 

 
Page 4

 

 

Mesa Laboratories, Inc.

Notes to Condensed Consolidated Financial Statements

 

Note 1 -Description of Business and Summary of Significant Accounting Policies

 

Description of Business

 

Mesa Laboratories, Inc. was incorporated under the laws of the State of Colorado on March 26, 1982. The terms “we,” “us,” “our,” the “Company” or “Mesa” are used in this report to refer collectively to the parent company and the subsidiaries through which our various businesses are actually conducted. We pursue a strategy of focusing primarily on quality control products and services, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into four divisions across eight physical locations. Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries. Our Biological Indicators Division provides testing services, along with the manufacturing and marketing of biological indicators and distribution of chemical indicators used to assess the effectiveness of sterilization processes, including steam, hydrogen peroxide, ethylene oxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. Our Continuous Monitoring Division designs, develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and a number of other laboratory and industrial environments. Our Cold Chain Division provides parameter monitoring of products in a cold chain, consulting services such as compliance monitoring, packaging development and validation or mapping of transport and storage containers, and thermal packaging products such as coolers, boxes, insulation materials and phase-change products to control temperature during transport.

 

Basis of Presentation

 

The accompanying condensed consolidated balance sheet as of March 31, 2015, has been derived from audited consolidated financial statements. The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as our annual audited consolidated financial statements and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. In the opinion of management, such unaudited information includes all adjustments (consisting only of normal recurring accruals) necessary for a fair presentation of this interim information. Operating results and cash flows for interim periods are not necessarily indicative of results that can be expected for the entire year. The information included in this report should be read in conjunction with our audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended March 31, 2015.

 

The summary of our significant accounting policies is incorporated by reference to our Annual Report on Form 10-K for the year ended March 31, 2015.

 

Recently Issued Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (“FASB”) and International Accounting Standards Board “(IASB”) issued a jointly converged standard on the recognition of revenue from contracts with customers. The issued guidance converges the criteria for reporting revenues, as well as requiring disclosures sufficient to describe the nature, amount, timing and uncertainty of revenues and cash flows arising from these contracts. Companies can transition to the standard either retrospectively or as a cumulative effective adjustment as of the date of adoption. The new standard is effective for our fiscal year (and interim periods within that year) ending March 31, 2019. We are evaluating the impact of this standard on our condensed consolidated financial statements and disclosures.

 

In November 2015, the FASB issued new requirements for the presentation of deferred tax assets and liabilities, requiring noncurrent classification for all deferred tax assets and liabilities on the condensed consolidated balance sheets. The requirements of the new standard are effective for our fiscal year (and interim periods within that year) ending March 31, 2018. We do not expect this guidance to have a material impact on our results of operations or financial position.

 

Note 2 – Acquisitions and Dispositions

 

Acquisitions

 

For the nine months ended December 31, 2015, our acquisitions of businesses (net of cash acquired) totaled $32,740,000, which consisted of the following material acquisitions:

 

 
Page 5

 

 

Infitrak

 

On July 6, 2015, we completed a business combination (the “Infitrak Acquisition”) whereby we acquired all of the common stock of 2396081 Ontario Inc. and its wholly owned operating subsidiary, Infitrak Inc. (collectively “Infitrak”), a company whose business provides consulting, packaging and measuring solutions for cold chain applications. The stock purchase agreement (the “Infitrak Agreement”) includes provisions for both contingent consideration based upon the two year growth in gross profit (as defined in the Earn-Out Agreement) of the packaging component of our cold chain business subsequent to the acquisition and for a holdback payment (subject to a post-closing adjustment), payable at the one year anniversary of the closing date.

 

Under the terms of the Infitrak Agreement, we are required to pay contingent consideration if the gross profit (as defined in the Earn-Out Agreement) for the packaging component of our cold chain business for the two years subsequent to the acquisition meets certain levels. The potential consideration payable ranges from $0 to $15,000,000 CDN (approximately $0 to $10,800,000 as of December 31, 2015) and is based upon a sliding scale of growth in gross profit (as defined in the Earn-Out Agreement) for year one and year two of 30 to 70 percent and 15 to 75 percent, respectively. Based upon both historical and projected growth rates, we recorded $9,541,000 of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. After the finalization of our purchase accounting, any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of the packaging component of our cold chain business and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in two annual installments beginning in the second quarter of our year ending March 31, 2017.

 

We expect to achieve savings and generate growth as we integrate the Infitrak operations and sales and marketing functions. These factors, among others, contributed to a purchase price in excess of the estimated fair value of the net identifiable assets acquired and, as a result, we recorded goodwill in connection with this transaction. The goodwill is not expected to be deductible for tax purposes and it was assigned to our Cold Chain segment.

 

The Infitrak Acquisition constituted the acquisition of a business and was recognized at fair value. Due to the recent nature of the transaction, the purchase price allocation was based upon a preliminary estimated fair value of the assets and liabilities acquired as we are in the process of finalizing our valuation of the assets acquired and liabilities assumed. We determined the preliminary estimated fair values using discounted cash flow analyses and estimates made by management. The following reflects our preliminary allocation of the consideration, subject to customary purchase price adjustments in accordance with the Infitrak Agreement (in thousands):

 

Cash consideration

  $ 8,748  

Holdback payment liability

    637  

Contingent consideration liability

    9,541  

Aggregate consideration

  $ 18,926  
         

Accounts receivable, net

  $ 925  

Inventories, net

    310  

Property, plant and equipment, net

    530  

Intangibles, net

    5,869  

Goodwill

    12,529  

Accounts payable

    (470 )

Accrued liabilities

    (767 )

Total purchase price allocation

  $ 18,926  

 

 
Page 6

 

 

The accompanying condensed consolidated statements of income include the results of the Infitrak Acquisition from the acquisition date of July 6, 2015. The pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on April 1, 2015 and 2014, are as follows (in thousands, except per share data):

 

   

Three Months Ended

December 31,

   

Nine Months Ended

December 31,

 
   

2015

   

2014

   

2015

   

2014

 

Revenues

  $ 19,913     $ 18,592     $ 61,687     $ 55,057  

Net income

    2,361       2,493       6,721       7,615  

Net Income per common share:

                               

Basic

  $ 0.65     $ 0.71     $ 1.87     $ 2.17  

Diluted

    0.63       0.68       1.80       2.09  

 

North Bay

 

On August 6, 2015, we completed a business combination (the “North Bay Acquisition”) whereby we acquired substantially all of the assets (other than certain fixed assets) and certain liabilities of the dental sterilizer testing business of North Bay Bioscience, LLC (“North Bay”). The asset purchase agreement (the “North Bay Agreement”) includes a provision for a holdback payment (subject to a post-closing adjustment), payable at the one year anniversary of the closing date.

 

We expect to achieve savings and generate growth as we integrate the North Bay operations and sales and marketing functions. These factors, among others, contributed to a purchase price in excess of the estimated fair value of the net identifiable assets acquired and, as a result, we recorded goodwill in connection with this transaction. The goodwill is expected to be deductible for tax purposes and it was assigned to our Biological Indicators segment.

 

The North Bay Acquisition constituted the acquisition of a business and was recognized at fair value. We determined the estimated fair values using discounted cash flow analyses and estimates made by management. The following reflects our allocation of the consideration, subject to customary purchase price adjustments in accordance with the North Bay Agreement (in thousands):

 

Cash consideration

  $ 10,322  

Holdback payment liability

    1,000  

Aggregate consideration

  $ 11,322  
         

Cash

  $ 20  

Accounts receivable, net

    285  

Inventories, net

    85  

Property, plant and equipment, net

    229  

Intangibles, net

    4,454  

Goodwill

    7,962  

Accrued liabilities

    (100 )

Unearned revenues

    (1,613 )

Total purchase price allocation

  $ 11,322  

 

The accompanying condensed consolidated statements of income include the results of the North Bay Acquisition from the acquisition date of August 6, 2015. The pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on April 1, 2015 and 2014, are as follows (in thousands, except per share data):

 

   

Three Months Ended

December 31,

   

Nine Months Ended

December 31,

 
   

2015

   

2014

   

2015

   

2014

 

Revenues

  $ 19,913     $ 18,910     $ 61,241     $ 56,009  

Net income

    2,361       2,553       6,713       7,793  

Net Income per common share:

                               

Basic

  $ 0.65     $ 0.72     $ 1.87     $ 2.22  

Diluted

    0.63       0.70       1.80       2.14  

 

 
Page 7

 

 

Note 3 - Inventories

 

Inventories consist of the following (in thousands):

 

   

December 31, 2015

   

March 31, 2015

 

Raw materials

  $ 9,282     $ 10,366  

Work-in-process

    549       530  

Finished goods

    5,383       1,913  

Less: reserve

    (498 )     (389 )
    $ 14,716     $ 12,420  

 

Note 4 - Long-Term Debt

 

Long-term debt consists of the following (in thousands):

 

   

December 31, 2015

   

March 31, 2015

 

Line of credit (2.42% at December 31, 2015)

  $ 28,500     $ 13,500  

Term loan (2.42% at December 31, 2015)

    18,500       12,750  

Less: current portion

    (3,000 )     (3,000 )

Long-term portion

  $ 44,000     $ 23,250  

 

In February 2012, we entered into a three year agreement (the “Credit Facility”) for a $20,000,000 revolving line of credit (“Line of Credit”) and up to $1,000,000 of letters of credit. Funds from the Credit Facility were used for general working capital and corporate needs, retiring existing debt, or to support acquisitions and capital expenditures.

 

In April 2014, the Credit Facility was amended to include a $15,000,000 term loan (the “Initial Term Loan”) and to extend the maturity date of the Credit Facility to June 30, 2017.

 

On July 1, 2015, we further amended our Credit Facility to extend the maturity date to June 30, 2020, increase the Line of Credit to $50,000,000 and establish a new $20,000,000 term loan (the “Term Loan”). The majority of the proceeds from the Term Loan were used to pay down the remaining $12,000,000 balance of the Initial Term Loan. The remaining $8,000,000 was combined with a $1,000,000 draw under the Line of Credit to fund the Infitrak Acquisition (see Note 2).

 

Under the Line of Credit, indebtedness bears interest at either: (1) LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25%; or (2) the bank’s commercial bank floating rate (“CBFR”), which is the bank’s prime rate adjusted down by 0.5%. We elect the interest rate with each borrowing under the line of credit. In addition, there is an unused line fee of 0.25%. Letter of credit fees are based on the applicable LIBOR rate.

 

The Term Loan bears interest at LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25% and requires 20 quarterly principal payments (the first due date was July 15, 2015) in the amount of $750,000 with the remaining balance of principal and accrued interest due on June 30, 2020.

 

The Credit Facility is secured by all of our assets and requires us to maintain a ratio of funded debt to our trailing four quarters of EBIDTA, as defined, of 3.25 to 1.0 through March 31, 2016 and 3.0 to 1.0 thereafter, and a minimum fixed charge coverage ratio of 1.35 to 1.0. We were in compliance with the required covenants at December 31, 2015.

 

As of December 31, 2015, future contractual maturities of debt as are as follows (in thousands):

 

Year Ending March 31,

       

2016

  $ 750  

2017

    3,000  

2018

    3,000  

2019

    3,000  

2020

    3,000  

Thereafter

    34,250  
    $ 47,000  

 

In January 2016, we made a $750,000 required principle payment on the Term Loan.

 

 
Page 8

 

 

Note 5 - Stock-Based Compensation

 

Amounts recognized in the condensed consolidated financial statements related to stock-based compensation are as follows (in thousands, except per share data):

 

   

Three Months Ended

December 31,

   

Nine Months Ended

December 31,

 
   

2015

   

2014

   

2015

   

2014

 

Total cost of stock-based compensation charged against income before income taxes

  $ 344     $ 260     $ 1,001     $ 776  

Amount of income tax benefit recognized in earnings

    109       92       343       274  

Amount charged against net income

  $ 235     $ 168     $ 658     $ 502  

Impact on net income per common share:

                               

Basic

  $ 0.07     $ 0.05     $ 0.18     $ 0.14  

Diluted

    0.06       0.05     $ 0.18       0.14  

 

Stock-based compensation expense is included in cost of revenues, selling, and general and administrative expense in the accompanying condensed consolidated statements of income.

 

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model (“Black-Scholes”). We use historical data to estimate the expected price volatility, the expected stock option life and expected forfeiture rate. The risk-free interest rate is based on the United States Treasury yield curve in effect at the time of grant for the estimated life of the stock option. The dividend yield is calculated based upon the dividend payments made during the prior four quarters as a percent of the average stock price for that period.

 

The following is a summary of stock option activity for the nine months ended December 31, 2015:

 

   

Number of
Shares

   

Weighted- Average Exercise Price per Share

   

Weighted- Average Remaining Contractual Term

   

Aggregate Intrinsic Value (000s)

 

Outstanding at March 31, 2015

    437,248     $ 55.81       4.9     $ 9,445  

Stock options granted

    183,550       72.87       6.9          

Stock options forfeited

    (12,384 )     76.89       7.2          

Stock options expired

    --       --                  

Stock options exercised

    (72,803 )     39.98                  

Outstanding at December 31, 2015

    535,611       63.32       5.3       19,412  
                                 

Exercisable at December 31, 2015

    173,949       41.4       3.6       10,107  

 

The total intrinsic value of stock options exercised was $4,263,767 and $2,003,000 for the nine months ended December 31, 2015 and 2014, respectively.

 

A summary of the status of our unvested stock option shares as of December 31, 2015 is as follows:

  

   

Number of
Shares

   

Weighted-

Average
Grant-Date
Fair Value

 

Unvested at March 31, 2015

    274,038     $ 18.42  

Stock options granted

    183,550       18.77  

Stock options forfeited

    (12,384 )     19.53  

Stock options vested

    (83,542 )     14.56  

Unvested at December 31, 2015

    361,662       19.43  

 

As of December 31, 2015, there was $4,966,245 of total unrecognized compensation expense related to unvested stock options. As of December 31, 2015, we have 914,110 shares available for future stock option grants.

 

 
Page 9

 

 

Note 6 - Net Income Per Share

 

Basic net income per share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. Diluted net income per share is computed similarly to basic net income per share, except that it includes the potential dilution that could occur if dilutive securities were exercised.

 

The following table presents a reconciliation of the denominators used in the computation of net income per share - basic and diluted (in thousands, except per share data):

 

   

Three Months Ended December 31,

   

Nine Months Ended December 31,

 
   

2015

   

2014

   

2015

   

2014

 

Net income available for shareholders

  $ 2,361     $ 2,403     $ 6,419     $ 7,344  

Weighted average outstanding shares of common stock

    3,614       3,532       3,596       3,513  

Dilutive effect of stock options

    141       122       133       136  

Common stock and equivalents

    3,755       3,654       3,729       3,649  
                                 

Net income per share:

                               

Basic

  $ 0.65     $ 0.68     $ 1.79     $ 2.09  

Diluted

    0.63       0.66       1.72       2.01  

 

For the three and nine months ended December 31, 2015, 91,000 and 136,000 outstanding stock options, respectively, were excluded from the calculation of diluted net income per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and, therefore, their inclusion would have been anti-dilutive.

 

For the three and nine months ended December 31, 2014, 155,000 and 173,000 outstanding stock options, respectively, were excluded from the calculation of diluted net income per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and, therefore, their inclusion would have been anti-dilutive.

 

Note 7- Commitments and Contingencies

 

Under the terms of the Amega Agreement, we were required to pay contingent consideration (the “Amega Earn-Out”) if the cumulative revenues for our Continuous Monitoring Division for the three years subsequent to the acquisition met certain levels. The potential consideration payable ranged from $0 to $10,000,000 and was based upon a sliding scale of three-year cumulative revenues between $31,625,000 and $43,500,000. Based upon both historical and projected growth rates, we recorded $500,000 of contingent consideration payable which represented our best estimate of the amount that would ultimately be paid. Any changes to the contingent consideration ultimately paid would have resulted in additional income or expense in our condensed consolidated statements of income. The contingent consideration was payable in the third quarter of our year ending March 31, 2017.

 

In November 2014, Amega and its owner Anthony Amato (“Amato”) filed a complaint (Anthony Amato and Amega Scientific Corporation v. Mesa Laboratories, Inc., Civil Action No. 1:14-cv-03228) in the United States District Court for the district of Colorado asserting, among other items, that our termination of Amato as an employee impacted his ability to maximize the potential consideration payable under the Amega Earn-Out and to exercise stock options that failed to vest. The plaintiff was seeking an immediate maximum payout of $10,000,000 under the Amega Earn-Out, the immediate acceleration of the 10,000 stock options granted Amato upon his initial employment along with other consequential damages in excess of $500,000, lost future earnings and punitive damages. In addition, Amato alleged that we improperly withheld $704,065.86 from the holdback consideration under the Amega Agreement. In January 2015 we filed a motion to dismiss the complaint with prejudice.

 

In October 2015, we entered into a settlement agreement (the “Amato Settlement”) whereby we paid Amato $3,165,000. In exchange, Amato agreed to dismiss the complaint, release Mesa of any and all claims by Amega and Amato, and relieve us of any future payment obligation under the Amega Earn-Out. Insurance covered $415,000 of the settlement payment and we had $1,041,000 accrued on our condensed consolidated balance sheet remaining from the original hold back and contingent consideration payable. The remaining $1,709,000 was recorded as general and administrative expense in the accompanying condensed consolidated statements of income for the nine months ended December 31, 2015.

 

 
Page 10

 

 

Under the terms of the PCD Agreement, we are required to pay contingent consideration if the cumulative revenues for our process challenge device business for the three years subsequent to the acquisition meet certain levels. The potential consideration payable ranges from $0 to $1,500,000 and is based upon a sliding scale of three-year cumulative revenues between $9,900,000 and $12,600,000. Based upon both historical and projected growth rates, we recorded $300,000 of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. We paid $150,000 of the contingent consideration during the three months ended December 31, 2015 (based upon the current run rate projected over the entire three-year contingent consideration period). This amount is subject to modification at the end of the second and third years of the earn-out period based upon the actual revenues earned over the contingent consideration period. Any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our process challenge device business and we will adjust the contingent liability on a go forward basis, based on then current information.

 

Under the terms of the Infitrak Agreement, we are required to pay contingent consideration if the gross profit (as defined in the Earn-Out Agreement) for the packaging component of our cold chain business for the two years subsequent to the acquisition meets certain levels. The potential consideration payable ranges from $0 to $15,000,000 CDN (approximately $0 to $10,800,000 as of December 31, 2015) and is based upon a sliding scale of growth in gross profit (as defined in the Earn-Out Agreement) for year one and year two of 30 to 70 percent and 15 to 75 percent, respectively. Based upon both historical and projected growth rates, we recorded $9,541,000 (valued at approximately $8,700,000 as of December 31, 2015 based on the then current exchange rate) of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. After the finalization of our purchase accounting, any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our cold chain business and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in two annual installments beginning in the second quarter of our year ending March 31, 2017.

 

A company is required to collect and remit state sales tax from certain of its customers if that company is determined to have “nexus” in a particular state. The determination of nexus varies state by state and often requires knowledge of each jurisdiction’s tax case law. During the year ended March 31, 2013, we determined that there are states in which we most likely had established nexus during prior periods without properly collecting and remitting sales tax. We recorded an estimate of $100,000 associated with one specific state but we were unable to estimate our remaining exposure at that time. During the year ended March 31, 2014, we completed our analysis associated with the remaining states and we recorded an estimate of $1,408,000, which was included in other accrued expenses on the consolidated balance sheets and in general and administrative expense on the consolidated statements of income for the year ended March 31, 2014. That estimate was based upon facts and circumstances known at such time and our ultimate liability was subject to change as further analysis is completed and state sales tax returns are filed.

 

During the year ended March 31, 2015 we successfully completed and filed several state sales tax returns which concluded our obligation for historical sales taxes in those states. In addition we continued to work through the process in the remaining states. As a result of this work, we determined that our exposure had increased above and beyond our original accrual and as a result, we recorded an additional accrual of $460,000 during the year ended March 31, 2015. During the nine months ended December 31, 2015 we successfully completed and filed additional state sales tax returns which concluded our obligation for historical sales taxes in those remaining states.

 

Note 8 – Comprehensive Income

 

The following table summarizes the changes in each component of accumulated other comprehensive income (“AOCI”), net of tax (in thousands):

 

   

Foreign Currency Translation

   

AOCI

 

Balance at September 30, 2015

  $ 397     $ 397  

Quarter ended September 30, 2015:

               

Unrealized loss arising during the period

    (1,847 )     (1,847 )

Balance at December 31, 2015

  $ (1,450 )   $ (1,450 )

 

   

Foreign Currency Translation

   

AOCI

 

Balance at September 30, 2014

  $ --     $ --  

Quarter ended September 30, 2014:

               

Unrealized loss arising during the period

    (250 )     (250 )

Balance at December 31, 2014

  $ (250 )   $ (250 )

 

 
Page 11

 

 

   

Foreign Currency Translation

   

AOCI

 

Balance at March 31, 2015

  $ (234 )   $ (234 )

Nine months ended December 31, 2015:

               

Unrealized loss arising during the period

    (1,216 )     (1,216 )

Balance at December 31, 2015

  $ (1,450 )   $ (1,450 )

 

   

Foreign Currency Translation

   

AOCI

 

Balance at March 31, 2014

  $ --     $ --  

Nine months ended December 31, 2014:

               

Unrealized gain arising during the period

    (250 )     (250 )

Balance at December 31, 2014

  $ (250 )   $ (250 )

 

Note 9 - Segment Information

 

We have four reporting segments: Biological Indicators, Instruments, Continuous Monitoring and Cold Chain. The following tables set forth our segment information (in thousands):

 

   

Three Months Ended December 31, 2015

 
   

Biological Indicators

   

Instruments

   

Continuous Monitoring

   

Cold Chain

   

Total

 

Revenues

  $ 7,819     $ 8,260     $ 2,595     $ 1,239     $ 19,913  
                                         

Gross profit

  $ 4,869     $ 5,511     $ 1,254     $ 575     $ 12,209  

Selling expenses

    505       784       132       96       1,517  
    $ 4,364     $ 4,727     $ 1,122     $ 479       10,692  

Reconciling items (1)

                                    (7,241 )

Earnings before income taxes

                                  $ 3,451  

 

   

Three Months Ended December 31, 2014

 
   

Biological Indicators

   

Instruments

   

Continuous Monitoring

   

Cold Chain

   

Total

 

Revenues

  $ 6,964     $ 8,216     $ 2,650     $ --     $ 17,830  
                                         

Gross profit

  $ 4,194     $ 5,412     $ 1,446     $ --     $ 11,052  

Selling expenses

    365       919       488       --       1,772  
    $ 3,829     $ 4,493     $ 958     $ --       9,280  

Reconciling items (1)

                                    (5,567 )

Earnings before income taxes

                                  $ 3,713  

 

   

Nine Months Ended December 31, 2015

 
   

Biological Indicators

   

Instruments

   

Continuous Monitoring

   

Cold Chain

   

Total

 

Revenues

  $ 23,537     $ 25,819     $ 7,412     $ 3,079     $ 59,847  
                                         

Gross profit

  $ 15,157     $ 16,571     $ 3,246     $ 1,443     $ 36,417  

Selling expenses

    1,372       2,975       1,098       159       5,604  
    $ 13,785     $ 13,596     $ 2,148     $ 1,284       30,813  

Reconciling items (1)

                                    (21,043 )

Earnings before income taxes

                                  $ 9,770  

 

 
Page 12

 

 

   

Nine Months Ended December 31, 2014

 
   

Biological Indicators

   

Instruments

   

Continuous Monitoring

   

Cold Chain

   

Total

 

Revenues

  $ 19,822     $ 24,966     $ 7,982     $ --     $ 52,770  
                                         

Gross profit

  $ 12,029     $ 15,794     $ 4,057     $ --     $ 31,880  

Selling expenses

    766       3,093       1,318       --       5,177  
    $ 11,263     $ 12,701     $ 2,739     $ --       26,703  

Reconciling items (1)

                                    (15,354 )

Earnings before income taxes

                                  $ 11,349  

 

(1) Reconciling items include general and administrative, research and development, and other expenses.

 

 

   

December 31, 2015

   

March 31, 2015

 

Total assets

               

Biological Indicators

  $ 54,285     $ 36,304  

Instruments

    50,436       44,401  

Continuous Monitoring

    25,965       31,558  

Cold Chain

    18,182       --  

Corporate and administrative

    6,813       5,057  
    $ 155,681     $ 117,320  

 

All long-lived assets are located in the United States except for $6,470,000 and $16,839,000 which are associated with our French and Canadian subsidiaries, respectively.

 

Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows (in thousands):

 

   

Three Months Ended

December 31,

   

Nine Months Ended

December 31,

 
   

2015

   

2014

   

2015

   

2014

 

Net revenues from unaffiliated customers:

                               

United States

  $ 12,787     $ 11,423     $ 37,510     $ 29,612  

Foreign

    7,126       6,407       22,337       23,158  
    $ 19,913     $ 17,830     $ 59,847     $ 52,770  

 

No foreign country exceeds 10 percent of total revenues.

 

Note 10 Income Taxes

 

For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year to date pre-tax income. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, settlement with taxing authorities and foreign currency fluctuations.

 

Our effective income tax rate was 31.6 and 35.3 percent for the three months ended December 31, 2015 and 2014, respectively and 34.3 and 35.3 percent for the nine months ended December 31, 2015 and 2014, respectively. The effective tax rate for the three and nine months ended December 31, 2015 differed from the statutory federal rate of 35 percent primarily as a result of the impact of state income taxes, domestic manufacturing deductions, research and development tax credits and certain discrete period items. We anticipate that our effective tax rate for the year ending March 31, 2016 will approximate 34 to 37 percent.

 

 
Page 13

 

 

Note 11 - Subsequent Event

 

In January 2016, our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on March 15, 2016, to shareholders of record at the close of business on February 29, 2016.

 

 
Page 14

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward Looking Statements

 

This report contains information that may constitute "forward-looking statements.” Generally, the words "believe," "expect," "project," “anticipate,” "estimate," "intend," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to those described in Part II, "Item 1A. Risk Factors" and elsewhere in this report and in our Annual Report on Form 10-K for the year ended March 31, 2015, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.

 

General Discussion

 

We pursue a strategy of focusing primarily on quality control products and services, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into four divisions across eight physical locations. Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries. Our Biological Indicators Division provides testing services, along with the manufacturing and marketing of biological indicators and distribution of chemical indicators used to assess the effectiveness of sterilization processes, including steam, hydrogen peroxide, ethylene oxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. Our Continuous Monitoring Division designs, develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and a number of other laboratory and industrial environments. Our Cold Chain Division provides parameter monitoring of products in a cold chain, consulting services such as compliance monitoring, packaging development and validation or mapping of transport and storage containers, and thermal packaging products such as coolers, boxes, insulation materials and phase-change products to control temperature during transport.

 

Our revenues come from two main sources – product sales and services. Product sales are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products and acquisitions. Biological indicator and cold chain packaging products are disposable and are used on a routine basis for quality control, thus product sales are less sensitive to general economic conditions. Instrument products, cold chain services and continuous monitoring systems have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Service demand is driven by our customers’ quality control and regulatory environments, some of which require periodic repair and recalibration or certification of our instrument products and continuous monitoring systems. We typically evaluate costs and pricing annually. Our policy is to price our products and systems competitively and, where possible, we try to pass along cost increases in order to maintain our margins.

 

Gross profit is affected by our product mix, manufacturing efficiencies and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross margins for some of the products have improved. There are, however, differences in gross margins between different product lines, and ultimately the mix of sales will continue to impact our overall gross margin.

 

Selling expense is driven primarily by labor costs, including salaries and commissions. Accordingly, it may vary with sales levels. Labor costs and amortization of intangible assets drive the substantial majority of general and administrative expense. Research and development expense is predominantly comprised of labor costs and third party consultants.

 

 
Page 15

 

 

Year Ending March 31, 2016 Acquisitions

 

During the year ending March 31, 2016, we completed the following ten acquisitions (the “2016 Acquisitions”):

 

In January 2016, we completed two business combinations (the “January 2016 European BI Distributor Acquisitions”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of CoaChrom Diagnostica GmbH of Austria and bioTRADING Benelux B.V of the Netherlands business segment associated with the distribution of our biological indicator products.

 

In October 2015, we completed six business combinations (the “October 2015 European BI Distributor Acquisitions”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of BIOLOGIK S.R.L., VWR International PBI S.R.L., Cruinn Diagnostics Ltd., Mecolab AG, Miclev Medical Products AB and Tiselab S.L.’s business segment associated with the distribution of our biological indicator products.

 

In August 2015, we completed a business combination (the “North Bay Acquisition”) whereby we acquired substantially all of the assets (other than certain fixed assets) and certain liabilities of the dental sterilizer testing business of North Bay Bioscience, LLC (“North Bay”).

 

In July 2015, we completed a business combination (the “Infitrak Acquisition”) whereby we acquired all of the common stock of 2396081 Ontario Inc. and its wholly owned operating subsidiary, Infitrak Inc. (collectively “Infitrak”), a company whose business provides consulting, packaging and measuring solutions for cold chain applications.

 

Year Ended March 31, 2015 Acquisitions

 

During the year ended March 31, 2015, we completed the following six acquisitions (the “2015 Acquisitions”):

 

In March 2015, we completed a business combination (the “Früh Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of Dr. Früh Control GmbH’s (“Fruh”) business segment associated with the distribution of our biological indicator products.

 

In February 2015, we completed a business combination (the “Cherwell Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of Cherwell Laboratories Limited’s (“Cherwell”), business segment associated with the distribution of our biological indicator products.

 

In October 2014, we completed a business combination (the “ATI Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of ATI Atlas Limited (“ATI”), a distributor of our biological indicator products.

 

In October 2014, we completed a business combination (the “PCD Acquisition”) with PCD-Process Challenge Devices, LLC (“PCD”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of PCD’s business segment associated with the sale of process challenge devices (“PCD’s”), which are used for quality control purposes in the field of ethylene oxide sterilization of medical devices.

 

In April 2014, we completed a business combination (the “BGI Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of BGI, Incorporated and BGI Instruments, Inc., (collectively “BGI”), businesses focused on the sale of equipment used primarily for particulate air sampling.

 

In April 2014, we completed a business combination (the “Amilabo Acquisition”) whereby we acquired all of the common stock of Amilabo SAS (“Amilabo”), a distributor of our biological indicator products.

 

General Trends and Outlook

 

Our strategic objectives include growth both organically and through further acquisitions. During the year ended March 31, 2015, we continued to build our infrastructure to prepare for future growth, including the addition of key personnel to our operations, sales and marketing, research and development, and finance teams. We also invested in upgrading our information systems and intend to continue doing so.

 

The markets for our biological indicators and cold chain packaging products remain strong, as the disposable nature of these products makes them less sensitive to general economic conditions. The worldwide market for biological indicators is growing as more countries focus on verifying the effectiveness of sterilization processes.

 

 
Page 16

 

 

In general, our instruments products, cold chain services and our continuous monitoring systems are impacted more by general economic conditions than our biological indicator and cold chain packaging products. As a result, uncertainty about global economic conditions may cause businesses to postpone spending in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values. Worldwide and regional economic conditions could also reduce the demand for our products and services, as our customers reduce or delay capital equipment and other types of purchases. However demand for our instruments products, cold chain services and continuous monitoring systems remains strong and we strive to continue to grow revenues going forward.

 

We are working on several research and development projects that, if completed, may result in new products for both existing customers and new markets. We are hopeful that all of our divisions will have new products available for sale in the coming year.

 

On October 1, 2015 we converted from our legacy enterprise resource planning (“ERP”) system to our new cloud based system. Due to significant employee time allocation associated with going live and operating on the new system, we were delayed in the fulfillment of several orders which resulted in an approximate $500,000 increase in our open-order backlog at quarter end. The increase in backlog was primarily associated with our Instruments and Biological Indicators Divisions and it resulted in lower than expected revenues for these Divisions during the three months ended December 31, 2015. We believe this issue is timing-related in nature and that we will fulfill orders and decrease our backlog to its normal level over the next one to two quarters.

 

Results of Operations

 

The following table sets forth, for the periods indicated, condensed consolidated statements of income data. The table and the discussion below should be read in conjunction with the accompanying condensed consolidated financial statements and the notes thereto appearing elsewhere in this report (in thousands, except percent data):

 

   

Three Months Ended December 31,

           

Percent

 
   

2015

   

2014

   

Change

   

Change

 

Revenues

  $ 19,913     $ 17,830     $ 2,083       12 %

Cost of revenues

    7,704       6,778       926       14 %

Gross profit

  $ 12,209     $ 11,052     $ 1,157       10 %

Gross profit margin

    61 %     62 %     (1 )%        
                                 

Operating expenses

                               

Selling

  $ 1,517     $ 1,772     $ (255 )     (14 )%

General and administrative

    5,885       4,740       1,145       24 %

Research and development

    975       832       143       17 %
    $ 8,377     $ 7,344     $ 1,033       14 %
                                 

Operating income

  $ 3,832     $ 3,708     $ 124       3 %

Net income

    2,361       2,403       (42 )     (2 )%

Net profit margin

    12 %     13 %     (1 )%        

 

   

Nine Months Ended December 31,

           

Percent

 
   

2015

   

2014

   

Change

   

Change

 

Revenues

  $ 59,847     $ 52,770     $ 7,077       13 %

Cost of revenues

    23,430       20,890       2,540       12 %

Gross profit

  $ 36,417     $ 31,880     $ 4,537       14 %

Gross profit margin

    61 %     60 %     1 %        
                                 

Operating expenses

                               

Selling

  $ 5,604     $ 5,177     $ 427       8 %

General and administrative

    17,404       12,581       4,823       38 %

Research and development

    2,929       2,459       470       19 %
    $ 25,937     $ 20,217     $ 5,720       28 %
                                 

Operating income

  $ 10,480     $ 11,663     $ (1,183 )     (10 )%

Net income

    6,419       7,344       (925 )     (13 )%

Net profit margin

    11 %     14 %     (3 )%        

 

 
Page 17

 

 

Revenues

 

The following table summarizes our revenues by source (in thousands, except percent data):

 

   

Three Months Ended December 31,

           

Percent

 
   

2015

   

2014

   

Change

   

Change

 

Biological Indicators

  $ 7,819     $ 6,964     $ 855       12 %

Instruments

    8,260       8,216       44       1 %

Continuous Monitoring

    2,595       2,650       (55 )     (2 )%

Cold Chain

    1,239       --       1,239       100 %

Total

  $ 19,913     $ 17,830     $ 2,083       12 %

 

   

Nine Months Ended December 31,

           

Percent

 
   

2015

   

2014

   

Change

   

Change

 

Biological Indicators

  $ 23,537     $ 19,822     $ 3,715       19 %

Instruments

    25,819       24,966       853       3 %

Continuous Monitoring

    7,412       7,982       (570 )     (7 )%

Cold Chain

    3,079       --       3,079       100 %

Total

  $ 59,847     $ 52,770     $ 7,077       13 %

 

Three and Nine months ended December 31, 2015 versus December 31, 2014

 

Biological Indicators revenues for the three and nine months ended December 31, 2015 increased as a result of the ATI, PCD, Früh, Cherwell, North Bay and October 2015 European BI Distributor Acquisitions, partially offset by decreases in organic growth of seven and one percent, respectively. The decreases in organic growth are directly related to the delays in shipping product resulting from the implementation of our new ERP system (see “General Trends and Outlook”). In addition, revenues generated from our wholly owned subsidiary in France were impacted for both the three and nine months ended December 31, 2015 due to the decrease in the value of the Euro as compared to the U.S. dollar.

 

Instruments revenues for the three months ended December 31, 2015 were flat. Instruments revenues for the nine months ended December 31, 2015 increased as a result of the timing of the BGI Acquisition and organic growth of three percent in our existing product lines which was achieved primarily through existing and new customers. Instruments revenues for both the three and nine months ended December 31, 2015 were impacted by delays in shipping product resulting from the implementation of our new ERP system (see “General Trends and Outlook”).

 

Continuous Monitoring revenues for the three months ended December 31, 2015 were flat. Continuous Monitoring revenues for the nine months ended December 31, 2015 decreased seven percent primarily due to the timing of certain system installations in the prior year. On a go forward basis, we anticipate the run rate for our Continuous Monitoring segment to approximate $2,500,000 per quarter over the next few quarters.

 

Cold Chain revenues were $1,239,000 for the three months ended December 31, 2015 as compared to $1,840,000 for the three months ended September 30, 2015. The decrease was due primarily to seasonality in the product line along with a decrease in the value of the Canadian dollar as compared to the U.S. dollar during the three months ended December 31, 2015. We expect revenues for the next few quarters to approximate those achieved during the three months ended September 30, 2015.

 

 
Page 18

 

 

Gross Profit

 

The following summarizes our gross profit by segment (in thousands, except percent data):

 

   

Three Months Ended December 31,

           

Percent

 
   

2015

   

2014

   

Change

   

Change

 

Biological Indicators

  $ 4,869     $ 4,194     $ 675       16 %

Gross profit margin

    62 %     60 %     2 %        
                                 

Instruments

    5,511       5,412       99       2 %

Gross profit margin

    67 %     66 %     1 %        
                                 

Continuous Monitoring

    1,254       1,446       (192 )     (13 )%

Gross profit margin

    48 %     55 %     (7 )%        
                                 

Cold Chain

    575       --       575       100 %

Gross profit margin

    46 %     -- %     46 %        
                                 

Total gross profit

  $ 12,209     $ 11,052     $ 1,157       10 %

Gross profit margin

    61 %     62 %     (1 )%        

 

   

Nine Months Ended December 31,

           

Percent

 
   

2015

   

2014

   

Change

   

Change

 

Biological Indicators

  $ 15,157     $ 12,029     $ 3,128       26 %

Gross profit margin

    64 %     61 %     3 %        
                                 

Instruments

    16,571       15,794       777       5 %

Gross profit margin

    64 %     63 %     1 %        
                                 

Continuous Monitoring

    3,246       4,057       (811 )     (20 )%

Gross profit margin

    44 %     51 %     (7 )%        
                                 

Cold Chain

    1,443       --       1,443       100 %

Gross profit margin

    47 %     -- %     47 %        
                                 

Total gross profit

  $ 36,417     $ 31,880     $ 4,537       14 %

Gross profit margin

    61 %     60 %     1 %        

 

Three and nine months ended December 31, 2015 versus December 31, 2014

 

Biological Indicators gross profit margin percentage for the three and nine months ended December 31, 2015 increased primarily as a result of the ATI, PCD, Früh, Cherwell and October 2015 European BI Distributor Acquisitions, price increases and volume-based efficiencies associated with revenues growth.

 

Instruments gross profit margin percentage for the three and nine months ended December 31, 2015 increased primarily as a result of changes in product and service mix.

 

Continuous Monitoring gross profit margin decreased for the three and nine months ended December 31, 2015 primarily as a result of a change in our product service mix. Additionally, the gross profit margin percentage for the nine months ended December 31, 2014 was positively impacted by the timing of revenues recognized in that period (see revenues). We have made substantial progress on our integration activities associated with this segment and we are now also focused on cost reduction initiatives to stream line the operations and increase profitability. We saw some impact of these initiatives during the three months ended December 31, 2015 as gross profit margin percentage increased to 48 percent as compared to 43 percent for the three months ended September 30, 2015. We are hopeful that we will continue to improve the gross margin percentage in the future but it is unclear as to how much improvement we will be able to obtain.

 

We expect that our Cold Chain gross profit margin percentage will continue to be lower than the historical results of our other segments due to the nature of the cold chain products. This lower gross profit percentage however is offset by lower operating expenses (as a percentage of revenues) and as a result, we expect that operating income margins for our Cold Chain segment to be similar to those of our other segments.

 

 
Page 19

 

 

Operating Expenses

 

Operating expenses for the three and nine months ended December 31, 2015 increased as compared to the prior year as follows (in thousands):

 

   

Increase (Decrease)

 
   

Three Months Ended

December 31, 2015

   

Nine Months Ended

December 31, 2015

 

Selling

  $ (255 )   $ 427  
                 

General and administrative

               

ERP system implementation

    187       869  

Recurring software related costs

    --       170  

Amortization

    411       924  

Personnel costs

    406       1,249  

Acquisition costs

    40       --  

Litigation settlement

    --       1,709  

Administrative costs related to acquired entities

    290       492  

Sales tax accrual

    (467 )     (498 )

Other, net

    278       (92 )
      1,145       4,823  
                 

Research and development

    143       470  
                 

Operating expenses

  $ 1,033     $ 5,720  

 

Selling

 

Three and nine months ended December 31, 2015 versus December 31, 2014

 

Selling expense for the three months ended December 31, 2015 decreased primarily due to the collection of old accounts receivable that had previously been written off, partially offset by additional personnel related to the Infitrak and North Bay acquisitions. As a percentage of revenues, selling expense was eight percent for the three months ended December 31, 2015 as compared to 10 percent for the three months ended December 31, 2014.

 

Selling expense for the nine months ended December 31, 2015 increased primarily due to additional personnel related to the PCD, Infitrak and North Bay Acquisitions. As a percentage of revenues, selling expense was nine percent for the nine months ended December 31, 2015 as compared to 10 percent for the nine months ended December 31, 2014.

 

Historically selling expense approximates 10 to 12 percent of revenues.

 

General and Administrative

 

Three and nine months ended December 31, 2015 versus December 31, 2014

 

General and administrative expenses for the three months ended December 31, 2015 increased primarily due to increased amortization, personnel and other administrative costs resulting from the PCD, Infitrak and North Bay Acquisitions and increased spending on our ERP system upgrade, partially offset by a decrease in sales tax accruals.

 

General and administrative expenses for the nine months ended December 31, 2015 increased primarily due to increased amortization, personnel and other administrative costs resulting from the PCD, Infitrak and North Bay Acquisitions, increased spending on our ERP system upgrade and the Amato Settlement, partially offset by a decrease in sales tax accruals.

 

 
Page 20

 

 

Research and Development

 

Three and nine months ended December 31, 2015 versus December 31, 2015

 

Research and development expenses for the three and six months ended September 30, 2015 increased as a result of the addition of several new engineers to support existing and acquired businesses.

 

Net Income

 

Net income for the nine months ended December 31, 2015 was significantly impacted by the $1,709,000 Amato Settlement. Our income tax rate varies based upon many factors but in general, we anticipate that on a go forward basis, our effective tax rate will approximate 34 to 37 percent. Otherwise, net income for the nine months ended December 31, 2015 varied with the changes in revenues, gross profit and operating expenses (which includes $4,364,000 of non-cash amortization of intangible assets).

 

Liquidity and Capital Resources

 

Our sources of liquidity may include cash generated from operations, working capital, capacity under our Credit Facility and potential equity and debt offerings. We believe that cash generated from these sources will be sufficient to meet our short-term and long-term needs. Our more significant uses of resources include quarterly dividends to shareholders, payment of debt obligations, long-term capital expenditures and potential acquisitions.

 

Due to continued organic and acquisition related growth, we have outgrown the capacity of our current building in Bozeman, Montana and as a result, we are building a new facility in the same general area. Construction began in July 2015 and we are hopeful that the building will be completed no later than September 30, 2016. During our year ended March 31, 2015 we acquired the related land for $741,000 and have spent $4,475,000 during the nine months ended December 31, 2015, which is included in property, plant and equipment, net on the accompanying condensed consolidated balance sheets. We anticipate that the total cost of the new facility will be approximately $14,750,000. Following the relocation from our current Bozeman building into the new facility, we expect to be able to sell the current facility for $2,000,000 - $3,000,000 to partially offset the cost of the new building.

 

We implemented a new ERP system which required a significant amount of cash. We incurred approximately $2,000,000 of expense associated with this project of which approximately $1,000,000 was incurred during the nine months ended December 31, 2015. On a go forward basis, we expect our annual operating costs for our ERP system to approximate $450,000 plus any costs necessary for additional projects and enhancements.

 

Working capital is the amount by which current assets exceed current liabilities. We had working capital of $13,345,000 and $14,965,000, respectively, at December 31, 2015 and March 31, 2015.

 

In February 2012, we entered into a three year agreement (the “Credit Facility”) for a $20,000,000 revolving line of credit (“Line of Credit”) and up to $1,000,000 of letters of credit. Funds from the Credit Facility were used for general working capital and corporate needs, retiring existing debt, or to support acquisitions and capital expenditures.

 

In April 2014, the Credit Facility was amended to include a $15,000,000 term loan (the “Initial Term Loan”) and to extend the maturity date of the Credit Facility to June 30, 2017.

 

On July 1, 2015, we further amended our Credit Facility to extend the maturity date to June 30, 2020, increase the Line of Credit to $50,000,000 and establish a new $20,000,000 term loan (the “Term Loan”). The majority of the proceeds from the Term Loan were used to pay down the remaining $12,000,000 balance of the Initial Term Loan.

 

Under the Line of Credit, indebtedness bears interest at either: (1) LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25%; or (2) the bank’s commercial bank floating rate (“CBFR”), which is the bank’s prime rate adjusted down by 0.5%.

 

The Term Loan bears interest at LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25% and requires 20 quarterly principal payments (the first due date was July 15, 2015) in the amount of $750,000 with the remaining balance of principal and accrued interest due on June 30, 2020.

 

The Credit Facility is secured by all of our assets and requires us to maintain a ratio of funded debt to our trailing four quarters of EBIDTA, as defined, of 3.25 to 1.0 through March 31, 2016 and 3.0 to 1.0 thereafter, and a minimum fixed charge coverage ratio of 1.35 to 1.0. We were in compliance with the required covenants at December 31, 2015.

 

As of January 31, 2015, we had $46,250,000 in outstanding indebtedness and unused capacity under our Credit Facility of $21,500,000.

 

 
Page 21

 

 

In April 2015, the SEC declared effective our Universal Shelf Registration Statement which allows us to sell, in one or more public offerings, common stock or warrants, or any combination of such securities for proceeds in an aggregate amount of up to $130,000,000. The terms of any offering, including the type of securities involved, would be established at the time of sale. We have no immediate plans to issue securities under this registration statement.

 

We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume third party debt or incur other long-term obligations. We believe that we have the option to utilize both equity and debt instruments as vehicles for the long-term financing of our investment activities and acquisitions.

 

On November 7, 2005, our Board of Directors authorized a program to repurchase up to 300,000 shares of our outstanding common stock. Under the plan, the shares may be purchased from time to time in the open market at prevailing prices or in negotiated transactions off the market. Shares purchased will be canceled and repurchases will be made with existing cash reserves. We do not maintain a set policy or schedule for our buyback program. We have purchased 162,486 shares of common stock under this program from inception through December 31, 2015.

 

We have been paying regular quarterly dividends since 2003. Dividends per share paid by quarter were as follows:

 

   

Year Ending March 31,

 
   

2016

   

2015

 

First quarter

  $ 0.16     $ 0.15  

Second quarter

    0.16       0.15  

Third quarter

    0.16       0.16  

Fourth quarter

    --       0.16  

 

In January 2016, our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on March 15, 2016, to shareholders of record at the close of business on February 29, 2016.

 

Cash Flows

 

Our cash flows from operating, investing and financing activities were as follows (in thousands):

 

   

Nine Months Ended December 31,

 
   

2015

   

2014

 

Net cash provided by operating activities

  $ 9,953     $ 6,176  

Net cash used in investing activities

    (29,490 )     (21,262 )

Net cash provided by financing activities

    20,826       11,019  

 

Net cash provided by operating activities for the nine months ended December 31, 2015 increased primarily due to the efficient management of working capital.

 

Net cash used in investing activities for the nine months ended December 31, 2015 resulted primarily from the $18,926,000 Infitrak and $11,322,000 North Bay Acquisitions and the purchase of $6,291,000 of property, plant and equipment. Net cash used in investing activities for the nine months ended December 31, 2014 resulted primarily from the $10,268,000 BGI and $5,000,000 PCD Acquisitions and the purchase of $2,212,000 of property, plant and equipment.

 

Net cash provided by financing activities for the nine months ended December 31, 2015 resulted from borrowings under our Credit Facility of $25,000,000 and proceeds from the exercise of stock options of $1,800,000, partially offset by the repayment of debt of $4,250,000 and the payment of dividends of $1,724,000. Net cash provided by financing activities for the nine months ended December 31, 2014 resulted from borrowings under our Line of Credit of $23,000,000 and proceeds from the exercise of stock options of $1,137,000, partially offset by the repayment of debt of $11,500,000 and the payment of dividends of $1,618,000.

 

At December 31, 2015, we had contractual obligations for open purchase orders of approximately $3,650,000 for routine purchases of supplies and inventory, which are payable in less than one year.

 

 
Page 22

 

 

Under the terms of the PCD Agreement, we are required to pay contingent consideration if the cumulative revenues for our process challenge device business for the three years subsequent to the acquisition meet certain levels. The potential consideration payable ranges from $0 to $1,500,000 and is based upon a sliding scale of three-year cumulative revenues between $9,900,000 and $12,600,000. Based upon both historical and projected growth rates, we recorded $300,000 of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. We paid $150,000 of the contingent consideration during the three months ended December 31, 2015 (based upon the current run rate projected over the entire three-year contingent consideration period). This amount is subject to modification at the end of the second and third years of the earn-out period based upon the actual revenues earned over the contingent consideration period. Any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our process challenge device business and we will adjust the contingent liability on a go forward basis, based on then current information.

 

Under the terms of the Infitrak Agreement, we are required to pay contingent consideration if the gross profit (as defined in the Earn-Out Agreement) for the packaging component of our cold chain business for the two years subsequent to the acquisition meets certain levels. The potential consideration payable ranges from $0 to $15,000,000 CDN (approximately $0 to $10,800,000 as of December 31, 2015) and is based upon a sliding scale of growth in gross profit (as defined in the Earn-Out Agreement) for year one and year two of 30 to 70 percent and 15 to 75 percent, respectively. Based upon both historical and projected growth rates, we recorded $9,541,000 (valued at approximately $8,700,000 as of December 31, 2015 based on the then current exchange rate) of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. After the finalization of our purchase accounting, any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our cold chain business and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in two annual installments beginning in the second quarter of our year ending March 31, 2017.

 

In October 2015, we entered into the Amato Settlement whereby we paid Amato $3,165,000. In exchange, Amato agreed to dismiss the complaint, release Mesa of any and all claims by Amega and Amato, and relieve us of any future payment obligation under the Amega Earn-Out. Insurance covered $415,000 of the settlement payment and we had $1,041,000 accrued on our condensed consolidated balance sheet remaining from the original hold back and contingent consideration payable. The remaining $1,709,000 was recorded as general and administrative expense in the accompanying condensed consolidated statements of income for the three and nine months ended December 31, 2015.

 

Critical Accounting Estimates

 

Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed consolidated financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2015 in the Critical Accounting Policies and Estimates section of “Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.”

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

We have no derivative instruments and minimal exposure to foreign currency and commodity market risks.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to reasonably ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of December 31, 2015. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective at December 31, 2015.

 

Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Management evaluated the effectiveness of our internal control over financial reporting based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013.

 

 
Page 23

 

 

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of December 31, 2015. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at December 31, 2015. As allowed, this evaluation excludes the operations of acquired entities during the nine months ended December 31, 2015 due to the timing of the acquisitions.

 

Changes in Internal Control Over Financial Reporting

 

There were no significant changes in our internal control over financial reporting that occurred during the nine months ended December 31, 2015, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

 

Part II. Other Information

 

Item 1. Legal Proceedings

 

See Note 7 – Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements (Part I, Item 1 of this Form 10-Q) for information regarding legal proceedings in which we are involved.

 

Item 1A. Risk factors

 

We are affected by risks specific to us as well as factors that affect all businesses operating in a global market.  The significant factors known to us that could materially adversely affect our business, financial condition or operating results are described in our Annual Report on Form 10-K for the year ended March 31, 2015, under the heading “Part I – Item 1A. Risk Factors.”  There have been no material changes to those risk factors.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

On November 7, 2005, our Board of Directors adopted a share repurchase plan which allows for the repurchase of up to 300,000 of our common shares. This plan will continue until the maximum is reached or the plan is terminated by further action of the Board of Directors. We made the following repurchases of our common stock, including settlement of loans to employees for the exercise of stock options:

 

   

Shares Purchased

   

Average Price

Paid

   

Total Shares Purchased as Part of Publicly Announced Plan

   

Remaining Shares to

Purchase Under Plan

 

October 2015

    --     $ --       162,486       137,514  

November 2015

    --       --       162,486       137,514  

December 2015

    --       --       162,486       137,514  

Total

    --       --                  

 

Item 6. Exhibits

 

 

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101

The following financial information from the quarterly report on Form 10-Q of Mesa Laboratories, Inc. for the quarter ended December 31, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Income, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Cash Flows, and (iv) Notes to the Condensed Consolidated Financial Statements.

 

 
Page 24

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

MESA LABORATORIES, INC.

(Registrant)

 

 

 

DATED: February 4, 2016                                                      BY:       /s/ John J. Sullivan, Ph.D..

John J. Sullivan, Ph.D.

Chief Executive Officer

 

 

 

DATED: February 4, 2016                                                      BY:       /s/ John V. Sakys

John V. Sakys

Chief Financial Officer

 

 

 

Page 25

EXHIBIT 31.1 CERTIFICATIONS PURSUANT TO RULE 13a-14(a)

 

I, John J. Sullivan, Ph.D., certify that:

 

 

1.

I have reviewed this quarterly report on Form 10-Q of Mesa Laboratories, Inc.;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

Date: February 4, 2016                                         /s/ John J. Sullivan, Ph.D.

John J. Sullivan, Ph.D.

Chief Executive Officer

EXHIBIT 31.2 CERTIFICATIONS PURSUANT TO RULE 13a-14(a)

 

I, John V. Sakys, certify that:

 

 

1.

I have reviewed this quarterly report on Form 10-Q of Mesa Laboratories, Inc.;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

 

Date: February 4, 2016                                         /s/ John V. Sakys

John V. Sakys

Chief Financial Officer

EXHIBIT 32.1 CERTIFICATIONS PURSUANT TO RULE 13a-14(b) AND 18 U.S.C SECTION 1350

 

In connection with the Quarterly Report of Mesa Laboratories, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John J. Sullivan, Ph.D., Chief Executive Officer of the Company, certify, pursuant to Rule 13a-14(b) and 18 U.S.C. § 1350, that:

 

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: February 4, 2016                                         /s/ John J. Sullivan, Ph.D.

John J. Sullivan, Ph.D.

Chief Executive Officer

EXHIBIT 32.2 CERTIFICATIONS PURSUANT TO RULE 13a-14(b) AND 18 U.S.C SECTION 1350

 

In connection with the Quarterly Report of Mesa Laboratories, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John V. Sakys, Chief Financial Officer of the Company, certify, pursuant to Rule 13a-14(b) and 18 U.S.C. § 1350, that:

 

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: February 4, 2016                                         /s/ John V. Sakys

John V. Sakys

Chief Financial Officer

v3.3.1.900
Document And Entity Information - shares
9 Months Ended
Dec. 31, 2015
Jan. 27, 2016
Entity Registrant Name MESA LABORATORIES INC /CO  
Entity Central Index Key 0000724004  
Trading Symbol mlab  
Current Fiscal Year End Date --03-31  
Entity Filer Category Accelerated Filer  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Entity Common Stock, Shares Outstanding (in shares)   3,626,528
Document Type 10-Q  
Document Period End Date Dec. 31, 2015  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
Amendment Flag false  
v3.3.1.900
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Dec. 31, 2015
Mar. 31, 2015
ASSETS    
Cash and cash equivalents $ 3,272,000 $ 2,034,000
Accounts receivable, net 13,283,000 12,145,000
Inventories, net 14,716,000 12,420,000
Prepaid expenses and other 1,294,000 1,334,000
Deferred income taxes 1,682,000 1,689,000
Total current assets 34,247,000 29,622,000
Property, plant and equipment, net 15,685,000 9,598,000
Intangibles, net 41,231,000 33,231,000
Goodwill 63,953,000 44,869,000
Total assets 155,116,000 117,320,000
LIABILITIES AND STOCKHOLDERS’ EQUITY    
Accounts payable 3,053,000 2,503,000
Accrued salaries and payroll taxes 4,340,000 4,105,000
Unearned revenues 2,809,000 1,314,000
Current portion of contingent consideration 4,696,000 1,220,000
Other accrued expenses 2,803,000 1,307,000
Income taxes payable 201,000 1,208,000
Current portion of long-term debt 3,000,000 3,000,000
Total current liabilities 20,902,000 14,657,000
Deferred income taxes 5,243,000 5,122,000
Long-term debt 44,000,000 23,250,000
Contingent consideration 4,327,000 812,000
Total liabilities $ 74,472,000 $ 43,841,000
Commitments and Contingencies (Note 7)
Stockholders’ equity:    
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 3,625,003 and 3,561,540 shares, respectively $ 21,437,000 $ 17,751,000
Retained earnings 60,657,000 55,962,000
Accumulated other comprehensive loss (1,450,000) (234,000)
Total stockholders’ equity 80,644,000 73,479,000
Total liabilities and stockholders’ equity $ 155,116,000 $ 117,320,000
v3.3.1.900
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
Dec. 31, 2015
Mar. 31, 2015
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, shares anthorized (in shares) 25,000,000 25,000,000
Common stock, shares issued (in shares) 3,625,003 3,561,540
Common stock, shares outstanding (in shares) 3,625,003 3,561,540
v3.3.1.900
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Revenues $ 19,913 $ 17,830 $ 59,847 $ 52,770
Cost of revenues 7,704 6,778 23,430 20,890
Gross profit 12,209 11,052 36,417 31,880
Operating expenses        
Selling 1,517 1,772 5,604 5,177
General and administrative 5,885 4,740 17,404 12,581
Research and development 975 832 2,929 2,459
Total operating expenses 8,377 7,344 25,937 20,217
Operating income 3,832 3,708 10,480 11,663
Other (expense) income, net (381) 5 (710) (314)
Earnings before income taxes 3,451 3,713 9,770 11,349
Income taxes 1,090 1,310 3,351 4,005
Net income $ 2,361 $ 2,403 $ 6,419 $ 7,344
Net income per share:        
Basic (in dollars per share) $ 0.65 $ 0.68 $ 1.79 $ 2.09
Diluted (in dollars per share) $ 0.63 $ 0.66 $ 1.72 $ 2.01
Weighted average common shares outstanding:        
Basic (in shares) 3,614 3,532 3,596 3,513
Diluted (in shares) 3,755 3,654 3,729 3,649
v3.3.1.900
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Net income available for shareholders $ 2,361 $ 2,403 $ 6,419 $ 7,344
Other comprehensive loss, net of tax:        
Foreign currency translation (1,847) (250) (1,216) (250)
Total comprehensive income $ 514 $ 2,153 $ 5,203 $ 7,094
v3.3.1.900
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities:    
Net income $ 6,419 $ 7,344
Depreciation and amortization 5,207 4,162
Stock-based compensation $ 1,001 776
Loss on disposition of assets $ 16
Deferred income taxes $ 128
Foreign currency adjustments 85 $ (169)
Change in assets and liabilities, net of effects of acquisitions    
Accounts receivable, net 72 (1,994)
Inventories, net (1,901) (3,340)
Prepaid expenses and other 40 538
Accounts payable 80 747
Accrued liabilities and taxes payable 710 (1,439)
Unearned revenues (118) $ (465)
Contingent consideration (1,770)
Net cash provided by operating activities 9,953 $ 6,176
Cash flows from investing activities:    
Acquisitions (23,199) (19,050)
Purchases of property, plant and equipment (6,291) (2,212)
Net cash used in investing activities (29,490) (21,262)
Cash flows from financing activities:    
Proceeds from the issuance of debt 25,000 23,000
Payments on debt (4,250) (11,500)
Dividends (1,724) (1,618)
Proceeds from the exercise of stock options 1,800 1,137
Net cash provided by financing activities 20,826 11,019
Effect of exchange rate changes on cash and cash equivalents (51) (81)
Net increase (decrease) in cash and cash equivalents 1,238 (4,148)
Cash and cash equivalents at beginning of period 2,034 5,575
Cash and cash equivalents at end of period 3,272 1,427
Cash paid for:    
Income taxes 3,375 2,789
Interest 563 354
Supplemental non-cash activity:    
Repayment of employee loans for stock options   24
Contingent consideration as part of an acquisition $ 9,541 $ 300
v3.3.1.900
Note 1 - Description of Business and Summary of Significant Accounting Policies
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
Note 1 -Description of Business and Summary of Significant Accounting Policies
 
Description of Business
 
Mesa Laboratories, Inc. was incorporated under the laws of the State of Colorado on March 26, 1982. The terms “we,” “us,” “our,” the “Company” or “Mesa” are used in this report to refer collectively to the parent company and the subsidiaries through which our various businesses are actually conducted. We pursue a strategy of focusing primarily on quality control products and services, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into four divisions across eight physical locations. Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries. Our Biological Indicators Division provides testing services, along with the manufacturing and marketing of biological indicators and distribution of chemical indicators used to assess the effectiveness of sterilization processes, including steam, hydrogen peroxide, ethylene oxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. Our Continuous Monitoring Division designs, develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and a number of other laboratory and industrial environments. Our Cold Chain Division provides parameter monitoring of products in a cold chain, consulting services such as compliance monitoring, packaging development and validation or mapping of transport and storage containers, and thermal packaging products such as coolers, boxes, insulation materials and phase-change products to control temperature during transport.
 
Basis of Presentation
 
The accompanying condensed consolidated balance sheet as of March 31, 2015, has been derived from audited consolidated financial statements. The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as our annual audited consolidated financial statements and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. In the opinion of management, such unaudited information includes all adjustments (consisting only of normal recurring accruals) necessary for a fair presentation of this interim information. Operating results and cash flows for interim periods are not necessarily indicative of results that can be expected for the entire year. The information included in this report should be read in conjunction with our audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended March 31, 2015.
 
The summary of our significant accounting policies is incorporated by reference to our Annual Report on Form 10-K for the year ended March 31, 2015.
 
Recently Issued Accounting Pronouncements
 
In May 2014, the Financial Accounting Standards Board (“FASB”) and International Accounting Standards Board “(IASB”) issued a jointly converged standard on the recognition of revenue from contracts with customers. The issued guidance converges the criteria for reporting revenues, as well as requiring disclosures sufficient to describe the nature, amount, timing and uncertainty of revenues and cash flows arising from these contracts. Companies can transition to the standard either retrospectively or as a cumulative effective adjustment as of the date of adoption. The new standard is effective for our fiscal year (and interim periods within that year) ending March 31, 2019. We are evaluating the impact of this standard on our condensed consolidated financial statements and disclosures.
 
In November 2015, the FASB issued new requirements for the presentation of deferred tax assets and liabilities, requiring noncurrent classification for all deferred tax assets and liabilities on the condensed consolidated balance sheets. The requirements of the new standard are effective for our fiscal year (and interim periods within that year) ending March 31, 2018. We do not expect this guidance to have a material impact on our results of operations or financial position.
v3.3.1.900
Note 2 - Acquisitions and Dispositions
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Mergers, Acquisitions and Dispositions Disclosures [Text Block]
Note 2 – Acquisition
s and Dispositions
 
Acquisitions
 
For the nine months ended December 31, 2015, our acquisitions of businesses (net of cash acquired) totaled $32,740,000, which consisted of the following material acquisitions:
 
Infitrak
 
On July 6, 2015, we completed a business combination (the “Infitrak Acquisition”) whereby we acquired all of the common stock of 2396081 Ontario Inc. and its wholly owned operating subsidiary, Infitrak Inc. (collectively “Infitrak”), a company whose business provides consulting, packaging and measuring solutions for cold chain applications. The stock purchase agreement (the “Infitrak Agreement”) includes provisions for both contingent consideration based upon the two year growth in gross profit (as defined in the Earn-Out Agreement) of the packaging component of our cold chain business subsequent to the acquisition and for a holdback payment (subject to a post-closing adjustment), payable at the one year anniversary of the closing date.
 
Under the terms of the Infitrak Agreement, we are required to pay contingent consideration if the gross profit (as defined in the Earn-Out Agreement) for the packaging component of our cold chain business for the two years subsequent to the acquisition meets certain levels. The potential consideration payable ranges from $0 to $15,000,000 CDN (approximately $0 to $10,800,000 as of December 31, 2015) and is based upon a sliding scale of growth in gross profit (as defined in the Earn-Out Agreement) for year one and year two of 30 to 70 percent and 15 to 75 percent, respectively. Based upon both historical and projected growth rates, we recorded $9,541,000 of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. After the finalization of our purchase accounting, any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of the packaging component of our cold chain business and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in two annual installments beginning in the second quarter of our year ending March 31, 2017.
 
We expect to achieve savings and generate growth as we integrate the Infitrak operations and sales and marketing functions. These factors, among others, contributed to a purchase price in excess of the estimated fair value of the net identifiable assets acquired and, as a result, we recorded goodwill in connection with this transaction. The goodwill is not expected to be deductible for tax purposes and it was assigned to our Cold Chain segment.
 
The Infitrak Acquisition constituted the acquisition of a business and was recognized at fair value. Due to the recent nature of the transaction, the purchase price allocation was based upon a preliminary estimated fair value of the assets and liabilities acquired as we are in the process of finalizing our valuation of the assets acquired and liabilities assumed. We determined the preliminary estimated fair values using discounted cash flow analyses and estimates made by management. The following reflects our preliminary allocation of the consideration, subject to customary purchase price adjustments in accordance with the Infitrak Agreement (in thousands):
 
Cash consideration
  $ 8,748  
Holdback payment liability
    637  
Contingent consideration liability
    9,541  
Aggregate consideration
  $ 18,926  
         
Accounts receivable, net
  $ 925  
Inventories, net
    310  
Property, plant and equipment, net
    530  
Intangibles, net
    5,869  
Goodwill
    12,529  
Accounts payable
    (470 )
Accrued liabilities
    (767 )
Total purchase price allocation
  $ 18,926  
 
The accompanying condensed consolidated statements of income include the results of the Infitrak Acquisition from the acquisition date of July 6, 2015. The pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on April 1, 2015 and 2014, are as follows (in thousands, except per share data):
 
 
 
Three
Months E
nded
December 31
,
 
 
Nine
Months E
nded
December 31
,
 
 
 
201
5
 
 
201
4
 
 
201
5
 
 
201
4
 
Revenues
  $ 19,913     $ 18,592     $ 61,687     $ 55,057  
Net income
    2,361       2,493       6,721       7,615  
Net Income per common share:
                               
Basic
  $ 0.65     $ 0.71     $ 1.87     $ 2.17  
Diluted
    0.63       0.68       1.80       2.09  
 
North Bay
 
On August 6, 2015, we completed a business combination (the “North Bay Acquisition”) whereby we acquired substantially all of the assets (other than certain fixed assets) and certain liabilities of the dental sterilizer testing business of North Bay Bioscience, LLC (“North Bay”). The asset purchase agreement (the “North Bay Agreement”) includes a provision for a holdback payment (subject to a post-closing adjustment), payable at the one year anniversary of the closing date.
 
We expect to achieve savings and generate growth as we integrate the North Bay operations and sales and marketing functions. These factors, among others, contributed to a purchase price in excess of the estimated fair value of the net identifiable assets acquired and, as a result, we recorded goodwill in connection with this transaction. The goodwill is expected to be deductible for tax purposes and it was assigned to our Biological Indicators segment.
 
The North Bay Acquisition constituted the acquisition of a business and was recognized at fair value. We determined the estimated fair values using discounted cash flow analyses and estimates made by management. The following reflects our allocation of the consideration, subject to customary purchase price adjustments in accordance with the North Bay Agreement (in thousands):
 
Cash consideration
  $ 10,322  
Holdback payment liability
    1,000  
Aggregate consideration
  $ 11,322  
         
Cash
  $ 20  
Accounts receivable, net
    285  
Inventories, net
    85  
Property, plant and equipment, net
    229  
Intangibles, net
    4,454  
Goodwill
    7,962  
Accrued liabilities
    (100 )
Unearned revenues
    (1,613 )
Total purchase price allocation
  $ 11,322  
 
The accompanying condensed consolidated statements of income include the results of the North Bay Acquisition from the acquisition date of August 6, 2015. The pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on April 1, 2015 and 2014, are as follows (in thousands, except per share data):
 
 
 
Three
Months E
nded
December 31
,
 
 
Nine
Months E
nded
December 31
,
 
 
 
201
5
 
 
201
4
 
 
201
5
 
 
201
4
 
Revenues
  $ 19,913     $ 18,910     $ 61,241     $ 56,009  
Net income
    2,361       2,553       6,713       7,793  
Net Income per common share:
                               
Basic
  $ 0.65     $ 0.72     $ 1.87     $ 2.22  
Diluted
    0.63       0.70       1.80       2.14  
v3.3.1.900
Note 3 - Inventories
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Inventory Disclosure [Text Block]
Note 3 - Inventories
 
Inventories consist of the following (in thousands):
 
 
 
December 31, 2015
 
 
March 31,
2015
 
Raw materials
  $ 9,282     $ 10,366  
Work-in-process
    549       530  
Finished goods
    5,383       1,913  
Less: reserve
    (498 )     (389 )
    $ 14,716     $ 12,420  
v3.3.1.900
Note 4 - Long-term Debt
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Debt Disclosure [Text Block]
Note 4 -
Long-T
erm Debt
 
Long-term debt consists of the following (in thousands):
 
 
 
December 31, 2015
 
 
March 31,
201
5
 
Line of credit (2.42% at December 31, 2015)
  $ 28,500     $ 13,500  
Term loan (2.42% at December 31, 2015)
    18,500       12,750  
Less: current portion
    (3,000 )     (3,000 )
Long-term portion
  $ 44,000     $ 23,250  
 
In February 2012, we entered into a three year agreement (the “Credit Facility”) for a $20,000,000 revolving line of credit (“Line of Credit”) and up to $1,000,000 of letters of credit. Funds from the Credit Facility were used for general working capital and corporate needs, retiring existing debt, or to support acquisitions and capital expenditures.
 
In April 2014, the Credit Facility was amended to include a $15,000,000 term loan (the “Initial Term Loan”) and to extend the maturity date of the Credit Facility to June 30, 2017.
 
On July 1, 2015, we further amended our Credit Facility to extend the maturity date to June 30, 2020, increase the Line of Credit to $50,000,000 and establish a new $20,000,000 term loan (the “Term Loan”). The majority of the proceeds from the Term Loan were used to pay down the remaining $12,000,000 balance of the Initial Term Loan. The remaining $8,000,000 was combined with a $1,000,000 draw under the Line of Credit to fund the Infitrak Acquisition (see Note 2).
 
Under the Line of Credit, indebtedness bears interest at either: (1) LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25%; or (2) the bank’s commercial bank floating rate (“CBFR”), which is the bank’s prime rate adjusted down by 0.5%. We elect the interest rate with each borrowing under the line of credit. In addition, there is an unused line fee of 0.25%. Letter of credit fees are based on the applicable LIBOR rate.
 
The Term Loan bears interest at LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25% and requires 20 quarterly principal payments (the first due date was July 15, 2015) in the amount of $750,000 with the remaining balance of principal and accrued interest due on June 30, 2020.
 
The Credit Facility is secured by all of our assets and requires us to maintain a ratio of funded debt to our trailing four quarters of EBIDTA, as defined, of 3.25 to 1.0 through March 31, 2016 and 3.0 to 1.0 thereafter, and a minimum fixed charge coverage ratio of 1.35 to 1.0. We were in compliance with the required covenants at December 31, 2015.
 
As of December 31, 2015, future contractual maturities of debt as are as follows (in thousands):
 
Year E
nding March 31,
 
 
 
 
2016
  $ 750  
2017
    3,000  
2018
    3,000  
2019
    3,000  
2020
    3,000  
Thereafter
    34,250  
    $ 47,000  
 
In January 2016, we made a $750,000 required principle payment on the Term Loan.
v3.3.1.900
Note 5 - Stock-based Compensation
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Note 5 -
Stock-B
ased Compensation
 
Amounts recognized in the condensed consolidated financial statements related to stock-based compensation are as follows (in thousands, except per share data):
 
 
 
Three Months E
nded
December 31
,
 
 
Nine Months E
nded
December 31
,
 
 
 
2015
 
 
2014
 
 
2015
 
 
2014
 
Total cost of stock-based compensation charged against
income before income taxes
  $ 344     $ 260     $ 1,001     $ 776  
Amount of income tax benefit recognized in earnings
    109       92       343       274  
Amount charged against net income
  $ 235     $ 168     $ 658     $ 502  
Impact on net income per common share:
                               
Basic
  $ 0.07     $ 0.05     $ 0.18     $ 0.14  
Diluted
    0.06       0.05     $ 0.18       0.14  
 
Stock-based compensation expense is included in cost of revenues, selling, and general and administrative expense in the accompanying condensed consolidated statements of income.
 
The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model (“Black-Scholes”). We use historical data to estimate the expected price volatility, the expected stock option life and expected forfeiture rate. The risk-free interest rate is based on the United States Treasury yield curve in effect at the time of grant for the estimated life of the stock option. The dividend yield is calculated based upon the dividend payments made during the prior four quarters as a percent of the average stock price for that period.
 
The following is a summary of stock option activity for the nine months ended December 31, 2015:
 
 
 
Number of
Shares
 
 
Weighted-
A
verage Exercise Price per Share
 
 
Weighted-
A
verage Remaining Contractual Term
 
 
Aggregate Intrinsic Value (000s)
 
Outstanding at March 31, 2015
    437,248     $ 55.81       4.9     $ 9,445  
Stock options granted
    183,550       72.87       6.9          
Stock options forfeited
    (12,384 )     76.89       7.2          
Stock options expired
    --       --                  
Stock options exercised
    (72,803 )     39.98                  
Outstanding at December 31, 2015
    535,611       63.32       5.3       19,412  
                                 
Exercisable at December 31, 2015
    173,949       41.4       3.6       10,107  
 
The total intrinsic value of stock options exercised was $4,263,767 and $2,003,000 for the nine months ended December 31, 2015 and 2014, respectively.
 
A summary of the status of our unvested stock option shares as of December 31, 2015 is as follows:
  
 
 
Number of
Shares
 
 
Weighted-
A
verage
Grant-Date
Fair Value
 
Unvested at March 31, 2015
    274,038     $ 18.42  
Stock options granted
    183,550       18.77  
Stock options forfeited
    (12,384 )     19.53  
Stock options vested
    (83,542 )     14.56  
Unvested at December 31, 2015
    361,662       19.43  
 
As of December 31, 2015, there was $4,966,245 of total unrecognized compensation expense related to unvested stock options. As of December 31, 2015, we have 914,110 shares available for future stock option grants.
v3.3.1.900
Note 6 - Net Income Per Share
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Earnings Per Share [Text Block]
Note 6 - Net Income Per Share
 
Basic net income per share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. Diluted net income per share is computed similarly to basic net income per share, except that it includes the potential dilution that could occur if dilutive securities were exercised.
 
The following table presents a reconciliation of the denominators used in the computation of net income per share - basic and diluted (in thousands, except per share data):
 
 
 
Three
M
onths
E
nded
December 31
,
 
 
Nine
M
onths
E
nded
December 31
,
 
 
 
2015
 
 
201
4
 
 
2015
 
 
2014
 
Net income available for shareholders
  $ 2,361     $ 2,403     $ 6,419     $ 7,344  
Weighted average outstanding shares of common stock
    3,614       3,532       3,596       3,513  
Dilutive effect of stock options
    141       122       133       136  
Common stock and equivalents
    3,755       3,654       3,729       3,649  
                                 
Net income per share:
                               
Basic
  $ 0.65     $ 0.68     $ 1.79     $ 2.09  
Diluted
    0.63       0.66       1.72       2.01  
 
For the three and nine months ended December 31, 2015, 91,000 and 136,000 outstanding stock options, respectively, were excluded from the calculation of diluted net income per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and, therefore, their inclusion would have been anti-dilutive.
 
For the three and nine months ended December 31, 2014, 155,000 and 173,000 outstanding stock options, respectively, were excluded from the calculation of diluted net income per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and, therefore, their inclusion would have been anti-dilutive.
v3.3.1.900
Note 7 - Commitments and Contingencies
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
Note 7-
Commitments and
Contingencies
 
Under the terms of the Amega Agreement, we were required to pay contingent consideration (the “Amega Earn-Out”) if the cumulative revenues for our Continuous Monitoring Division for the three years subsequent to the acquisition met certain levels. The potential consideration payable ranged from $0 to $10,000,000 and was based upon a sliding scale of three-year cumulative revenues between $31,625,000 and $43,500,000. Based upon both historical and projected growth rates, we recorded $500,000 of contingent consideration payable which represented our best estimate of the amount that would ultimately be paid. Any changes to the contingent consideration ultimately paid would have resulted in additional income or expense in our condensed consolidated statements of income. The contingent consideration was payable in the third quarter of our year ending March 31, 2017.
 
In November 2014, Amega and its owner Anthony Amato (“Amato”) filed a complaint (
Anthony Amato and Amega Scientific Corporation v. Mesa Laboratories, Inc., Civil Action No. 1:14-cv-03228
) in the United States District Court for the district of Colorado asserting, among other items, that our termination of Amato as an employee impacted his ability to maximize the potential consideration payable under the Amega Earn-Out and to exercise stock options that failed to vest. The plaintiff was seeking an immediate maximum payout of $10,000,000 under the Amega Earn-Out, the immediate acceleration of the 10,000 stock options granted Amato upon his initial employment along with other consequential damages in excess of $500,000, lost future earnings and punitive damages. In addition, Amato alleged that we improperly withheld $704,065.86 from the holdback consideration under the Amega Agreement. In January 2015 we filed a motion to dismiss the complaint with prejudice.
 
In October 2015, we entered into a settlement agreement (the “Amato Settlement”) whereby we paid Amato $3,165,000. In exchange, Amato agreed to dismiss the complaint, release Mesa of any and all claims by Amega and Amato, and relieve us of any future payment obligation under the Amega Earn-Out. Insurance covered $415,000 of the settlement payment and we had $1,041,000 accrued on our condensed consolidated balance sheet remaining from the original hold back and contingent consideration payable. The remaining $1,709,000 was recorded as general and administrative expense in the accompanying condensed consolidated statements of income for the nine months ended December 31, 2015.
 
Under the terms of the PCD Agreement, we are required to pay contingent consideration if the cumulative revenues for our process challenge device business for the three years subsequent to the acquisition meet certain levels. The potential consideration payable ranges from $0 to $1,500,000 and is based upon a sliding scale of three-year cumulative revenues between $9,900,000 and $12,600,000. Based upon both historical and projected growth rates, we recorded $300,000 of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. We paid $150,000 of the contingent consideration during the three months ended December 31, 2015 (based upon the current run rate projected over the entire three-year contingent consideration period). This amount is subject to modification at the end of the second and third years of the earn-out period based upon the actual revenues earned over the contingent consideration period. Any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our process challenge device business and we will adjust the contingent liability on a go forward basis, based on then current information.
 
Under the terms of the Infitrak Agreement, we are required to pay contingent consideration if the gross profit (as defined in the Earn-Out Agreement) for the packaging component of our cold chain business for the two years subsequent to the acquisition meets certain levels. The potential consideration payable ranges from $0 to $15,000,000 CDN (approximately $0 to $10,800,000 as of December 31, 2015) and is based upon a sliding scale of growth in gross profit (as defined in the Earn-Out Agreement) for year one and year two of 30 to 70 percent and 15 to 75 percent, respectively. Based upon both historical and projected growth rates, we recorded $9,541,000 (valued at approximately $8,700,000 as of December 31, 2015 based on the then current exchange rate) of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. After the finalization of our purchase accounting, any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our cold chain business and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in two annual installments beginning in the second quarter of our year ending March 31, 2017.
 
A company is required to collect and remit state sales tax from certain of its customers if that company is determined to have “nexus” in a particular state. The determination of nexus varies state by state and often requires knowledge of each jurisdiction’s tax case law. During the year ended March 31, 2013, we determined that there are states in which we most likely had established nexus during prior periods without properly collecting and remitting sales tax. We recorded an estimate of $100,000 associated with one specific state but we were unable to estimate our remaining exposure at that time. During the year ended March 31, 2014, we completed our analysis associated with the remaining states and we recorded an estimate of $1,408,000, which was included in other accrued expenses on the consolidated balance sheets and in general and administrative expense on the consolidated statements of income for the year ended March 31, 2014. That estimate was based upon facts and circumstances known at such time and our ultimate liability was subject to change as further analysis is completed and state sales tax returns are filed.
 
During the year ended March 31, 2015 we successfully completed and filed several state sales tax returns which concluded our obligation for historical sales taxes in those states. In addition we continued to work through the process in the remaining states. As a result of this work, we determined that our exposure had increased above and beyond our original accrual and as a result, we recorded an additional accrual of $460,000 during the year ended March 31, 2015. During the nine months ended December 31, 2015 we successfully completed and filed additional state sales tax returns which concluded our obligation for historical sales taxes in those remaining states.
v3.3.1.900
Note 8 - Comprehensive Income
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Comprehensive Income (Loss) Note [Text Block]
Note
8
– Comprehensive Income
 
The following table summarizes the changes in each component of accumulated other comprehensive income (“AOCI”), net of tax (in thousands):
 
 
 
Foreign Currency Translation
 
 
AOCI
 
Balance at September 30, 2015
  $ 397     $ 397  
Quarter ended September 30, 2015:
               
Unrealized loss arising during the period
    (1,847 )     (1,847 )
Balance at December 31, 2015
  $ (1,450 )   $ (1,450 )
 
 
 
Foreign Currency Translation
 
 
AOCI
 
Balance at September 30, 2014
  $ --     $ --  
Quarter ended September 30, 2014:
               
Unrealized loss arising during the period
    (250 )     (250 )
Balance at December 31, 2014
  $ (250 )   $ (250 )
 
 
 
Foreign Currency Translation
 
 
AOCI
 
Balance at March 31, 2015
  $ (234 )   $ (234 )
Nine months ended December 31, 2015:
               
Unrealized loss arising during the period
    (1,216 )     (1,216 )
Balance at December 31, 2015
  $ (1,450 )   $ (1,450 )
 
 
 
Foreign Currency Translation
 
 
AOCI
 
Balance at March 31, 2014
  $ --     $ --  
Nine months ended December 31, 2014:
               
Unrealized gain arising during the period
    (250 )     (250 )
Balance at December 31, 2014
  $ (250 )   $ (250 )
v3.3.1.900
Note 9 - Segment Information
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
Note
9
-
Segment Information
 
We have four reporting segments: Biological Indicators, Instruments, Continuous Monitoring and Cold Chain. The following tables set forth our segment information (in thousands):
 
 
 
Three Months Ended December 31, 2015
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
  $ 7,819     $ 8,260     $ 2,595     $ 1,239     $ 19,913  
                                         
Gross profit
  $ 4,869     $ 5,511     $ 1,254     $ 575     $ 12,209  
Selling expenses
    505       784       132       96       1,517  
    $ 4,364     $ 4,727     $ 1,122     $ 479       10,692  
Reconciling items
(1)
                                    (7,241 )
Earnings before income taxes
                                  $ 3,451  
 
 
 
Three Months Ended December 31, 2014
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
  $ 6,964     $ 8,216     $ 2,650     $ --     $ 17,830  
                                         
Gross profit
  $ 4,194     $ 5,412     $ 1,446     $ --     $ 11,052  
Selling expenses
    365       919       488       --       1,772  
    $ 3,829     $ 4,493     $ 958     $ --       9,280  
Reconciling items
(1)
                                    (5,567 )
Earnings before income taxes
                                  $ 3,713  
 
 
 
Nine Months Ended December 31, 2015
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
  $ 23,537     $ 25,819     $ 7,412     $ 3,079     $ 59,847  
                                         
Gross profit
  $ 15,157     $ 16,571     $ 3,246     $ 1,443     $ 36,417  
Selling expenses
    1,372       2,975       1,098       159       5,604  
    $ 13,785     $ 13,596     $ 2,148     $ 1,284       30,813  
Reconciling items
(1)
                                    (21,043 )
Earnings before income taxes
                                  $ 9,770  
 
 
 
Nine Months Ended December 31, 2014
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
  $ 19,822     $ 24,966     $ 7,982     $ --     $ 52,770  
                                         
Gross profit
  $ 12,029     $ 15,794     $ 4,057     $ --     $ 31,880  
Selling expenses
    766       3,093       1,318       --       5,177  
    $ 11,263     $ 12,701     $ 2,739     $ --       26,703  
Reconciling items
(1)
                                    (15,354 )
Earnings before income taxes
                                  $ 11,349  
 
(1)
Reconciling items include general and administrative, research and development, and other expenses.
 
 
 
 
December 31, 2015
 
 
March 31,
201
5
 
Total assets
               
Biological Indicators
  $ 54,285     $ 36,304  
Instruments
    50,436       44,401  
Continuous Monitoring
    25,965       31,558  
Cold Chain
    18,182       --  
Corporate and administrative
    6,813       5,057  
    $ 155,681     $ 117,320  
 
All long-lived assets are located in the United States except for $6,470,000 and $16,839,000 which are associated with our French and Canadian subsidiaries, respectively.
 
Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows (in thousands):
 
 
 
Three
M
onths
E
nded
December 31
,
 
 
Nine Months Ended
December 31,
 
 
 
201
5
 
 
2014
 
 
2015
 
 
2014
 
Net revenues from unaffiliated customers:
                               
United States
  $ 12,787     $ 11,423     $ 37,510     $ 29,612  
Foreign
    7,126       6,407       22,337       23,158  
    $ 19,913     $ 17,830     $ 59,847     $ 52,770  
 
No foreign country exceeds 10 percent of total revenues.
v3.3.1.900
Note 10 - Income Taxes
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Income Tax Disclosure [Text Block]
Note
10
Income Taxes
 
For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year to date pre-tax income. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, settlement with taxing authorities and foreign currency fluctuations.
 
Our effective income tax rate was 31.6 and 35.3 percent for the three months ended December 31, 2015 and 2014, respectively and 34.3 and 35.3 percent for the nine months ended December 31, 2015 and 2014, respectively. The effective tax rate for the three and nine months ended December 31, 2015 differed from the statutory federal rate of 35 percent primarily as a result of the impact of state income taxes, domestic manufacturing deductions, research and development tax credits and certain discrete period items. We anticipate that our effective tax rate for the year ending March 31, 2016 will approximate 34 to 37 percent.
v3.3.1.900
Note 11 - Subsequent Event
9 Months Ended
Dec. 31, 2015
Notes to Financial Statements  
Subsequent Events [Text Block]
Note
11
- Subsequent Event
 
In January 2016, our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on March 15, 2016, to shareholders of record at the close of business on February 29, 2016.
v3.3.1.900
Significant Accounting Policies (Policies)
9 Months Ended
Dec. 31, 2015
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
 
The accompanying condensed consolidated balance sheet as of March 31, 2015, has been derived from audited consolidated financial statements. The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as our annual audited consolidated financial statements and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. In the opinion of management, such unaudited information includes all adjustments (consisting only of normal recurring accruals) necessary for a fair presentation of this interim information. Operating results and cash flows for interim periods are not necessarily indicative of results that can be expected for the entire year. The information included in this report should be read in conjunction with our audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended March 31, 2015.
 
The summary of our significant accounting policies is incorporated by reference to our Annual Report on Form 10-K for the year ended March 31, 2015.
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Issued Accounting Pronouncements
 
In May 2014, the Financial Accounting Standards Board (“FASB”) and International Accounting Standards Board “(IASB”) issued a jointly converged standard on the recognition of revenue from contracts with customers. The issued guidance converges the criteria for reporting revenues, as well as requiring disclosures sufficient to describe the nature, amount, timing and uncertainty of revenues and cash flows arising from these contracts. Companies can transition to the standard either retrospectively or as a cumulative effective adjustment as of the date of adoption. The new standard is effective for our fiscal year (and interim periods within that year) ending March 31, 2019. We are evaluating the impact of this standard on our condensed consolidated financial statements and disclosures.
 
In November 2015, the FASB issued new requirements for the presentation of deferred tax assets and liabilities, requiring noncurrent classification for all deferred tax assets and liabilities on the condensed consolidated balance sheets. The requirements of the new standard are effective for our fiscal year (and interim periods within that year) ending March 31, 2018. We do not expect this guidance to have a material impact on our results of operations or financial position.
v3.3.1.900
Note 2 - Acquisitions and Dispositions (Tables)
9 Months Ended
Dec. 31, 2015
Notes Tables  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
Cash consideration
  $ 8,748  
Holdback payment liability
    637  
Contingent consideration liability
    9,541  
Aggregate consideration
  $ 18,926  
         
Accounts receivable, net
  $ 925  
Inventories, net
    310  
Property, plant and equipment, net
    530  
Intangibles, net
    5,869  
Goodwill
    12,529  
Accounts payable
    (470 )
Accrued liabilities
    (767 )
Total purchase price allocation
  $ 18,926  
Cash consideration
  $ 10,322  
Holdback payment liability
    1,000  
Aggregate consideration
  $ 11,322  
         
Cash
  $ 20  
Accounts receivable, net
    285  
Inventories, net
    85  
Property, plant and equipment, net
    229  
Intangibles, net
    4,454  
Goodwill
    7,962  
Accrued liabilities
    (100 )
Unearned revenues
    (1,613 )
Total purchase price allocation
  $ 11,322  
Business Acquisition, Pro Forma Information [Table Text Block]
 
 
Three
Months E
nded
December 31
,
 
 
Nine
Months E
nded
December 31
,
 
 
 
201
5
 
 
201
4
 
 
201
5
 
 
201
4
 
Revenues
  $ 19,913     $ 18,592     $ 61,687     $ 55,057  
Net income
    2,361       2,493       6,721       7,615  
Net Income per common share:
                               
Basic
  $ 0.65     $ 0.71     $ 1.87     $ 2.17  
Diluted
    0.63       0.68       1.80       2.09  
 
 
Three
Months E
nded
December 31
,
 
 
Nine
Months E
nded
December 31
,
 
 
 
201
5
 
 
201
4
 
 
201
5
 
 
201
4
 
Revenues
  $ 19,913     $ 18,910     $ 61,241     $ 56,009  
Net income
    2,361       2,553       6,713       7,793  
Net Income per common share:
                               
Basic
  $ 0.65     $ 0.72     $ 1.87     $ 2.22  
Diluted
    0.63       0.70       1.80       2.14  
v3.3.1.900
Note 3 - Inventories (Tables)
9 Months Ended
Dec. 31, 2015
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
 
 
December 31, 2015
 
 
March 31,
2015
 
Raw materials
  $ 9,282     $ 10,366  
Work-in-process
    549       530  
Finished goods
    5,383       1,913  
Less: reserve
    (498 )     (389 )
    $ 14,716     $ 12,420  
v3.3.1.900
Note 4 - Long-term Debt (Tables)
9 Months Ended
Dec. 31, 2015
Notes Tables  
Schedule of Debt [Table Text Block]
 
 
December 31, 2015
 
 
March 31,
201
5
 
Line of credit (2.42% at December 31, 2015)
  $ 28,500     $ 13,500  
Term loan (2.42% at December 31, 2015)
    18,500       12,750  
Less: current portion
    (3,000 )     (3,000 )
Long-term portion
  $ 44,000     $ 23,250  
Schedule of Maturities of Long-term Debt [Table Text Block]
Year E
nding March 31,
 
 
 
 
2016
  $ 750  
2017
    3,000  
2018
    3,000  
2019
    3,000  
2020
    3,000  
Thereafter
    34,250  
    $ 47,000  
v3.3.1.900
Note 5 - Stock-based Compensation (Tables)
9 Months Ended
Dec. 31, 2015
Notes Tables  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
 
 
Three Months E
nded
December 31
,
 
 
Nine Months E
nded
December 31
,
 
 
 
2015
 
 
2014
 
 
2015
 
 
2014
 
Total cost of stock-based compensation charged against
income before income taxes
  $ 344     $ 260     $ 1,001     $ 776  
Amount of income tax benefit recognized in earnings
    109       92       343       274  
Amount charged against net income
  $ 235     $ 168     $ 658     $ 502  
Impact on net income per common share:
                               
Basic
  $ 0.07     $ 0.05     $ 0.18     $ 0.14  
Diluted
    0.06       0.05     $ 0.18       0.14  
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
 
 
Number of
Shares
 
 
Weighted-
A
verage Exercise Price per Share
 
 
Weighted-
A
verage Remaining Contractual Term
 
 
Aggregate Intrinsic Value (000s)
 
Outstanding at March 31, 2015
    437,248     $ 55.81       4.9     $ 9,445  
Stock options granted
    183,550       72.87       6.9          
Stock options forfeited
    (12,384 )     76.89       7.2          
Stock options expired
    --       --                  
Stock options exercised
    (72,803 )     39.98                  
Outstanding at December 31, 2015
    535,611       63.32       5.3       19,412  
                                 
Exercisable at December 31, 2015
    173,949       41.4       3.6       10,107  
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
 
 
Number of
Shares
 
 
Weighted-
A
verage
Grant-Date
Fair Value
 
Unvested at March 31, 2015
    274,038     $ 18.42  
Stock options granted
    183,550       18.77  
Stock options forfeited
    (12,384 )     19.53  
Stock options vested
    (83,542 )     14.56  
Unvested at December 31, 2015
    361,662       19.43  
v3.3.1.900
Note 6 - Net Income Per Share (Tables)
9 Months Ended
Dec. 31, 2015
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
 
 
Three
M
onths
E
nded
December 31
,
 
 
Nine
M
onths
E
nded
December 31
,
 
 
 
2015
 
 
201
4
 
 
2015
 
 
2014
 
Net income available for shareholders
  $ 2,361     $ 2,403     $ 6,419     $ 7,344  
Weighted average outstanding shares of common stock
    3,614       3,532       3,596       3,513  
Dilutive effect of stock options
    141       122       133       136  
Common stock and equivalents
    3,755       3,654       3,729       3,649  
                                 
Net income per share:
                               
Basic
  $ 0.65     $ 0.68     $ 1.79     $ 2.09  
Diluted
    0.63       0.66       1.72       2.01  
v3.3.1.900
Note 8 - Comprehensive Income (Tables)
9 Months Ended
Dec. 31, 2015
Notes Tables  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
 
 
Foreign Currency Translation
 
 
AOCI
 
Balance at September 30, 2015
  $ 397     $ 397  
Quarter ended September 30, 2015:
               
Unrealized loss arising during the period
    (1,847 )     (1,847 )
Balance at December 31, 2015
  $ (1,450 )   $ (1,450 )
 
 
Foreign Currency Translation
 
 
AOCI
 
Balance at September 30, 2014
  $ --     $ --  
Quarter ended September 30, 2014:
               
Unrealized loss arising during the period
    (250 )     (250 )
Balance at December 31, 2014
  $ (250 )   $ (250 )
 
 
Foreign Currency Translation
 
 
AOCI
 
Balance at March 31, 2015
  $ (234 )   $ (234 )
Nine months ended December 31, 2015:
               
Unrealized loss arising during the period
    (1,216 )     (1,216 )
Balance at December 31, 2015
  $ (1,450 )   $ (1,450 )
 
 
Foreign Currency Translation
 
 
AOCI
 
Balance at March 31, 2014
  $ --     $ --  
Nine months ended December 31, 2014:
               
Unrealized gain arising during the period
    (250 )     (250 )
Balance at December 31, 2014
  $ (250 )   $ (250 )
v3.3.1.900
Note 9 - Segment Information (Tables)
9 Months Ended
Dec. 31, 2015
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Three Months Ended December 31, 2015
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
  $ 7,819     $ 8,260     $ 2,595     $ 1,239     $ 19,913  
                                         
Gross profit
  $ 4,869     $ 5,511     $ 1,254     $ 575     $ 12,209  
Selling expenses
    505       784       132       96       1,517  
    $ 4,364     $ 4,727     $ 1,122     $ 479       10,692  
Reconciling items
(1)
                                    (7,241 )
Earnings before income taxes
                                  $ 3,451  
 
 
Three Months Ended December 31, 2014
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
  $ 6,964     $ 8,216     $ 2,650     $ --     $ 17,830  
                                         
Gross profit
  $ 4,194     $ 5,412     $ 1,446     $ --     $ 11,052  
Selling expenses
    365       919       488       --       1,772  
    $ 3,829     $ 4,493     $ 958     $ --       9,280  
Reconciling items
(1)
                                    (5,567 )
Earnings before income taxes
                                  $ 3,713  
 
 
Nine Months Ended December 31, 2015
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
  $ 23,537     $ 25,819     $ 7,412     $ 3,079     $ 59,847  
                                         
Gross profit
  $ 15,157     $ 16,571     $ 3,246     $ 1,443     $ 36,417  
Selling expenses
    1,372       2,975       1,098       159       5,604  
    $ 13,785     $ 13,596     $ 2,148     $ 1,284       30,813  
Reconciling items
(1)
                                    (21,043 )
Earnings before income taxes
                                  $ 9,770  
 
 
Nine Months Ended December 31, 2014
 
 
 
Biological Indicators
 
 
Instruments
 
 
Continuous Monitoring
 
 
Cold Chain
 
 
Total
 
Revenues
  $ 19,822     $ 24,966     $ 7,982     $ --     $ 52,770  
                                         
Gross profit
  $ 12,029     $ 15,794     $ 4,057     $ --     $ 31,880  
Selling expenses
    766       3,093       1,318       --       5,177  
    $ 11,263     $ 12,701     $ 2,739     $ --       26,703  
Reconciling items
(1)
                                    (15,354 )
Earnings before income taxes
                                  $ 11,349  
Reconciliation of Assets from Segment to Consolidated [Table Text Block]
 
 
December 31, 2015
 
 
March 31,
201
5
 
Total assets
               
Biological Indicators
  $ 54,285     $ 36,304  
Instruments
    50,436       44,401  
Continuous Monitoring
    25,965       31,558  
Cold Chain
    18,182       --  
Corporate and administrative
    6,813       5,057  
    $ 155,681     $ 117,320  
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
 
 
Three
M
onths
E
nded
December 31
,
 
 
Nine Months Ended
December 31,
 
 
 
201
5
 
 
2014
 
 
2015
 
 
2014
 
Net revenues from unaffiliated customers:
                               
United States
  $ 12,787     $ 11,423     $ 37,510     $ 29,612  
Foreign
    7,126       6,407       22,337       23,158  
    $ 19,913     $ 17,830     $ 59,847     $ 52,770  
v3.3.1.900
Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual)
9 Months Ended
Dec. 31, 2015
Number of Operating Segments 4
Number of Physical Locations in Which Entity is Organized 8
v3.3.1.900
Note 2 - Acquisitions and Dispositions (Details Textual)
1 Months Ended 9 Months Ended
Jul. 31, 2015
Dec. 31, 2015
USD ($)
Sep. 30, 2016
Dec. 31, 2015
CAD
Dec. 31, 2015
USD ($)
Jul. 06, 2015
CAD
Jul. 06, 2015
USD ($)
Mar. 31, 2015
USD ($)
Infitrak Acquisition [Member] | Minimum [Member] | Contingent Consideration Year 1 [Member]                
Business Combination, Contingent Consideration, Sliding Scale of Growth       30.00% 30.00% 30.00% 30.00%  
Infitrak Acquisition [Member] | Minimum [Member] | Contingent Consideration Year 2 [Member]                
Business Combination, Contingent Consideration, Sliding Scale of Growth       15.00% 15.00% 15.00% 15.00%  
Infitrak Acquisition [Member] | Maximum [Member] | Contingent Consideration Year 1 [Member]                
Business Combination, Contingent Consideration, Sliding Scale of Growth       70.00% 70.00% 70.00% 70.00%  
Infitrak Acquisition [Member] | Maximum [Member] | Contingent Consideration Year 2 [Member]                
Business Combination, Contingent Consideration, Sliding Scale of Growth       75.00% 75.00% 75.00% 75.00%  
Infitrak Acquisition [Member] | Scenario, Forecast [Member]                
Business Combination, Contingent Consideration, Payment Installments     2          
Infitrak Acquisition [Member]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low         $ 0 CAD 0    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High         10,800,000 CAD 15,000,000    
Business Combination, Contingent Consideration, Liability       CAD 9,541,000 8,700,000   $ 9,541,000  
Business Acquisition, Earn Out Period for Determination of Contingent Consideration 2 years              
Payments to Acquire Businesses, Net of Cash Acquired   $ 32,740,000            
Business Combination, Contingent Consideration, Liability         $ 4,327,000     $ 812,000
v3.3.1.900
Note 2 - Acquisitions and Dispositions - Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Aug. 06, 2015
Jul. 06, 2015
Infitrak Acquisition [Member]    
Cash consideration   $ 8,748
Holdback payment liability   637
Contingent consideration liability   9,541
Aggregate consideration   18,926
Accounts receivable, net   925
Inventories, net   310
Property, plant and equipment, net   530
Intangibles, net   5,869
Goodwill   12,529
Accounts payable   470
Accrued liabilities   767
Total purchase price allocation   $ 18,926
North Bay Acquisition [Member]    
Cash consideration $ 10,322  
Holdback payment liability 1,000  
Aggregate consideration 11,322  
Accounts receivable, net 285  
Inventories, net 85  
Property, plant and equipment, net 229  
Intangibles, net 4,454  
Goodwill 7,962  
Accrued liabilities 100  
Total purchase price allocation 11,322  
Cash 20  
Unearned revenues $ 1,613  
v3.3.1.900
Note 2 - Acquisitions and Dispositions - Pro Forma Effects (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Infitrak Acquisition [Member]        
Revenues $ 19,913 $ 18,592 $ 61,687 $ 55,057
Net income $ 2,361 $ 2,493 $ 6,721 $ 7,615
Net Income per common share:        
Basic (in dollars per share) $ 0.65 $ 0.71 $ 1.87 $ 2.17
Diluted (in dollars per share) $ 0.63 $ 0.68 $ 1.80 $ 2.09
Revenues $ 19,913 $ 18,592 $ 61,687 $ 55,057
Net income 2,361 2,493 6,721 7,615
North Bay Acquisition [Member]        
Revenues 19,913 18,910 61,241 56,009
Net income $ 2,361 $ 2,553 $ 6,713 $ 7,793
Net Income per common share:        
Basic (in dollars per share) $ 0.65 $ 0.72 $ 1.87 $ 2.22
Diluted (in dollars per share) $ 0.63 $ 0.70 $ 1.80 $ 2.14
Revenues $ 19,913 $ 18,910 $ 61,241 $ 56,009
Net income $ 2,361 $ 2,553 $ 6,713 $ 7,793
v3.3.1.900
Note 3 - Inventories - Summary of Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2015
Mar. 31, 2015
Raw materials $ 9,282 $ 10,366
Work-in-process 549 530
Finished goods 5,383 1,913
Less: reserve (498) (389)
Total $ 14,716 $ 12,420
v3.3.1.900
Note 4 - Long-term Debt (Details Textual)
1 Months Ended
Jul. 02, 2015
USD ($)
Jan. 31, 2016
USD ($)
Feb. 29, 2012
USD ($)
Apr. 30, 2014
USD ($)
Line of Credit [Member] | Infitrak Acquisition [Member]        
Proceeds from Lines of Credit $ 1,000,000      
Line of Credit [Member] | Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member]        
Debt Instrument, Basis Spread on Variable Rate 1.50%      
Line of Credit [Member] | Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member]        
Debt Instrument, Basis Spread on Variable Rate 2.25%      
Line of Credit [Member] | Debt Instrument, Variable Rate Base CBFR Using One Month LIBOR [Member]        
Debt Instrument, Basis Spread on Variable Rate Used to Calculate Commercial Bank Floating Rate 0.50%      
Line of Credit [Member] | Through March 31, 2016 [Member]        
Debt Instrument Covenant, Ratio of Funded Debt to Consolidated EBITDA 3.25      
Line of Credit [Member] | After March 31, 2016 [Member]        
Debt Instrument Covenant, Ratio of Funded Debt to Consolidated EBITDA 3      
Line of Credit [Member]        
Debt Instrument, Term     3 years  
Line of Credit Facility, Maximum Borrowing Capacity $ 50,000,000      
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.25%      
Debt Instrument Covenant, Fixed Charge Coverage Ratio 1.35      
Revolving Credit Facility [Member]        
Line of Credit Facility, Maximum Borrowing Capacity     $ 20,000,000  
Letter of Credit [Member]        
Line of Credit Facility, Maximum Borrowing Capacity     $ 1,000,000  
Initial Term Loan [Member]        
Long-term Debt, Gross       $ 15,000,000
Term Loan [Member] | Infitrak Acquisition [Member]        
Proceeds from Issuance of Long-term Debt $ 8,000,000      
Term Loan [Member] | Maximum [Member]        
Debt Instrument, Basis Spread on Variable Rate 2.25%      
Term Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]        
Debt Instrument, Basis Spread on Variable Rate 1.50%      
Term Loan [Member] | Subsequent Event [Member]        
Repayments of Long-term Debt   $ 750,000    
Term Loan [Member]        
Long-term Debt, Gross $ 20,000,000      
Repayments of Long-term Debt $ 12,000,000      
Line of Credit Facility, Periodic Payment, Number of Quarterly Payments 20      
Line of Credit Facility, Periodic Payment, Principal $ 750,000      
v3.3.1.900
Note 4 - Long-Term Debt - Long-term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2015
Mar. 31, 2015
Line of Credit [Member]    
Long-term debt $ 28,500 $ 13,500
Term Loan [Member]    
Long-term debt 18,500 12,750
Long-term debt 47,000  
Less: current portion (3,000) (3,000)
Long-term portion $ 44,000 $ 23,250
v3.3.1.900
Note 4 - Long-Term Debt - Long-term Debt (Details) (Parentheticals)
Dec. 31, 2015
Line of Credit [Member]  
Line of credit, interest rate at end of period 2.42%
Term Loan [Member]  
Term loan, interest rate at end of period 2.42%
v3.3.1.900
Note 4 - Long-Term Debt - Future Contractual Maturities of Debt (Details)
$ in Thousands
Dec. 31, 2015
USD ($)
2016 $ 750
2017 3,000
2018 3,000
2019 3,000
2020 3,000
Thereafter 34,250
Total $ 47,000
v3.3.1.900
Note 5 - Stock-based Compensation (Details Textual) - USD ($)
9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value $ 4,263,767 $ 2,003,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized $ 4,966,245  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 914,110  
v3.3.1.900
Note 5 - Stock-Based Compensation - Allocation of Share-Based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Total cost of stock-based compensation charged against income before income taxes $ 344 $ 260 $ 1,001 $ 776
Amount of income tax benefit recognized in earnings 109 92 343 274
Amount charged against net income $ 235 $ 168 $ 658 $ 502
Basic (in dollars per share) $ 0.07 $ 0.05 $ 0.18 $ 0.14
Diluted (in dollars per share) $ 0.06 $ 0.05 $ 0.18 $ 0.14
v3.3.1.900
Note 5 - Stock-Based Compensation - Summary of Option Activity (Details)
$ in Thousands
9 Months Ended
Dec. 31, 2015
USD ($)
$ / shares
shares
Outstanding (in shares) | shares 437,248
Weighted-Average Exercise Price per Share (in dollars per share) | $ / shares $ 55.81
Weighted-Average Remaining Contractual Term 4 years 328 days
Aggregate Intrinsice Value | $ $ 9,445
Stock options granted (in shares) | shares 183,550
Stock options granted (in dollars per share) | $ / shares $ 72.87
Stock options granted 6 years 328 days
Stock options forfeited (in shares) | shares (12,384)
Stock options forfeited (in dollars per share) | $ / shares $ 76.89
Stock options forfeited 7 years 73 days
Stock options exercised (in shares) | shares (72,803)
Stock options exercised (in dollars per share) | $ / shares $ 39.98
Outstanding (in shares) | shares 535,611
Weighted-Average Exercise Price per Share (in dollars per share) | $ / shares $ 63.32
Aggregate Intrinsice Value | $ $ 19,412
Exercisable (in shares) | shares 173,949
Weighted-Average Exercise Price per Share, Exercisable (in dollars per share) | $ / shares $ 41.40
Weighted-Average Remaining Contractual Term, Exercisable 3 years 219 days
Aggregate Intrinsice Value, Exercisable | $ $ 10,107
v3.3.1.900
Note 5 - Stock-Based Compensation - Summary of Unvested Options (Details)
9 Months Ended
Dec. 31, 2015
$ / shares
shares
Unvested (in shares) | shares 274,038
Unvested (in dollars per share) | $ / shares $ 18.42
Stock options granted (in shares) | shares 183,550
Stock options granted (in dollars per share) | $ / shares $ 18.77
Stock options forfeited (in shares) | shares (12,384)
Stock options forfeited (in dollars per share) | $ / shares $ 19.53
Stock options vested (in shares) | shares (83,542)
Stock options vested (in dollars per share) | $ / shares $ 14.56
Unvested (in shares) | shares 361,662
Unvested (in dollars per share) | $ / shares $ 19.43
v3.3.1.900
Note 6 - Net Income Per Share (Details Textual) - shares
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Employee Stock Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 91,000 155,000 136,000 173,000
v3.3.1.900
Note 6 - Net Income Per Share - Computation of Net Income per Share - Basic & Diluted (Details) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Net income available for shareholders $ 2,361 $ 2,403 $ 6,419 $ 7,344
Weighted average outstanding shares of common stock (in shares) 3,614 3,532 3,596 3,513
Dilutive effect of stock options (in shares) 141 122 133 136
Common stock and equivalents (in shares) 3,755 3,654 3,729 3,649
Basic (in dollars per share) $ 0.65 $ 0.68 $ 1.79 $ 2.09
Diluted (in dollars per share) $ 0.63 $ 0.66 $ 1.72 $ 2.01
v3.3.1.900
Note 7 - Commitments and Contingencies (Details Textual)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 15, 2014
CAD
Nov. 06, 2013
USD ($)
Oct. 31, 2015
USD ($)
Jul. 31, 2015
Nov. 30, 2014
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2016
Dec. 31, 2015
CAD
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jul. 06, 2015
CAD
Jul. 06, 2015
USD ($)
Mar. 31, 2015
USD ($)
Oct. 15, 2014
USD ($)
Mar. 31, 2014
USD ($)
Mar. 31, 2013
USD ($)
May. 15, 2012
USD ($)
Amega Scientific Corporation [Member] | Minimum [Member]                                    
Business Acquisition, Revenue Required in Three Years Subsequent to Acquisition for Payment of Contingent Consideration   $ 31,625,000                                
Amega Scientific Corporation [Member] | Maximum [Member]                                    
Business Acquisition, Revenue Required in Three Years Subsequent to Acquisition for Payment of Contingent Consideration   $ 43,500,000                                
Amega Scientific Corporation [Member]                                    
Business Acquisition, Earn Out Period for Determination of Contingent Consideration   3 years                                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low                                   $ 0
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High                                   $ 10,000,000
Business Acquisition, Agreement Holdback, Payment Period from Effective Date Less Any Losses Incurred by Buyer Payable To Seller   3 years                                
Business Combination, Contingent Consideration, Liability   $ 500,000                                
PCD [Member] | Minimum [Member]                                    
Business Acquisition, Revenue Required in Three Years Subsequent to Acquisition for Payment of Contingent Consideration                             $ 9,900,000      
PCD [Member] | Maximum [Member]                                    
Business Acquisition, Revenue Required in Three Years Subsequent to Acquisition for Payment of Contingent Consideration                             12,600,000      
PCD [Member]                                    
Business Acquisition, Earn Out Period for Determination of Contingent Consideration 3 years                                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low CAD 0                           0      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High CAD 15,000,000                           1,500,000      
Business Combination, Contingent Consideration, Liability                             $ 300,000      
Business Combination, Payment of Contingent Consideration           $ 150,000                        
Infitrak Acquisition [Member] | Minimum [Member] | Contingent Consideration Year 1 [Member]                                    
Business Combination, Contingent Consideration, Sliding Scale of Growth                 30.00% 30.00%   30.00% 30.00%          
Infitrak Acquisition [Member] | Minimum [Member] | Contingent Consideration Year 2 [Member]                                    
Business Combination, Contingent Consideration, Sliding Scale of Growth                 15.00% 15.00%   15.00% 15.00%          
Infitrak Acquisition [Member] | Maximum [Member] | Contingent Consideration Year 1 [Member]                                    
Business Combination, Contingent Consideration, Sliding Scale of Growth                 70.00% 70.00%   70.00% 70.00%          
Infitrak Acquisition [Member] | Maximum [Member] | Contingent Consideration Year 2 [Member]                                    
Business Combination, Contingent Consideration, Sliding Scale of Growth                 75.00% 75.00%   75.00% 75.00%          
Infitrak Acquisition [Member] | Scenario, Forecast [Member]                                    
Business Combination, Contingent Consideration, Payment Installments               2                    
Infitrak Acquisition [Member]                                    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low                   $ 0   CAD 0            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High                   10,800,000   CAD 15,000,000            
Business Combination, Contingent Consideration, Liability                 CAD 9,541,000 8,700,000     $ 9,541,000          
Minimum [Member] | Anthony Amato and Amega Scientific Corporation [Member] | Lost Future Earnings and Punitive Damages [Member]                                    
Loss Contingency, Damages Sought, Value         $ 500,000                          
Anthony Amato and Amega Scientific Corporation [Member] | Improperly with holding Amount [Member]                                    
Loss Contingency, Damages Sought, Value         704,065.86                          
Anthony Amato and Amega Scientific Corporation [Member] | Subsequent Event [Member] | General and Administrative Expense [Member]                                    
Gain (Loss) Related to Litigation Settlement             $ 1,709,000                      
Anthony Amato and Amega Scientific Corporation [Member] | Subsequent Event [Member]                                    
Payments for Legal Settlements     $ 3,165,000                              
Litigation Settlement, Insurance Covered     $ 415,000                              
Anthony Amato and Amega Scientific Corporation [Member]                                    
Loss Contingency, Damages Sought, Value         10,000,000                          
Loss Contingency Expected Immeditate Accelaration of Stock Option Granted         $ 10,000                          
Loss Contingency Accrual                     $ 1,041,000              
General and Administrative Expense [Member] | Other Accrued Expenses [Member]                                    
Sales and Excise Tax Payable                           $ 460,000   $ 1,408,000 $ 100,000  
Business Acquisition, Earn Out Period for Determination of Contingent Consideration       2 years                            
Business Combination, Contingent Consideration, Liability                   $ 4,327,000       $ 812,000        
Number of States Due Sales Tax                                 1  
v3.3.1.900
Note 8 - Comprehensive Income - Changes in Accumulated Other Comprehensive Income (Details) - USD ($)
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]        
Balance $ 397,000 $ 0 $ (234,000) $ 0
Unrealized loss arising during the period (1,847,000) (250,000) (1,216,000) (250,000)
Balance (1,450,000) 0 (1,450,000) 0
Balance 397,000 0 (234,000) 0
Unrealized loss arising during the period (1,847,000) (250,000) (1,216,000) (250,000)
Balance $ (1,450,000) $ 0 $ (1,450,000) $ 0
v3.3.1.900
Note 9 - Segment Information (Details Textual)
Dec. 31, 2015
USD ($)
FRANCE  
Long-Lived Assets $ 6,470,000
CANADA  
Long-Lived Assets $ 16,839,000
v3.3.1.900
Note 9 - Segment Information - Operating Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Biological Indicators [Member]        
Revenues $ 7,819 $ 6,964 $ 23,537 $ 19,822
Gross profit 4,869 4,194 15,157 12,029
Selling expenses 505 365 1,372 766
Gross profit after deducting selling expense and impairment of intangible asset $ 4,364 $ 3,829 $ 13,785 $ 11,263
Reconciling items (1) [1] [1]
Earnings before income taxes
Instruments [Member]        
Revenues $ 8,260 $ 8,216 $ 25,819 $ 24,966
Gross profit 5,511 5,412 16,571 15,794
Selling expenses 784 919 2,975 3,093
Gross profit after deducting selling expense and impairment of intangible asset $ 4,727 $ 4,493 $ 13,596 $ 12,701
Reconciling items (1) [1] [1]
Earnings before income taxes
Continuous Monitoring [Member]        
Revenues $ 2,595 $ 2,650 $ 7,412 $ 7,982
Gross profit 1,254 1,446 3,246 4,057
Selling expenses 132 488 1,098 1,318
Gross profit after deducting selling expense and impairment of intangible asset $ 1,122 $ 958 $ 2,148 $ 2,739
Reconciling items (1) [1] [1]
Earnings before income taxes
Cold Chain [member]        
Revenues $ 1,239   $ 3,079  
Gross profit 575   1,443  
Selling expenses 96   159  
Gross profit after deducting selling expense and impairment of intangible asset $ 479   $ 1,284  
Reconciling items (1) [1] [1]
Earnings before income taxes
Revenues $ 19,913 $ 17,830 $ 59,847 $ 52,770
Gross profit 12,209 11,052 36,417 31,880
Selling expenses 1,517 1,772 5,604 5,177
Gross profit after deducting selling expense and impairment of intangible asset 10,692 9,280 30,813 26,703
Reconciling items (1) (7,241) [1] (5,567) [1] (21,043) (15,354)
Earnings before income taxes $ 3,451 $ 3,713 $ 9,770 $ 11,349
[1] Reconciling items include general and administrative, research and development, and other expenses.
v3.3.1.900
Note 9 - Segment Information - Operating Segment Asset Reconciliation (Details) - USD ($)
$ in Thousands
Dec. 31, 2015
Mar. 31, 2015
Biological Indicators [Member]    
Assets $ 54,285 $ 36,304
Instruments [Member]    
Assets 50,436 44,401
Continuous Monitoring [Member]    
Assets 25,965 31,558
Cold Chain [member]    
Assets 18,182  
Corporate Segment [Member]    
Assets 6,813 5,057
Assets $ 155,116 $ 117,320
v3.3.1.900
Note 9 - Segment Information - Revenues from External Customers (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
UNITED STATES        
Revenues $ 12,787 $ 11,423 $ 37,510 $ 29,612
Foreign [Member]        
Revenues 7,126 6,407 22,337 23,158
Revenues $ 19,913 $ 17,830 $ 59,847 $ 52,770
v3.3.1.900
Note 10 - Income Taxes (Details Textual)
3 Months Ended 9 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Minimum [Member] | Scenario, Forecast [Member]        
Effective Income Tax Rate Reconciliation, Percent     34.00%  
Maximum [Member] | Scenario, Forecast [Member]        
Effective Income Tax Rate Reconciliation, Percent     37.00%  
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 35.00%   35.00%  
Effective Income Tax Rate Reconciliation, Percent 31.60% 35.30% 34.30% 35.30%
v3.3.1.900
Note 11 - Subsequent Event (Details Textual)
1 Months Ended
Jan. 31, 2016
$ / shares
Subsequent Event [Member]  
Common Stock, Dividends, Per Share, Declared $ 0.16
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )Q 1$@]SG18X0$   D>   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,V9S4[C,!2%7Z7*%C6N?V 81-D 6T""%_ DMXW5.+9L4\K;8Z> 9JHR
M@ADJG4U^>J[O.L3ODV
M+)G7S4HOB8G9[(0U;D@TI&DJ/:J+\]LUA6!:FEQNA=)[7FGO>]/H9-S UD.[
MTW7J%@O34.N:1YN7U"E;TU'6J\F=#NE&V]R";7HV"MLCKXO.OL)^;=YE=7X*8?=
MA7]+9FP9FA^6?ZPH]__X+#LO<6W[JZ"?S([!^F!C*N?::C/L&]63"ZM?SJV^
M:J6VJD/N3 DLV>7Y.*[K$:66_^7]]M.:5R@3QF6P@-^%)T.U-ZGD.>[
M_]OXO>!P.[%    *P(   L   !?.0Q(OW[CMB PD.MQ-*O>X^NO ZIK XTHO8<4M?'
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M5:MA]VTR0.%11PPBG8DMV]*M?_2I5+[O4KUXCH4H'DY:$X)NBD'W5"";LM!MY2@
MNW+0'25(:B!CS4E"6'.T%L"U<+P6 +9PQ!9 MG#,%H"V<-06P+9PW!8 MW#D
M%D"W<.P6@+=P]%:@MW+T5J"WDO;::+/-T5N!WLK16X'>RM%;@=[*T5N!WLK1
M6X'>RM%;@=[*T5N!WLK1VX#>QM';@-[&T=N WD8Z*T&')1R]#>AM'+T-Z&T<
MO0WH;1R]#>AM'+T-Z&TCM'+T=Z.TCMI+-N=-C-
MT=N!WL[1VX'>SM';@=[.T=N!WL[1V\_T3FTSQO6?/.ZZ;;ITS:?A\%_.&=XI
MOQWBY5-.4V'#F=9Y6BF&T_7B3I^FOH>$;W]>'_X#4$L#!!0    ( )Q 1$@.
M)V[: @,  /0,   0    9&]C4')O<',O87!P+GAM;+V746_:,!#'OXJ5I^Z!
M!@)M*:*16NBT2EV'!.N>C7,$JXF=V@Z"??J=$V"!XJSA87VI<[G?.7?W/R<,
MA6X/)DIFH P'3=9I(O0 C7?>TIALX/N:+2&E^A)=!-Y=2)52@Y4^RQ+.J.%2A-\Y4U++A2&/:P;)T#]V
M* B,/ 66*VXV8;OTJ9H*GRFC"8QPKW!!$PVEUU]CX3.2:4;%QB^OGKEXTS^S
MF1Q3 U7J\$89?4D51+CI0?2]L?#YML$\$\N.EE3$$%5]/][(5E+:9=H++
M-O[M2["SE[&!1ES$$\J5#H
M>2NJ.!7&(YK_QLO *[.#J
MT-/?9Q9NRW:0M[7,N$E _UA,J#+_J11%3KM"]/I>)?M="'(O(O(H#,J1/(ER
M*VQ>M23[U4CB7 @-$<&5E@F/4&81>: )%0S(&4RW"3,U^ ^?^0SFZ@SF^B3S
M(@V0#FF1,6BF>&:+1>2"/.2:"]!N)D#FGKWG7'/+:$*Q\&.N,^EFNL@\B16V
M22I>%[R'CL]2Q"T#*L5'FQNW[Q7Z3HUD;RTK%)M[BCK3V'8W1_
MJ;?L7+LH:9'%C*[K:MJQ79[FQSB:CDDUG]B@9LI=
MW0ENSF#Z9S -5&"5FJ94;4Z?PDX=C,%0GGR"F>V9K:$YTSU]VKN9K[G)57.-
M=D^?]D?,PR%3HP,G4Z,#)U.C ]?\=&MTX)RYFOZXCN9>YXPYK=G'.:?CYDRK
M1MC R=3]]8_?G?LQJ?I2Z3@/GQT5K\>C[X5_ '%B$A)#(&XA\;:PYD.)IZ[_GBSK6L:X[,:MKOT^?ATG
MI7!,6 _/WCKPJ"#<['5M A-NGFT0'2,DB UH'D:QPL3DRGK-,89^31P76[X&
M,[email protected]!SUQ.SJI2""0\_P4O1XM_-U@DE!H 8-!@,I1@7)JE>S
M-;8Q)1GT51D=USS@PDJU4B#OVJ'L,A4[(W@=CG*0??OT]T\/*4.RKG(?5%_5
M-,VHF:2Z.'!!WA=/+^EL#.F&Z;%MH&^MEJ-+]&J+#RXDK6UO?'E._HK-757T#4$L#
M!!0    ( )Q 1$B97)PC$ 8  )PG   3    >&PO=&AE;64O=&AE;64Q+GAM
M;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'
M-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D
M$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%
M/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:C
MTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D
M00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'
MPZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP=M;,[email protected]=90:
MV1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0
MUL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CD
MGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&
MF&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F
M<]%L^P>E1M'V5;SCFED)O816:I^JAS0^
MJ!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$
MKYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"0AMNZ5/U2I77Y:^Y
M*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9
M!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE T%&UL
MK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2
MX]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,
M$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T
M74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT
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ME4+SL+)'"A5/TY")I\@1EJ1J+&7*^40C*D]%1605-+C(K&!#$:C,-P$C!$.$QC
MWK(94PW(1O=ECV*_\D?-UX8XZ \GC4O!_1F-H0/2
MN'D&2T2U?V3<W0YF>X32[>UI((UKI!26?*8GH+?GJUIOC@N.
MG4CK=\"[DF@5C:\V NR@\V9"%[email protected]*8XE+I $FJA1F5J(UTH91@VB@(
MJ@1'U%"N(WI#T^:8TD?SE?PHM[B[$C@?<\T)5# AV-ZIJN[BBI.,-.K(-FHI\=HH_VT*17Q+5<]RIOH*#KMRG\-@MG[HFGU\7W?\\$%O[<$?/WR58Z+YE&98S
M^W?X[\(NK]]/V9O6\]'W] :'9)K:B=Z?:8HG*^T=:^N557_S2F5!WQ@VNL]6
M[QE0D+6$*L+7$I!Y+=P;V72K+?B^HSF+SK<ON;D1]-!J_Y0)% ;W_'!6G9C57@7YKI;U!+ P04    " "<0$1(E]:K
ML28$  !,$   #P   'AL+W=O4I^9^ H0\*"/YQQT/OC9
M@VON5L[=B<>JK/VLF2?;$':ST/92)*[<-E88,IYDE&E^[!#!J:=G?1VC)>3,:39!1A^Z'>
M-")WA>EAMUOK?SS=2$1AUKHMPRUU=O_=>9+*3,IISXB/?;?FP2,P-@B=!WMO
M;O5JGHP3H=O@OM@RF&:A@_F[<>W.UAMB)6)M&Q^6<;C=DY6M;65_QW[3E=^Z
MAW]<8W^[.NARF3>N++NWXHWN)?J"?VZA/@:;#QX,>O5?7(EY,AT3\-YZN[*E
M#;_F27=>FCB2T:NA=-/_P#/7Q5=!]N
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M9.Y09SV*LNF61D6YZ*EW"$*7TP,R=Z#S.$]FTP4^$^VHMBMO?K:Q-Y?1'[email protected]!@Y=V4UOZ6>F8P_+4$_I5.(AWE-A+X__"7(A:2T[K/R-CST(4:BTY
MK;D(D1)1@Q3-BB
MT';%V?Z"NABBT':%MBO.=A:%MBNT77&VLRBT7:'MBK.=RU<*;5=HN^)L9U,?
M>I6A[1EG.[<]R%)$H>T99SN;10>]0MLSSG8VBRX0A;9GG.TMV21N8.+U-ZJ2YTDL9:EJ;O*^!O[X/U!+ P04    " "<0$1(=*H3ZFL"  #A"   &    'AL+W=O
MU%I=5>
MM-=.X@2T@*GMA.W;UP?"&M[N1 FD9%DN3?8]!/IC+:XT?T
MKSI=N?TCYN1 FU_U651RMR ,SN2";XUXH\,W,N:0JH GVG#]&YQN7-#V80F#
M%G^8:]WIZV#NI&BT^0UH-*#)@++_&N+1$$\&F.A,SQ-9!;&U_
MZD7,)-DR @*WZH =P?^XYYHUE']J&]H1-KZC>Q@UYNS&&2BD(WR
M'Z^9!JTX7] M=6A7,O*?L+EFQ1&#;KU#N^!1[*UX:)<\ JL>CUOQT"YHY']U
MC9K$:%:\O*!;]M"N:I3Y*3--[E BJZ.TA%UUI^7!B=XZ85K'M#IU\Q?=\Z)/
M>5GT^$I^8':M.QXT"Z6"R$V )YEJ);\WIDE#+D(-^0CRCE(:GMU73?^I/60_*C;<[]X^8T
M#)>'-.U?3KJM^D_FHL_C+T?3M=4P'G:O:7_I='68B]HF12&RM*WJ\V:WG<]]
MZ79;\S8T]5E_Z9+^K6VK[I\GW9CKXP8VMQ-?Z]?3,)U(=]OT7G>H6WWN:W-.
M.GU\W'R&A[W$*3(G_JKUM6??DPG^V9AOT\$?A\>-F!ATHU^&J8EJ_'C7>]TT
M4TMCS]_71O_K]
M7H.:&GPQ33__35[>^L&TMY)-TE8_EL_Z/']>EU\*L9;Y"W MP'L!T(<%?#>;B6L^\[++;I^]2.
M%7E:(KA$?(F]E2COD73LWPN!#@3.]=E<+\7_UTNG7L[U(CSH)=GB:@Y A(+&0*R@@BDHHB40Z0XD?02*=X1
MY9"%B*P@TC24$4290Y1Q(O(2959')86 K)R,O&>YPY-S'N7ER7D_61%\AIQ<
M&<53.#P%Y\F\/ 7K1Q)2'@+B02PSQ"BBTB$J.5'N)2KYE:NL4"$B'BQ5640!
M@7#E)3A2X45:,TM7!"@AQ&0EI7228:J?E JLKDZ4*_O];2:(BBWN<
MP'4L(*,B;U]/:^9V_Q2$)6!'(9>1&@#7W2"9_ DB6G!M"URWY-.NRO4M<.&27[C 14JSM@),5A!$W!0 KG&!*Y?\R@7N4BQ$&62RI0MQ
MT@77NL"U2W[M OX.HEOWJAL,]R-5+?O4B6,-4
MBN \;B6!,A5W\_"GY2U7;V!M@=RG"BGX0-E!B)S+T=4N\C6S\D\':^8V]7QT
M^W@2):K(^^>J'+G*E7\ECV1I$X.K'BM80.1 N29';G+EGUW6S+)KR(G"VPLK
M2;*@N#4&NBY'[G+ES"_KOLW.D"^S#V7")*[!,6?SMU(1+;B^1>Y;Y??MFEGW
M94 R?-=Y$O)<18ZP:USDQE5^XR(W:28<05A4/*G4N :/HI*N="67KO)+5W*7
M_K+L& .;72N)D3LGZ5I7*26AV
MT?=D6Q&K<(+?'8QJ,4>6?2_$BPT>ZUT46P1@<- V S7#&2I@S"8RA?]..?^7
MM,;E_)+]I^O6T.^I@DJP/UVM6P,;1ZB&AIZ8?A;C TPM.,*#8,K=T>&DM. 7
M2X0X??5CU[MQ]$_NXLD6-J23(9T-2?ZA(9L,VUU^]5QND@*?;9XKR;V7I$Z2AA35E>+;+,&F?A B74&D
MSI]YB%6)WD-XR:V3Q"%%%5:\RY"M&+(E0Q9D\!+BVR2QNX(H'PK?):@F@,&C;;36S.7?N_Z0(OA,[9\J 7D !YOWCZ<
MS*BU35G3U;/AV/5^:KL'?;?TI[G@M=%E?3>E5^O2V^D(W*>N1GOC[JA^U
M]=WK.O]NS(_NX<_CVXIT?="Y/C1=BJS]^-")SO,N4UOYGS'I9\TNT/[^S/Y[
M+[?M_GM6Z\3DWZ_'YM+VEJR\HSYE][SY9AY_Z%&#Z!(>3%[W?[W#O6Y,\0Q9
M>47V<_B\EOWG8_B/(F,8'L#& #8%3'7P@& ,"#X#^/\&\#& +ZT@Q@#A5/ '
M[?W([;,FVVTK\_#J6]:M)[II\:I+TF;VVN&J^\=^0H;6CUT8;OV/+@] X@%A
M R(Q9&\C="+\MC[:"08[$3,KG&$%$IL(%=J'ETG2F22SW0RN0F@T 6[AXDDG=$%RU&^0);KZ-2V=(E;^LB,D\'%
MC"Q 2=SX]X"*)&ZV*: H#?B2G>::.K5='5\:,>5@!44HE4 JP*=C#Z@@P(3EUSI[:[*]S=1T;U#%F'N&NXU,P99%-TC6^A%%!L39:L9]?BJ>WQ"O?X
MD9GZC+]]NQ3J0GM MJG!/9= M!;Z>(14*_'W!R37S(N3D
M^N5\]JW?X(6NSOWM1^T=S+UL!C%3ZW3#\H5UO^&=]IAN$HJT[^DF'>Y//M/O
MMK?LK/_*JO.UK+UWTS2FZ"\-3L8TNNTV6;>#?-'9<7K(]:GIOLIN](=;E.&A
M,;?GI=!T,[7[#U!+ P04    " "<0$1(_BE*WT,"   5!P  &    'AL+W=O
M\8QB=-(DT 0S#-""H;OTBU[$W5N3T(IJZQ6_,
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MB89\ 8LXM]P[TDLKC(\Q.D[T5ZB&QBR^ :LM<,1W
M\@8P _LN7^0=.N,?B)WKEGL'*N2HTE.JI%1@677X(KM;R3MJW#2X%.HQ4VTW
M8]ML!.UNE]!X$Q9_ 5!+ P04    " "<0$1(J@+"YG4$  !Y%0  &    'AL
M+W=O_Y^](I3Q900;F))N45>O@Z+W%SKYE=[M+8+?E?E
MN7U8';ONM_NCK8KV2WVQY_X_3W53%5W_VCROVTMCB\,85)5K#,-X716G
M\VJ[&;_]:+:;^J4K3V?[HPG:EZHJFO]VMJRO#RM8O7WX>7H^=L.']7:SOL4=
M3I4]MZ?Z'#3VZ6'U%>YS2@?)J/C[9*\M>PX&\X]U_6MX^?/PL H'#[:T^VXH
MHNA_7FUNRW(HJ:_YW[G0]SJ'0/[\5OJWL;F]_<>BM7E=_G,Z=,?>;;@*#O:I
M>"F[G_7UNYW;$ T%[NNR'?\&^Y>VJZNWD%50%;^GW]-Y_+U._TG#.4P/P#D 
M;P&W>O0 F@/H/<",+9VWZH^B*[::IKT%[*8;1AOM>W@R%]"4'?6/:\77L
MKNGKZS:CS?IU*$=(=I,$1PG<%.N^<+4&E#7LD(6C5D'.%7'Z>0WDM('&^'AJ
M@_D\WCCQ9HRG,3X%:?$\-6*2))-% YDFRKDH(>/A)'*<1,Q)%JE.)DDT2B(,
M$]4)%QF(\7,GL>,DYDYBU4G,F@MAJ'9<'C,G21)_;B1QC"3<2*).4"Z)C&HC
MX5X]7*2.BY150?K I+P*3-69GNI.%VUDCHV,=T:JVLA8AZ>JTSQC3N\@SC[W
M :&+C9"O.9\2/H '>)>BVI99,\\>59,+S1UD/@  =,[email protected]&905+4QX*2,R
MH8S9E[DH6Z&:R+R8"NX< 1.1[,P3H9/N@4K7).8Q,.*2T?@
M>.R)HWOA[$M@P4PDQM*0SPQV$0F.TCL31QYN7$Z"H*"^
MB\V:-S=)$JJ4@@6@+IMQ<0FI&*D%-RESDV61NNQRX%R-P6<+ 1>;D#%:0>BQ
M':(+/ Q%BW1$S**Y?Y$@TQ,%J>M1$GE  EV"(@A+^@1$@<<8,YU:4H8(/GWD
M4A11&-*W211\Q,QD^A)U=( ^60RZ($42(^\Q>= %(!K1*C7AVB&G&T:A#J=<
MRHC+E@VY&$2)03T-0$$X@]&"(0E"B+PM=G
M^KKL(\D^/0,A3C7T<>HRC033<&$4>?*6149GB%#1AQUHS6ZT*ML\CS=];;"O
M7\[==&UT^WJ[3?R*PXV8\WT']_ET)_A>S'9S*9[M7T7S?#JWP6/==74U7K4]
MU75G>W?AEWY4C[8XW%Y*^]0-CTG_W$PW@]-+5U_>+CIOMZW;_P%02P,$%   
M  @ G$!$2(*H_]2? 0  L0,  !@   !X;"]W;W)K^E-1V2WOGA@UCMNY!<7N# VC_IT6CN/.IZ9@=
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M+K?SOHAG\@VORH%W\,I-)[0E>W3^[email protected](GLYI:2WK^?)9'0NA#^\+%)
M5RHE#H?C UE>:?474$L#!!0    ( )Q 1$BZ'<9,H@$  +$#   8    >&PO
M=V]R:W-H965T&ULC5/+;MLP$/P5@A\0RO(C@2$+B!,4[:% 
MD$-[IJ651(3DJB1EI7\?/F3%-@PD%W%W-3,[RT!5MYT*!E06;>;50H*U 30PT._JXV.Y7 1$!?P2,]BPF
MP?L!\2TDO^H=S8(%D%"YH,#]?-9I34T/!!NE*C!MO#J65#AHES9OKLZW\S&/9_()+XN>M_";FU9H2P[H_,G&
M0VT0'7@3V=V:DLZ_GSF1T+@0WOO8I"N5$H?]Z8',K[3\ %!+ P04    " "<
M0$1(Y,DS!:,!  "Q P  &    'AL+W=O/*NE7%;VGG?;QAS50=:N!OLP80_#5HM?$AMRUQO0=2)
MI!7C67;'M)"&ED6J/=NRP,$K:>#9$C=H+>S'#A2.6[JBQ\*+;#L?"ZPLV,*K
MI0;C)!IBH=G2A]5FMXZ(!'B5,+J3F$3O>\2WF/RNMS2+%D!!Y:."",L!'D&I
M*!0:_YTUOUI&XFE\5/^9I@WN]\+!(ZH_LO9=,)M14D,C!N5?Q6FP"W420HD^#-I31-/U4/Y8K?%^P0AZ'>SP_\06%\(K)- /@M\OSKB&2;/+IJPDSW58-MT=1RI<#!^VKRE
MNMS.!Y[.Y M>%KUHX4G85AI']NC#R:9#;1 ]!!/9S2TE77@_2Z*@\3'\%F([
M7:DI\=@?'\CR2LM/4$L#!!0    ( )Q 1$A#&GJ(H@$  +$#   9    >&PO
M=V]R:W-H965TTN&YP;
MMY3:9@#%[1V.H/V?#HWBSJ>FIW8TP-M(4I*R/'^@B@N=U56LO9BZPLE)H>'%
M$#LIQ
MQ21X/R"^A>1'N\OR8 $D-"XH<+\?OL(QP'P0;E#9^23-9A^I$R8CB'VD5.JYS^E/F
M"^TV@2T$MA*^1@)-C:+-9^YX71F":?\+H:>0\_N>F%MN2 SI]L
M/-0.T8$WD=_=9V3P[V=-)'0NA%]\;-*52HG#\?1 UE=:_P502P,$%     @ 
MG$!$2-*7D[^C 0  L0,  !D   !X;"]W;W)K&UL
MC5/+;MLP$/P5@A\0RO(C@2$+B!,4[:% D$-[IJ651(3DJB1EI7\?/F3%-@PD
M%W%W-3,[RT!5MYT*!E06;
M>;50H*U 30PT._JXV.Y7 1$!?P2,]BPFP?L!\2TDO^H=S8(%D%"YH,#]?-9I34T/!!NE<8S=[PL#([$
M]CR&7BO=F8QNE3]5@NEJN"'8/0!6:?,'G"S CFU6^VR"];[/,S
M>OXU?7GE8C973=C9GBHP;;PZEE0X:)F!S*^T_ !02P,$%     @ G$!$2-B.F(:C 0  L0,  !D   !X
M;"]W;W)K&ULC5/+;MLP$/P50A\0RI3SJ"$+B%,$
M[:% D$-[IJ651(3D*B1EI7]?/F3%-@RD%W%W-3,[RTFH'0SP)I*4I"S/[ZCB0F=5&6LOIBIQ=%)H
M>#'$CDIQ\W<'$J=MMLJ.A5?1]2X4:%72A=<(!=H*U,1 N\T>5YO=.B BX+> 
MR9[$)'C?([Z%Y&>SS?)@ 234+BAPOQS@":0,0K[Q^ZSYV3(03^.C^G.;)Z1!EH^2O>*TP^81[@-@C5*&[^D'JU#=:1D1/&/M H=URG]
M*=A,NTY@,X$MA(<\&D^-HLWOW/&J-#@1._!P=JN-AYL@XI6)]V9C&J=/U4.U
M*NY+>@A"9YA=PK"$61#4JU]MP+)O1D3Q68+EX=2VH1'YSFY'>OY\ED="Z$-[[V*0KE1*'P_&!+*^T^@=02P,$%   
M  @ G$!$2%RRD_*B 0  L0,  !D   !X;"]W;W)K&ULC5/;CILP$/T5RQ^P!D*V5420-EM5[4.EU3ZTSPX,8*WMH;8)V[^O+X1-
MHDCM"YX9SCESQI=J1O-F!P!'WI74=D\'Y\8=8[890''[@"-H_Z=#H[CSJ>F9
M'0WP-I*49$66/3+%A:9U%6LOIJYP#'$3DIQ\^< $N<]S>FY\"KZP84"
MJRNV\EJA0%N!FACH]O0IWQW*@(B GP)F>Q&3X/V(^!:2[^V>9L$"2&A<4.!^
M.<$S2!F$?./?B^9'RT"\C,_J7^.TWOV16WA&^4NT;O!F,TI:Z/@DW2O.WV 9
M81L$&Y0V?DDS68?J3*%$\?>T"AW7.?W9E@OM/J%8",5*^)Q%XZE1M/F%.UY7
M!F=B1Q[.+M]YN DB7IEX;S:F$*1)F13"O?K=%<=WB
M4%S0BW_3-S<.-Y'^F+H7_R%0W@B446"SC)C?'?$:<]N$7>RI M/'JV-)@Y-V
M:?/6ZGH[GXIX)A_PNAIY#S^XZ86VY(C.GVP\U [1@3>1/6PI&?S[61,)G0OA
M)Q^;=*52XG \/Y#UE=9_ 5!+ P04    " "<0$1(>-J?,J,!  "Q P  &0  
M 'AL+W=OQ-W5S.PL'^6$YLWV (Y\**GM
M/NN=&W:4VKH'Q>T##J#]GQ:-XLZGIJ-V,,";2%*2LCS?4L6%SJHRUEY,5>+H
MI-#P8H@=E>+FSP$D3OMLE9T+KZ+K72C0JJ0+KQ$*M!6HB8%VGSVN=H#\BOH7D1[//\F !)-0N*'"_G. )I Q"OO'[K/G9,A OX[/ZMSBM
M=W_D%IY0_A:-Z[W9/",-M'R4[A6G[S"/L F"-4H;OZ0>K4-UIF1$\8^T"AW7
M*?TIMC/M/H'-!+80ON;1>&H4;3YSQZO2X$3LP,/9K78>;H*(5R;>FXUIG#Y5
M3]6J6)?T%(2N,(>$80FS(*A7O]N"7;-P'>G;U)W]AT!Q(U!$
M@?4\8G%WQ&O,YJ8)O=A3!::+5\>2&D?MTN8MU>5V/K)X)I_PJAQX!S^YZ82V
MY(C.GVP\U!;1@3>1/VPRTOOWLR026A?"+SXVZ4JEQ.%P?B#+*ZW^ E!+ P04
M    " "<0$1(Q-W5S.PL'^6$YMWV (Y\*JGM+NN=&[:4VKH'Q>T=#J#]GQ:-XLZG
MIJ-V,,";2%*2LCS?4,6%SJHRUEY-5>+HI-#P:H@=E>+FSQXD3KMLE9T*;Z+K
M72C0JJ0+KQ$*M!6HB8%VESVMMOLB("+@EX#)GL4D>#\@OH?D1[/+\F !)-0N
M*'"_'.$9I Q"OO''K/G5,A#/XY/ZMSBM=W_@%IY1_A:-Z[W9/",-M'R4[@VG
M[S"/K:G"DP7KXXE
M-8[:IQ-W5S.PL'\6(YM5V (Z\
M*ZGMEG;.]1O&;-6!XO8&>]#^3X-&<>=3TS+;&^!U)"G)\BR[98H+3#@I-#P;(@=E.+F8P<2QRU=T*GP(MK.A0(K"S;S:J% 6X&:&&BV]'ZQV:T"
M(@+^"ACM24R"]SWB:TC^U%N:!0L@H7)!@?OE  \@91#RC=^.FE\M _$TGM0?
MX[3>_9Y;>$#Y3]2N\V8S2FIH^"#="XZ_X3C".@A6*&W\DFJP#M5$H43Q][0*
M'=;(.*5B?=F8QJG
M3]5#N5C]+-@A")UA=@F3)\R,8%[]:HO\O,4N/Z'GW].7%PZ7D7Z;NN?_(;"Z
M$%A%@6426&=71SS'7 [)3O94@6GCU;&DPD&[M'ES=;Z=]WD\DR]X6?2\A2=N
M6J$MV:/S)QL/M4%TX$UD-VM*.O]^YD1"XT)XYV.3KE1*'/;3 YE?:?D)4$L#
M!!0    ( )Q 1$@W"6RAH@$  +$#   9    >&PO=V]R:W-H965TU#I=4^M,\.#&"M[:&V"=N_
MKR^$3:)([0N>&2DT/!BB)V4XN;/ 23.^ZS(SH57
MT0\N%&A=T977"@7:"M3$0+?/GHK=81,0$?!3P&PO8A*\'Q'?0O*]W6=YL  2
M&A<4N%].\ Q2!B'?^/>B^=$R$"_CL_K7.*UW?^06GE'^$JT;O-D\(RUT?)+N
M%>=OL(RP#8(-2AN_I)FL0W6F9$3Q][0*'=IW
M6[#K%@=V06?_IIZK ]/'J
M6-+@I%W:O+6ZWLXG%L_D UY7(^_A!S>]T)8&ULA53=;ILP%'X5BP>H"2EI
M%A&DIM6T74RJ>K%=.W  J[8/LTWHWG[^(31$D7*#?8Z_/\LVQ8CZPW0 EGQ*
MHI^D/@((J*Q78&XXP0L(X86<\=])\\O2$R_G9_7O
M8;$'QA]>VN
MPCC&E7P[T6X3LHF0S81M&H)'HQ#SE5E6%AI'8GKFSVZU;FYQB=G>-\FO3/*%P+>;)@O,)KTRH1<')T&WX7X:4N&@;#RAN3L_
M@>&ULC51;;YLP%/XK%C^@!G+9%!&DIM.T/4RJ
M^K ].W  J[8/LTWH_OU\([email protected]+]CG^;I9MBA'UJ^D +'F30IECTEG;'R@U
M50>2F0?L0;F5!K5DUI6ZI:;7P.I DH+F:;JGDG&5E$7H/>NRP,$*KN!9$S-(
MR?2_$P@$+Q
MA]>VNPCC&E:_I1+M/
MR"="OB+0:!1B?F.6E87&D9B>^;/+#@ZNO8A3)BZ;"678?>Q>RFR?%?3BA1:8
M4\3D$3,CJ%._:Y$O+4[Y#3W_F+Y9)=P$^GY*^ F![4I@&P0VD\#F[A:7F.W'
M)KN5R6XAL+MKLL3L5R;TYN DZ#;<3T,J')2-)S1WYR?PF(>#?X>71<]:^,5T
MRY4A9[3N^H2;TR!:<"'2!Y>B5_4$L#
M!!0    ( )Q 1$A#KS.CH@$  +$#   9    >&PO=V]R:W-H965TZ:EE42$Y"HD9:5_
M7SYDQ38,I!=Q=S4S.\M',:)YLQV (Q]*:KNCG7/]EC%;=:"XO<,>M/_3H%'<
M^=2TS/8&>!U)2K(\RS9,<:%I6<3:BRD+')P4&EX,L8-2W/S=@\1Q1Q?T5'@5
M;>="@94%FWFU4*"M0$T,-#OZN-CN5P$1 ;\%C/8L)L'[ ?$M)#_K'#AYHB7F&]73=C9GBHP;;PZ
MEE0X:)&ULC53;;J,P$/T5BP^H@5Q:
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MA76,7[;I1+M-R"="/A,> H%&HQ#S![.L+#2.Q/3,GUVV_@O(34$L#!!0    ( )Q 1$A,D<@WNP$  'L$   9    >&PO=V]R
M:W-H965T[#2E4?
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M=V]R:W-H965TV6=L[U
M&\9LU8'B]@9[T/Y/@T9QYU/3,ML;X'4D*)[2'[56YH%"R"A!H?U9_BM-[]GEMX
M0/E'U*[S9C-*:FCX(-TKCL\PC7 ;!"N4-GY)-5B'ZDBA1/'/M H=US']6?^<
M:-<)^43(9\)=%HVG1M'F(W>\+ R.Q/8\G-UBX^$FB'AEXKW9F,;I4_50+N[R
M@AV"T!EFES!YPLP(YM6OMLC/6^SR$WK^;_KRPN$RTM>I^_H_!%87 JLHL)Q&
M7%X=\1RSNFC"3O94@6GCU;&DPD&[M'ES=;Z=]WD\DV]X6?2\A=_:H/HP)O(;FXIZ?S[F1,)C0OA#Q^;=*52XK _/I#YE99?4$L#!!0    (
M )Q 1$B]H$4AHP$  +$#   9    >&PO=V]R:W-H965TLV(:!
M]B+NKF9F9_DH1C3OM@-PY%-);?>T"V^B[5PHL+)@
M,Z\6"K05J(F!9D^?%KO#*B BX)> T5[$)'@_(KZ'Y$>]IUFP !(J%Q2X7T[P
M#%(&(=_X8]+\:AF(E_%9_5N;$9)#0T?I'O#\3M,(ZR#
M8(72QB^I!NM0G2F4*/Z95J'C.J8_V^U$NT_()T(^$QZS:#PUBC9?N.-E87 D
MMN?A[!8[#S=!Q"L3[\W&-$Z?JJ=R\;@NV"D(76$."9,GS(Q@7OUNB_RZQ2&_
MH.?_IB]O'"XC?9.Z;_Y#8'4CL(H"RVG$S=T1KS';FR;L8D\5F#9>'4LJ'+1+
MFS=7Y]OYE,&PO=V]R:W-H965TU)+Q8FQH6JP[A20RI,XPVD<9Y@3*J(B][D75>2R-XP*
M>%%(]YP3]>\$3 ['*(FNB5?:M,8E<)'CB5=1#D)3*9""^A@])(=3YA >\(?"
MH&_VR-5^EO+-!;^J8Q2[$H!!:9P"L'&T[/@GGU#8+L0V'J!S=CB
M_6J+,\Q]_+7);F&RFPDDJR9SS#-92VG %A'?V59;^Q), 8/:
MN.T/NU?A

9I@$ -$# 9 M >&PO=V]R:W-H965TSN:M&%%_F [ DD\IE-DE MG;7]EE)3=2"9N<$>E/O3H);,NE*WU/0:6!U(4M L36^I9%PE91%Z+[HL<+"" M*WC1Q Q2,OU_#P+'7;)*3HU7WG;6-VA9T)E7X1 ?#& M832+.?'9#X@?OOA3[Y+41P !E?4*S U'> (AO) S_C=I?EMZXG)^4O\55NO2 M'YB!)Q3OO+:="YLFI(:&#<*^XO@;IB5LO&"%PH0OJ09C49XH"9'L,XYM@4].B%SC#[B,DB9D90IW[5(CNWV&<+>O8S?7V147 M4$L#!!0 ( )Q 1$CB$,Q*,@, %X. 9 >&PO=V]R:W-H965T)JM)#OC_VJKRHW?FT&WMMYE-RIF51X]?&:<]5 ME3?_%K@DEYD+[G7@K3@<*1_PYE-OT.V*"M=M06JGP?N9^PR3#20(G+DCNQR'^%Z2TF%]Y?7]W3KER6 M_GO>XB4I_Q0[>F39^JZSP_O\7-(WD;+O_SO;<4E)=):Y3Y5_] M9U%WGY?^F]@7,KT "0$:!$,&",DS=2UGK4 M&8R$0?38(% , LE ^["L9$;[L*063&;!K$V,L:!0*2B\-P#_L<%8,1A;S(C$ M@/8922V8S()9FQAC09%24"09H,<&L6(06\R(Q(#^S;)@,@MF;6*,!25*08ED M$#PV %_ML;[%G,@0:%M :@-E-M#:")G+^O;3 9*%14,"I%H@R2*24^U_)%X$ M%/:0112U[X'4^""VL% ['TBM!A)=HJF H@[R=4@FD$1!S(FH'0NDEH6T45(! M]3,&?NSS/WT^X5T^$/HR:4Y+[8,@-1YDV &,[X(E80"&K%(!]OG'D3']M0 C MK:,Y>[7I@=3UD'8[L% @BTX":F\$J1FA0%?34D!]32,4!99+HO8M2!XO22J@ M/EC HAEF>B.!,:#O.7EW&\\*-X?NV-(Z6W*N:9_&,#HZ-_OY])0?\*^\.11UZ[P3RK;+W4YY3PC%+''_B3WA1W;8&VY*O*?\ M,F+737_\Z6\H.5U/<\.1&PO=V]R:W-H965TN)7T-\;VZ>!N.9=,?+\,_::C#I@-0!^ M *(/ X@.(%9 M,%36S^MK(8O5HN473YR*;K7A4D-'*@ M1!8E&E&R29:06(S499)*1&@P"X3PCLQB9R:"3C,Q@Q,2! :%M MQ]"D3&]BK=&8-,D<..]L#R9G>AMKC5Y\C-$%9-L:3%]'T\NO-0,HHB[WS38_ MC-Q_9YMIT<"AB8,QP;8_C/Q_9ZMI$?V,:\#N 3!N I%#"MO@D,RWQ%R+=+$A M070@V1X'.M\6U@X5'.//[VJT6P*.'_KQ-,E\ZJ/+A.Q^ M@&8_B*)I"C4;3P+$X@3&B^RI.+"?17LH&^%MN%3OQ/WK\)YSR52N\$'=FZ/Z M5KD-*K:7W2E5Y^WP]CX,)#]=/T9N7T2K?U!+ P04 " "<0$1(90J15U$# M ")#P &0 'AL+W=O/U:W-F3 3O95$UR]E9B,M#&#;[,RNS9LXOK)+_''E=9D(^UJ>PN=0L.RBC ML@AA%.&PS/)JMEJHM:=ZM>!74>05>ZJ#YEJ66?UWS0I^6\[ [+[PG)_.HET( M5XMPL#OD):N:G%=!S8[+V2-XV ':(HKXE;-;H]T';? OG+^V#S\.RUG4QL * MMA>MBTQ>WMB&%47K2>[\IW?ZL6=KJ-_?O7]3(/'= ?4&R-HA[+2KS&TSD:T6-;\%S25KOR?P(/&Z M=2(]!S)=C7I4+Z1;?5O!&"_"M]:1P:P[!BH&$Q>RU1$P$*$,P!D%-*-80\T< MNC;8Z 2FSA@FG>Q&G(R&&5O)BI5]W.T /!PDEH-$L0G ,/3=321'5-B5,3-36YOU\+HDY-U-3DE$0-25$Z+2FU)*73-9EZ MU63J59.I5TVF7Z])$-FM/9JNRIY!GY>E28W5I4&-%J9!^54F^._0 GHCCA,/ M%]!V :=?>\^@B?=N8C0%D3L].H8!3$;RHV,(1SZ?-+ /*A![O/K8IR.;%$(C MKSXV>K([43N#(D3[C,:5V2&M!8@S8@>>CX%*M]D@+B4:S$JTF;V'BQ$J-- MCQ:KCOD6JWVF NI1K-2K6*E7L5*O8J6?%VNHS1DEJT]JPFN"/;]6HA,SK Y3 MY"-LYQ1K?0T>-L"QOFVG3C77?+A?+2[9B?W,ZE->-<$+%W(Z4H/1D7/!9-C1 M7";Y+.?BX:%@1]'>DC;[W:38/0A^N0^^P_2]^@=02P,$% @ G$!$2+6J M=H#P 0 G04 !D !X;"]W;W)K&ULC93-CILP M%(5?!;'O&# 0B C2A*IJ%Y5&LVC73C !C<&,[83IV]<_A,'(:KK!ON:<>[]K ML(N)LC?>8BR\CYX,_."W0HQ[ /BYQ3WB3W3$@WS34-8C(4-V 7QD&-7:U!,0 M!4$*>M0-?EGHM1=6%O0J2#?@%^;Q:]\C]N>("9T.?NC?%UZ[2RO4 B@+L/CJ MKL<#[^C@,=P<_.=P7Z5*H06_.CSQU=Q3["=*WU3PHS[X@4+ !)^%RH#D<,,5 M)D0EDH7?YYR?)95Q/;]G_Z:[E?0GQ'%%R>^N%JV$#7ROQ@VZ$O%*I^]X;B%1 M"<^4;X3K4VV56;V4$LP+<5")+SDK2P-#!Z#Q!N0V ()G2"Q522#3I*U*,Q#^!@EV: D%HISZX_)JLJ7 M.,^<*)8(9O_QJZ0;E-1"<39\3-=_0;P+4R>+I9)=;3\16)VD$5WP3\0NW<"] M$Q7R4.KSV% JL,P5/,G&6GE7+@'!C5#3G9PS$WMMHP#K K;3MR\G M.\QD6T;QA3GXGW]F#]_">GXQY6MUT+IVWO*LJ!;NH:Z/]YY7;0XZ3ZJ9.>JB M^65GRCRIF\MR[U7'4B?;+BC///#]R,N3M'"7\^[>4[FE,W-9N,*]WGA.]X>ZO>$MY]XM;IOFNJA24SBEWBW<+^+^4:I6TBE^IOI2 MCNW->A,;^K6(FD.9[W66=8Z-9E_#Z;O.=O \?G5_6O7 MW*;\EZ32:Y/]2K?UH:G6=YVMWB6GK'XVEV]Z:$/8&FY,5G7?SN94U2:_AKA. MGKSUQ[3HCI?^E]@?PNP!, 3 +0#$?P/D$""Y <$0$' #PB$@) %>W_:NYQZ2 M.EG.2W-QJF/2SB=QW\C+UJ1Q=IKNJKK+;D#ZN^<2:^*;QFK98&P2D0= 9R,'@;MI $@,Y-@A]7&71]TBO49U& M^-UG.E% $@4HD9@V"(E!B S .G98(Z>31"1)A R":0-%#!2C2JP)IY/$)$F, M#*)I@SMB<(<,K'-SA36,N2E\2IN/+!BS4WP 5HPM(OO\'$1=_O-2SH#1I8*2 M)!!*$6.""LJ2D)QB>U'8U\K(0D$2B*0(&!84)8$XB:1]_<(B!@N"TB003E%H M[Y!HM+R$/G=]$90\@;"*K(ORBH@4(P^%3R#ZHMC>J'@\)<5,3-ULVKK]VLZ86C=N_JPIY=!L MUV\7F=[5[:EJ:^PWL/U%;8[7_?CM3X'E7U!+ P04 " "<0$1($XZW_O$! M #_!0 &0 'AL+W=O]=@GHT(4I>J:@^55GMHSTXP :V-J>V$[;^O'R0U%)I<\(.9^68^L(N1\3?1 M8BR]=TIZL?=;*8<= .+88HK$$QMPK]XTC%,DU9*?@!@X1K4A40)@$*2 HJ[W MR\+LO?"R8&=)NAZ_<$^<*47\]S,F;-S[H7_=>.U.K=0;H"S C5=W%/>B8[W' M<;/W/X6[*M<( _C1X5$XJ7X'D7O=NQZ,X[V399.M'4"G CP1@CC_Q*BB1 M", Z,[D^(XG*@K/1 M$P/2'SO<*3C7(DK94V&$69IVV=U+"7-8@(L6FF&>+09:S!JBFB$^WB! &5AU M 13.;Q+'6V9<%(S@/_T'SED=T E_1_S4]<([,*F. MO3GQ#6,2*ZW@27W,5MW&MP7!C=333,VYO:#L0K+A>MW>[OSR#U!+ P04 M" "<0$1(&H?6TY4! #= P &0 'AL+W=OW?V .0L2; M]9RS\_W.U[3-.E1;70,8\B5%HY=1;4R[H%07-4BF;["%QOZI4$EF;*HV5+<* M6.E%4M DCJ=4,MY$>>9KKRK/<&<$;^!5$;V3DJGO%0CLEM$H.A;>^*8VKD#S MC/:ZDDMH-,>&**B6T=UHL4I=AV]XY]#I04R<]S7BUB7/Y3**G0404!A'8';9 MPST(X4!V\.>!^3O2"8?QD?[H=VO=KYF&>Q0?O#2U-1M'I(2*[81YP^X)#EOP M#@L4VG])L=,&Y5$2$::P M([IE[NQ&"]NN',22B?6F?>IW'ZK[/)FG&=T[T$G/*O0DH:?OH)9^<41R-B+Q M\G&03_\!&)\!QD/ ?'K1XVG/[/J0R=F0R1 PN[T.2,\ Z8F#^467Z9\NZ>#H M6K:!%Z8VO-%DC<;> G\!*D0#EA3?6%1MWUJ?"*B,"VWQ,_8O. M?P!02P,$% @ G$!$2 603W76 0 8P4 !D !X;"]W;W)K&ULE93;CILP$(9?Q>(!U@[AE(@@-5M5[46EU5ZTUTX8 EH; M4]L)V[>O#X$"1>KF!GO,/_\WENW)>R'?5 V@T3MGK3H$M=;='F-UKH%3]20Z M:,V?2DA.M0GE!:M. BU=$F!;>0B(+0$8G+5UH&:XP3,P9HT,^-?=\R_2)D[G@_L7MUM3_8DJ>!;L9U/J MVA1+ E1"1:],OXK^*]RW$%O#LV#*?='YJK3@0TJ .'WW8].ZL?=_,G)/6T\( M[PGAF!#ZPCW(E?F9:EKD4O1(==2>W69OY-*:&&=D:E,N=+OWJ[;H-:'7D,VHP<9_%1(.D-9#0F<0#P;)G.)%1R]*G2B-R?\IVP5E.Z>DJY2I M:$O(!S#1 A/-,=DJ)GH8$R\P\1RS6\7$#V.2!2:984*RBDD>QJ2+:Y8ZAZW' M[-8IZ902A1^Y MD"DTTQT785DTWN693^NQL\>4 =O&ULA53; MCILP$/T5BP]8P%RRB0C2AJIJ'RJM]J%]=F"X:&U,;2=L_[Z^$$(04EZP9SAG MSAGP.!NY^)0M@$)?C/;RZ+5*#0??EV4+C,@7/D"OW]1<,*)T*!I?#@)(94F, M^C@(4I^1KO?RS.;>19[QBZ)=#^\"R0MC1/P[ >7CT0N]6^*C:UIE$GZ>^3.O MZACTLN,]$E ?O;?P4"0&80&_.QCE8H^,]S/GGR;X61V]P%@ "J4R%8A>KE MI::0%OX[U;Q+&N)R?ZO^W7:KW9^)A(+3/UVE6FTV\% %-;E0]<'''S"U8!V6 MG$K[1.5%*LYN% \Q\N76KK?KZ-Z\!A-MFX G IX)L\XV(9H(T9T0VTZ=,]O7 M-Z)(G@D^(CD0\[/#@X8+4T171KH9:4/[N5SVFN-]F/E74^@!0PB<7LPS@,UPWYBR/# M0#1VE"0J^:57[K?,V7E:W[ YM,%6WS-S0*%69KO3>^%&SP6*#[>+9+[-\O]02P,$% @ G$!$ M2! P(*]Q @ @P@ !D !X;"]W;W)K&ULC99= MCZ(P%(;_"N$'2"D?58,D [K9O=AD,A>[UU6KD '*T"JS_W[[@5A(9]0+H>5Y M3\][*!R2GG;OK""$.Y]UU;"-6W#>KCV/'0I28[:@+6G$E1/M:LS%L#M[K.T( M/BI177D0@-BK<=FX::+F7KLTH1=>E0UY[1QVJ6O<_;Y+?H/Y59DO\>,Y+3Z6QYY(9(%KG,D)WRI M^!OM?Y+!0B0#'FC%U+]SN#!.ZYO$=6K\J8]EHXZ]OK($@\PN@(, CH)Q';L@ M& 3!71!^*P@'0?CL"M$@B&8K>-J[JMP6T=UF*YG?RUP#L91$1V1+F8 M&JH;HF>O*5Q%B7>5@29,IAFHF!C9D*V)^"/AB02L60;WL37ISJJY M,>= +PW71L;9L7^^0/F*GLUG_CKW+?-;T6]U>[R'3Y,6G\EOW)W+ACE[RD5C M4#WA1"DG(FNP$.4MQ!?!.*C(B<-K>6O[XW9'^!U!+ P04 M" "<0$1(8T713= " #3"@ &0 'AL+W=O_6]+3ZR:$ M\#;QTAU/?)Z(FSI>UNV[@8RLHV,PD<,F?(2'+9(2J?C5D2M;O0=S\J^4OLV# M'_M-F,PYD)[L^!RB%8]W\D3Z?HXDR']TT$_FO'#]?HO^398KTG]M&7FB_>]N MST\BVR0,]N307GK^0J_?B:XAFP/N:,_D;["[,$Z'VY(P&-H/]>Q&^;RJ?\I$ M+W,O0'H!6A;@0B:N0#+-KRUOFWJBUX"=V_GPX$'(ISF(B!R(W)@A^06)#<"9,Y:E*:0 MFBI-L_N4PJ(4!B5W4HK5R4")L\SC"R@M3FEP"B>G7)U,@:*RN(^I+$QE8$KG MR9B:ZCX$$OO*)>L0D#BKT2*U;5\ X=+C(X#_;C<8*/?5T2*]W!L+P###"!U5[1V@R\%*A,?E&T'8/@!N.\0K T!5U'[email protected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email protected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email protected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email protected]:C5KL#6 ^_.?\Y1UG-H6EZ! (XS56+1B M2_::DY7W]Z Q$%3]&7D23]L! M!6#4I-L.:+IA^1]RX+T^FCNPS_4F>Z1U#WE*IE#C6K:M_SZ(0$_9LGXPDV92 MSM4K0)$D^4F_@44W*=>/C(YCYA!T$\=4ZC)\D,[email protected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email protected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
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){	
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}
		
	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};
	
Show.toggleNext = function( link ){
	var ref = link;
	
	do{
		ref = ref.nextSibling;	
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';
			
		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};

/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em; 
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}



  3.3.1.900
  
  html
  129
  218
  1
  true
  35
  0
  false
  5
  
    
      false
      false
      R1.htm
      000 - Document - Document And Entity Information
      Sheet
      http://www.mesalabs.com/20151231/role/statement-document-and-entity-information
      Document And Entity Information
      Cover
      1
    
    
      false
      false
      R2.htm
      001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited
      Condensed Consolidated Balance Sheets (Current Period Unaudited)
      Statements
      2
    
    
      false
      false
      R3.htm
      002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals
      Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
      Statements
      3
    
    
      false
      false
      R4.htm
      003 - Statement - Condensed Consolidated Statements of Income (Unaudited)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-condensed-consolidated-statements-of-income-unaudited
      Condensed Consolidated Statements of Income (Unaudited)
      Statements
      4
    
    
      false
      false
      R5.htm
      004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-condensed-consolidated-statements-of-comprehensive-income-unaudited
      Condensed Consolidated Statements of Comprehensive Income (Unaudited)
      Statements
      5
    
    
      false
      false
      R6.htm
      005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited
      Condensed Consolidated Statements of Cash Flows (Unaudited)
      Statements
      6
    
    
      false
      false
      R7.htm
      006 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies
      Note 1 - Description of Business and Summary of Significant Accounting Policies
      Notes
      7
    
    
      false
      false
      R8.htm
      007 - Disclosure - Note 2 - Acquisitions and Dispositions
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-2-acquisitions-and-dispositions
      Note 2 - Acquisitions and Dispositions
      Notes
      8
    
    
      false
      false
      R9.htm
      008 - Disclosure - Note 3 - Inventories
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-3-inventories
      Note 3 - Inventories
      Notes
      9
    
    
      false
      false
      R10.htm
      009 - Disclosure - Note 4 - Long-term Debt
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-4-longterm-debt
      Note 4 - Long-term Debt
      Notes
      10
    
    
      false
      false
      R11.htm
      010 - Disclosure - Note 5 - Stock-based Compensation
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-5-stockbased-compensation
      Note 5 - Stock-based Compensation
      Notes
      11
    
    
      false
      false
      R12.htm
      011 - Disclosure - Note 6 - Net Income Per Share
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-6-net-income-per-share
      Note 6 - Net Income Per Share
      Notes
      12
    
    
      false
      false
      R13.htm
      012 - Disclosure - Note 7 - Commitments and Contingencies
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-7-commitments-and-contingencies
      Note 7 - Commitments and Contingencies
      Notes
      13
    
    
      false
      false
      R14.htm
      013 - Document - Note 8 - Comprehensive Income
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-8-comprehensive-income
      Note 8 - Comprehensive Income
      Uncategorized
      14
    
    
      false
      false
      R15.htm
      014 - Disclosure - Note 9 - Segment Information
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-9-segment-information
      Note 9 - Segment Information
      Uncategorized
      15
    
    
      false
      false
      R16.htm
      015 - Disclosure - Note 10 - Income Taxes
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-10-income-taxes
      Note 10 - Income Taxes
      Uncategorized
      16
    
    
      false
      false
      R17.htm
      016 - Disclosure - Note 11 - Subsequent Event
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-11-subsequent-event
      Note 11 - Subsequent Event
      Uncategorized
      17
    
    
      false
      false
      R18.htm
      017 - Disclosure - Significant Accounting Policies (Policies)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-significant-accounting-policies-policies
      Significant Accounting Policies (Policies)
      Uncategorized
      18
    
    
      false
      false
      R19.htm
      018 - Disclosure - Note 2 - Acquisitions and Dispositions (Tables)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-2-acquisitions-and-dispositions-tables
      Note 2 - Acquisitions and Dispositions (Tables)
      Uncategorized
      19
    
    
      false
      false
      R20.htm
      019 - Disclosure - Note 3 - Inventories (Tables)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-3-inventories-tables
      Note 3 - Inventories (Tables)
      Uncategorized
      20
    
    
      false
      false
      R21.htm
      020 - Disclosure - Note 4 - Long-term Debt (Tables)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-4-longterm-debt-tables
      Note 4 - Long-term Debt (Tables)
      Uncategorized
      21
    
    
      false
      false
      R22.htm
      021 - Disclosure - Note 5 - Stock-based Compensation (Tables)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-5-stockbased-compensation-tables
      Note 5 - Stock-based Compensation (Tables)
      Uncategorized
      22
    
    
      false
      false
      R23.htm
      022 - Disclosure - Note 6 - Net Income Per Share (Tables)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-6-net-income-per-share-tables
      Note 6 - Net Income Per Share (Tables)
      Uncategorized
      23
    
    
      false
      false
      R24.htm
      023 - Disclosure - Note 8 - Comprehensive Income (Tables)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-8-comprehensive-income-tables
      Note 8 - Comprehensive Income (Tables)
      Uncategorized
      24
    
    
      false
      false
      R25.htm
      024 - Disclosure - Note 9 - Segment Information (Tables)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-9-segment-information-tables
      Note 9 - Segment Information (Tables)
      Uncategorized
      25
    
    
      false
      false
      R26.htm
      025 - Disclosure - Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-1-description-of-business-and-summary-of-significant-accounting-policies-details-textual
      Note 1 - Description of Business and Summary of Significant Accounting Policies (Details Textual)
      Uncategorized
      26
    
    
      false
      false
      R27.htm
      026 - Disclosure - Note 2 - Acquisitions and Dispositions (Details Textual)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-2-acquisitions-and-dispositions-details-textual
      Note 2 - Acquisitions and Dispositions (Details Textual)
      Uncategorized
      27
    
    
      false
      false
      R28.htm
      027 - Statement - Note 2 - Acquisitions and Dispositions - Purchase Price Allocation (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-2-acquisitions-and-dispositions-purchase-price-allocation-details
      Note 2 - Acquisitions and Dispositions - Purchase Price Allocation (Details)
      Uncategorized
      28
    
    
      false
      false
      R29.htm
      028 - Statement - Note 2 - Acquisitions and Dispositions - Pro Forma Effects (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-2-acquisitions-and-dispositions-pro-forma-effects-details
      Note 2 - Acquisitions and Dispositions - Pro Forma Effects (Details)
      Uncategorized
      29
    
    
      false
      false
      R30.htm
      029 - Statement - Note 3 - Inventories - Summary of Inventories (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-3-inventories-summary-of-inventories-details
      Note 3 - Inventories - Summary of Inventories (Details)
      Uncategorized
      30
    
    
      false
      false
      R31.htm
      030 - Disclosure - Note 4 - Long-term Debt (Details Textual)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-4-longterm-debt-details-textual
      Note 4 - Long-term Debt (Details Textual)
      Uncategorized
      31
    
    
      false
      false
      R32.htm
      031 - Statement - Note 4 - Long-Term Debt - Long-term Debt (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-4-longterm-debt-longterm-debt-details
      Note 4 - Long-Term Debt - Long-term Debt (Details)
      Uncategorized
      32
    
    
      false
      false
      R33.htm
      032 - Statement - Note 4 - Long-Term Debt - Long-term Debt (Details) (Parentheticals)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-4-longterm-debt-longterm-debt-details-parentheticals
      Note 4 - Long-Term Debt - Long-term Debt (Details) (Parentheticals)
      Uncategorized
      33
    
    
      false
      false
      R34.htm
      033 - Statement - Note 4 - Long-Term Debt - Future Contractual Maturities of Debt (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-4-longterm-debt-future-contractual-maturities-of-debt-details
      Note 4 - Long-Term Debt - Future Contractual Maturities of Debt (Details)
      Uncategorized
      34
    
    
      false
      false
      R35.htm
      034 - Disclosure - Note 5 - Stock-based Compensation (Details Textual)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-5-stockbased-compensation-details-textual
      Note 5 - Stock-based Compensation (Details Textual)
      Uncategorized
      35
    
    
      false
      false
      R36.htm
      035 - Statement - Note 5 - Stock-Based Compensation - Allocation of Share-Based Compensation (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-5-stockbased-compensation-allocation-of-sharebased-compensation-details
      Note 5 - Stock-Based Compensation - Allocation of Share-Based Compensation (Details)
      Uncategorized
      36
    
    
      false
      false
      R37.htm
      036 - Statement - Note 5 - Stock-Based Compensation - Summary of Option Activity (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-5-stockbased-compensation-summary-of-option-activity-details
      Note 5 - Stock-Based Compensation - Summary of Option Activity (Details)
      Uncategorized
      37
    
    
      false
      false
      R38.htm
      037 - Statement - Note 5 - Stock-Based Compensation - Summary of Unvested Options (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-5-stockbased-compensation-summary-of-unvested-options-details
      Note 5 - Stock-Based Compensation - Summary of Unvested Options (Details)
      Uncategorized
      38
    
    
      false
      false
      R39.htm
      038 - Disclosure - Note 6 - Net Income Per Share (Details Textual)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-6-net-income-per-share-details-textual
      Note 6 - Net Income Per Share (Details Textual)
      Uncategorized
      39
    
    
      false
      false
      R40.htm
      039 - Statement - Note 6 - Net Income Per Share - Computation of Net Income per Share - Basic & Diluted (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-6-net-income-per-share-computation-of-net-income-per-share-basic-diluted-details
      Note 6 - Net Income Per Share - Computation of Net Income per Share - Basic & Diluted (Details)
      Uncategorized
      40
    
    
      false
      false
      R41.htm
      040 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-7-commitments-and-contingencies-details-textual
      Note 7 - Commitments and Contingencies (Details Textual)
      Uncategorized
      41
    
    
      false
      false
      R42.htm
      041 - Statement - Note 8 - Comprehensive Income - Changes in Accumulated Other Comprehensive Income (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-8-comprehensive-income-changes-in-accumulated-other-comprehensive-income-details
      Note 8 - Comprehensive Income - Changes in Accumulated Other Comprehensive Income (Details)
      Uncategorized
      42
    
    
      false
      false
      R43.htm
      042 - Disclosure - Note 9 - Segment Information (Details Textual)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-9-segment-information-details-textual
      Note 9 - Segment Information (Details Textual)
      Uncategorized
      43
    
    
      false
      false
      R44.htm
      043 - Statement - Note 9 - Segment Information - Operating Segment Information (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-9-segment-information-operating-segment-information-details
      Note 9 - Segment Information - Operating Segment Information (Details)
      Uncategorized
      44
    
    
      false
      false
      R45.htm
      044 - Statement - Note 9 - Segment Information - Operating Segment Asset Reconciliation (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-9-segment-information-operating-segment-asset-reconciliation-details
      Note 9 - Segment Information - Operating Segment Asset Reconciliation (Details)
      Uncategorized
      45
    
    
      false
      false
      R46.htm
      045 - Statement - Note 9 - Segment Information - Revenues from External Customers (Details)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-9-segment-information-revenues-from-external-customers-details
      Note 9 - Segment Information - Revenues from External Customers (Details)
      Uncategorized
      46
    
    
      false
      false
      R47.htm
      046 - Disclosure - Note 10 - Income Taxes (Details Textual)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-10-income-taxes-details-textual
      Note 10 - Income Taxes (Details Textual)
      Uncategorized
      47
    
    
      false
      false
      R48.htm
      047 - Disclosure - Note 11 - Subsequent Event (Details Textual)
      Sheet
      http://www.mesalabs.com/20151231/role/statement-note-11-subsequent-event-details-textual
      Note 11 - Subsequent Event (Details Textual)
      Uncategorized
      48
    
    
      false
      false
      All Reports
      Book
      All Reports
    
  
  
    mlab-20151231.xml
    mlab-20151231.xsd
    mlab-20151231_cal.xml
    mlab-20151231_def.xml
    mlab-20151231_lab.xml
    mlab-20151231_pre.xml
  
  
  
  true
  true



begin 644 0001437749-16-024703-xbrl.zip
M4$L#!!0    ( )Q 1$C>:NR\4L0  ,TS$0 1    ;6QA8BTR,#$U,3(S,2YX
M;6SLO6ESVTBR*/K]1)S_@*?I<\..(&5LW.RV7VBQ>W2.+?G(ZND[[TM'"2B2
M-08!-@K0,K_^918 $ER*.T0 JHF9,86ED)F5F959E:,A9X'\\
M,4[U$XWZ3N R?_#QY/Z?M;MA[+LT
MO Q&5/N_Y[=?M::FF^^-]O=OVN]W%YJI&^VF;C9UH]G\].O3?>BQ]_C_&GS/
MYQ]/AE$T?O_NW>/CXRE>/@W"P3M3UZUWS.<1\1UZDCSYW@EB/PJ?)V^(ISEU
M3@?!P[OT)KQI6/@IRYB\%HP%C_D_5SR-M^\)GQ!YY)'[F<='E!.X
MQD^=8(3PM QS"HU/F,.78R!NX0O&+ )^X/OQ:#E$;A2^BY[']!T\U(2G:,B<
M[#W.G.4?@AM+/L.C<2AY'NXL>2%*N-@%+IX![O;RMR\,J#00%,B>CGES0,AX
M\F2?\'N!0GI#4&KV W$42N>A]P[N9@_B#7>.]=+GVN^2F_E'V18B]+3 #8^6
M>-KH]7KOQ-W)HWS9[_?OOZPQG2$6DNC,_9-F]]^L__T+1?\:OON;AU
M2_N:@.+],*3]CR?(C)0[I_)E* 0)C\-4\P..$W#/OG4)QZGO[Y;&&W.9+\*%F4[?@2O(IV9C3KUX&3CR://(=I")PO\ U
MOA6"ULFG_[623TH'E'T3P=K^B^;))U3^R[XY&7#QBPDX.Q#6,,3WTJNS7YT9
M=/&;=\!.6WU*/_EDZ,W_G?T(CC(=^[,?L>CY JZ'Q+L"W?+T/_1YFX\ ^73X
M3\>T==U.OK1TS(5/!J-1X/^( N?GCR$)*;^)(Q0X7,EGOL_^3-9FHVG"7%U_R6#HG6BQSY+'A;)IK;;9;9G<&KA4?7@ RX?I;.@["
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MKP'GE%_YPNQTSY_/XV<:PIODWJ-WP0_ LSYR((01@(WOY&1_)R$7GS&,C?T@?JQ_26PA40ERO_
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MPE>X&^EY^),OW1[I-2U]>U;Y$W]'\+@\=HN$BYG87L3\EGSY]Q@TV\
M*WD"=;:QZZ)MV!T)I?53:VM:+Z/1JR#V9@NV87>EQ.XH8B\EMKD[9R]NXV;$
M-EJ*VIM2>T/6;NERUJX M<7N: D4R8:NU@I%4@&M719B;^AFK5 D%=#:1R'V
MSEK;7*%'JJ"URT+M#5F[91Q7:V^UGY*Z;88^>Z:UR7:W? NE+?736JO=M/WV
M0FZI$PQ\]F_J7KG)IB<>%)UQ3J,$#W#XSGPW\_48Y7 O'L%%QPECFK]Q0.-!
M[NGWI/YLI[W:TS\@IL7YI\7
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MCPDQ,AW]@P[$!J,@RCD+O&# '!&S!O]$0^'N?>1]/@ :3
M:,_C8S6=%+X02Z#[email protected]*3F&YQ$'-8,1A,$.CG)5C)%NK28N6A$F:+D2ZZ
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M0+,Y?2HEE"%GKEX-Z+0"L'K\<8G]*2BJY
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M"=.!+@A/(EC/_&@8^,]G(]"LN%^\KNK%-!/_\P--2JTE^;2SU]=&N4@%&):?![\XS\I@34>"P$4X!1NUBX3 2IH5B1(FTFS'^\1L6[%I&
M1GM:X$?\M/0#D'$58>1[BSE';6]$%@7\<$FVNC(%$TE01*Q^O_R(42O78]^$S1VOM:^"(
M9_F5_\>0.5KR=*$NAG2VP*T!!EA.?#+
MF/X@'N5WY&E9&2$!]*J$)EEBI#$'Z<+7BZD'E!/5I\_*!L,00F&$PTSG=(G"@F
M'JZ"6Y3O$^DCO>[)I^_M?UIF]S)%[2A@KR5;4BSO1I01@]=A\.PYYFR[ZS\S
MV5:W*SGO;XYIV)PMW*F?ZIV59%H%YH%Q7+V7.(^C1#$OQ[%5%AQ7KSWS.$HT
MZU(,SC*(DG6(ZC_>(X7C(O7FJ2;2>1DLV Y=S:W@7+%-"#X[F=
M5$H<^0-*95%X;B69,M_[@))9W'QN(9T]R:;G :53@N?][NOUER#L4Q;1#5?J
M#7EA&JRB8Z73;\F@!
M2V\EFRJKO[DK7 O&ZQQ/1":Y*Z)&4>F&
M= AZESW0A/"X,P5<>]-?ZBZOI:@\4J&92,LLT-M LE2Z_XKYM%HZ9:OGE^Z6]+M/*NWP(O'
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M"=T[5N%T%X5N=SC"DA?\&$,S4]_AR07D=AK26
MXZ>6;79;^]*J"(CEF]YM2[<+IO'F:2"&M HC6$'V_'IQ<-)N ZC4][?!:S8*
[email protected]*&+A5QL]5K%\VU.T$L50T6:*5NX33>+"W0D!^^&EVC:Q8.9A+33]>"
M*74PVED&7Y'3ORF4TIV0EM[J; CE[J$<\HPJRS;M9=]??CZ]#HQUBZ+4O35[
M;7,92RT% \,>^4T_#>? B*O 8\YS\O]W -(Y>)(_MPM^LBV8HD__QXL^N.Q!
MX]&S1^$MQL<>>7ZO,=^#R?^@]6'(9I^,F <7(S:B7//IHP8V#?'3NYS]F[[7
M#'TJWZ_>:1_O1!^W;V>UO5_ 7O/%!^WIU
M_;GY]\]7O_W]#@8Y-5L;@?7EYOJN^>/J__N?B/IF(_9S4
MR=?NB8C02NRR:
M'Z[/?!B.$0\02]='?JHM !/[V=L,5''(1C+PEHT'\#S0!*!Q2,<$LS #7XO@
M(YR,X([@540E#C7B^S&\O3&P\ (")< -74&:1Q8-Q=_)F@(?9?#6V(,9&"0%
M_[QGO$_'"4("DM]]\;TDMTA[([CJ;T] 3^?#;V=GWZ=_NQ_>@M"%$T),@6(^
M7!\ES8\0*APVC/&S^%=(!W%R!"GF#&].G6KQ!'C60PS'U;#[".,$:>1O07<[8&N1\%D 2[0^82&RP40I)<0 
M!L@0R4%QJMV,12X=# FOQ%XZWYB8I_6]X)'/D& LLI_@D9 "2-'DV["4P#/"
M%P5QP ]F@T5# N8/\8$[-9KFAHHAD6B8E HC/5,2)B*QA#XI_P#XP-E!&(%<
M!K'GXGC89 ;O KW^%?N.>$NPIF#SK?@;D*$(+ UI%,Q\&LCT8H)<"<.*><#7S,B"9@GN=5&5K&
MJ"^$O#B9TP+\]@S\U@?^0 4(/%(H7QSB]]0_V,P)F',<%GMY?0^Q1_6(+.R@
M;IJMN%_/M;FL%-EFQM*LE'8K1XTM,3LT798<'1R4+MMD7W6,\M!ER5'6(>DB
MVZ-90A?CM-LI#UV6''D9IT:)Z+*%?MFH >$<762-,^JD7W:BRS9Z
MMV.6ARY;Z)>=Z+*YWJVL?MF%+O;F>M<\-8_!+UMD=Q]6\TJVXY=K&&LGRLPD
MUAZ2-@5;,;)#@.6TZ9:+-D5;,IM7]@!-HY>+-D5;,YM7!#%/]5ZY:%.P16-O
MD\=?87VS$VVVT<6=DLE4P9:-O;DNKK2^V8DVF^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M^/SA. *+Y6;CD>8'B,/WL\O+J^O?)C=!BJNLG:H,N]*LN\W;-=P\@-B64#4S)M)9E*
M,I5DEE RU9JI)%-)9ADE4ZV9BZYS]HWSLXO_^>WVYO?KR^;%S=>;6V!-QZ&T
MWS\Y-"72DSZ[^U\2JL@2#J;L#V*T'MS2YS#F]#>6D/\^B*)@
MM(ZZ+J5JNAM^K)U1L[1'WQGX,[
M1(=T@N9!++T3=$TCD98]6HB-**4;E*-O&91022 L0O?D\# ;5MLHN>9)P:W0
M>JI8^2BL;/RR5@6F1NVP@"H2I$X-B?>QNK:M>3IBIPJ[.H,5>Z@(:TG6 EWJ&11
MG"6!L.#@3:S^6G)%I.*1ZP%A\9S<59Q< SXI/X1%)S^==G7%R37@D_)#6# G
M8]W].G)RWLUY)RI=+[.L55%M553[M<"N2K_N-F^JJ'9YYT95;E6%H8X/N]*L
MN\V;*JI=X\E5JED5U2ZMQJXR[*H,X6[SI@J$5H&[JPR[DLQC2J8J$*HD4TEF
M&253K9E*,I5DEE$RU9JYZ#J_?$BD*JJMBFJ_Z%$Z@E?%^&Q55%MQ=;VYN@M<
MK2++%%/7B:G;1L.T2Y_TJ+A:#81SVO^GA'
MU=2N!TSUKA:J8#H^3(K#%$R*PQ1,58:IWAQ6D3,"55-;G1@LZK'E3/WA
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MH=[NF,>?]0GJ1>$5O=/KR9 V>KTM)CP%_P#X
M%KR,ZU)\NZV>>01\"UZ[#:D\&^UNYRCS6^B"+5VU6BV]=0Q\BUVES6Z%Y7<7
M?.7ZJMM#JZ3,\KO+HB355VW#M#^\, O
MX!WFTC!QQT/B\SX-0^H:2R>ZT]3;^9^'7(A7+$P]L[T4\4WP.# %NE,*=%=1
M8(>I-^2JS+#,Y4OSH2@0,7] _6AFC+,0!AG0$5SG%T/\>>6?C8+8CV[ZDE>^
M,G+//!8]+R?>G)Z0,X/=D9&B:70ZR[5&;C(6TI[X>Y]Y'T^B
M,*8G[PZ!S"W^NNG?Q!$:^_P?Q(OIW]E@. ,S.YBVN+K^,L74-NQE=HY#4%A:
M2?G8?3E$AM]+T^X )N(\[:0^KJ%W:T0[LZD#^5I2VIV-Z(#\0F32JJBE09J>QE&V^5UFI?@\<7
M6A"6<9D@72$T [Q>F&0%K /2;=Y:D*Q(]2]U5FI!N8-H?46BM=I>:L.6C403
MC^1E='E+:C'T6I(]GRUP*( (5M,P5A%A'U4C/979W7@JDA0'T1U2G*U2XES 
MXFRVI,JAI#)0"!&D%HHXNBDM$:0[6VU3>CYC6^;RXYEC8Z1;JS&2SY&QR:9E
ML0A=Q&$(-W>8*5VZ'6NW>YOL1V\"5Y'XK9DW77Z2)#:;7P:_6^H$ Y_]F[I7
M;K(Z8ESA&>9;2X.";]%*J
MK:?9 7$MD*[)Q"5/PB@4/@EO+J?NP0^!Y(:?N3S:K$B42T+D0[.P*?7,S&X-
MB9R_X3AX\,*_DV<!/FRT?W@
M_"ZUPFV[9=>3[B!041 6M2RD/G@S"O/"#&+6]J*)7.F
MIY=^&JMUOPC_RB/?-HG].P2>QR/FP;E4&CNW41CAX8F9[E[@/[D=C+/H@H3A
M,_,'XG!J^PVZ5E?JQUIF9Q;/C4 X$-2KM]U:7>D*:.J6?22H[350=SIRL[[5
M:1T-ZC5AI!VY$VC/;;;O G4P&K%('+?BF]F&J,.6[^/,!6O:EC2(8&6PYI9?
M3>7(Q$
MDKQ/'[40D^33NQR45I)3OZS(5#DK56V$]F)3^^[email protected]_4:H>1M-S,:L1W
MM0.,.<,>*XMPI;^U:I05FZN,4%U$?O==&FK@JFL1#4=<"_KB#Q&EH)T-0BJ"
M2!K:(X7_AE0+:;+N:U&@C4GB*2:'/_AS>OJCO<%A!)G^]@2B[GQ(AOQ,0K]Y
M$T?3.^Z'MQI+ONK$H]B#UQ_P.V*/C -CA5H0AUK"27$0<^U; $HK".&SVB5[
M %L(/H>/"2R& ++V3$G(-1[?

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email protected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

9.$C.-!:"Z8.4EV4?[W7F#NHO..AL@J MEV4[_;>C4_/&:'3M8_LU2U7?OL[.VV,S8HG83,F+DI>MY47M"93.ALCMVR\D M,%7';'AQPHV:F+[,R;$]D5C'5-+LY$DE0CIOGP012KXH]3V@GV4"'"KS"\ MM@XXJ!#$W>9/A0B7G+U5B/"KEL^-5G)%@IJ30(4(JQ#A6AQ7K@H1MJNSUUC& M(Y?7&#S9;%:(Z"I"6#&Y8G)U&%CN%7I-@+"M H15F*0*DSP^,F6&37%^J5%2 M <*OR.-6 <(JX+&$ 8]FZ0(45'BPDA8E+2HX6.T';!H<7*$->Q7@6*L Q_+I MP\.$-QZ;(Y7@*,&IA>#,&Q+KPH*S)_(K<@I4!JB> _3NYKNX,- 7A6\ MJP)?ZX.#"@[<;?Y4\&[)V5L%[[YJ^=Q$!A4)ZDX"%;RK@G=K<928VPJ<[8I: MG7W ,AZ&O,:8QC>F95>([!79K%/ M'YDRPZ8XO]0HJ6C=5^1BJVA=%7]8POA#HV$:[9(%#JAX724O2EZ.+2]J6Z!T M-H0JYZL"#TL7>/B*2I(JV5&RHV1'E?-5Y7Q51+"*"%81ARHB6$4$JXA@)9]K MY>YUA,,J$JB(X(TU6:F.*%5$\*81P16J#%#&XY;7&#-9XRJGBLD5D]>>R=5! M8.E6Y_7QP:J:KXJ25%&2)4"FS+ ISB\U2BH^^!4YW+GXX %AOHH/5O&.98AW M+%]9,14=K*1%28N*#59; JJ:KXIO+'=\8_GTH:KFJP1'"4YI!&?>D%@=%9S_ M_>N[F#<'A(S?7P2C<4B'U.?L@5[Y3C"BUT%$[^A3=.X%SL]/__D?FO;K]&D> MW?1OZ0/U8ZHY@1_!<[>T#TORGYA'TS3TIFZD/\VF99QH+G78B'C\XTG3.M&8 M^_'$L2S3:MOFB1;[+'F;\< VC4XSYN[)ITY'MX$M\C#FOKH50/84('LM0)8, MH':GTST00*VF;F],(5L&D&G9EGXP$DT@6D^BEA0BO=O;&*)+>A]=,NYX 8_# M*:MM1BV$AANF >">?-HHR*9/1LR#BY$0:Q_$.D2Q3N]R]F^::(%EEF:M(N=1 ML#5;:RZHA1W&^AKX@^;= 0:BX4A#AM@H_DTE-E2-%H)/(IQD%R8919PS'G$M MZ(M=V7[@><$C[M&^83Y<"6).?)>_E1[ 5@3MDI2J[RTFIA@J,:5D0>-UP$$% MON\V?]MEHI=G>H\? JVR4;:,6E<2N='D30*V#V#;'L+0!J5P@%%*IU>JE%=1 MY"Y2>]/0VKQI>Z (CM)8RU\Q(A,\ B<$#HBT-^:I;?[7TD(M;ZMS&E/&(^E2 M!I?;Q0:7F]U&"Y:]"E%>I5$H3M^%TPT+.;U"A#]$*L71HB*V6) W#8DHS8)\ MAQMV7D#\FJS%I3S@+1&812BF'#)&MRJ*:<7QJV*/2\DGKH\W*F$ MJ-Y"9%J-FN8D;+YI4(^2Y9N'=98;D2M?^T+OPYB$S[B7;S:T1ZJ)V!WJPD>B M0"-:- PIU9XI"34R@)\CW))X@U&[@@Q_>X(7G0\7R9G]%^(PCT7/TUONA[=: M/X!WM5],'1<1L9"$]"'P'C#@UYL[],\/F@4$)(//CDE\5XO'&H#XBS$9%I[U M: 3@\^F0I]J7V'>YU@^#D0@VG@,54 ZI%G/ &.$<4)^&Q-,>@_ GPN>0,8O@ M;_R>$X1@AY&(:CZE+E RI!$3I27H$^.1*#5![Z.&!N, 8#P>H]FF$>>OF'&& M]AM/QDG'I$]CZ@,L<4CY:<59J4XR<38.F2>R?AO+.8; /(Z2HF$PS\QWO-BE MR.)&:\*+T?3P;%Y8KGQ@!IA_<;[V%1Y99&T8ECY%%'_!RR,"/()?=I'YTJ#Y M>:C@E?^.06 L71S,=4ZE>5\5F8G:L-2-#S/C/6OIB:G0LOTXA$D,)WP4Q.&R M&94RP>QL@VI%-@PIX50\/*LZA9IL3=4OP;O+>?94 MNQ,0_BL0$*8<.@X#!Q7E5/=.WLYI78!M3 "KX-$7SX1T1)B/RO076)$RD.[3 MW/QTZ 412B#(O=N=O(KBZ@2C>R")JSVR:"@D=7+;#M3SK5[L&PX M&CO D#S"$ ?*4#+?:V^,MP Z^ 8-#3C(I7UDH(8V]F)!% AANW_6= #R M5/L#C#Z/.I$88$()\880%TI@_/L@#),DEC*8.-@A@<&^##7SJM=-U WI]=D7*KT/2+"!5QG#!.G*8$ M:_QDX,^NT\@'@QG6PBT!306WLZ> K8C?1BWD?"C-@*.'<4CD( G ,<9@G!AWO\# M>+<#.@77.+6R3XF%0-AE@!$L22"8@MESW5IFW@D0K-93@O MVZ(6R6"OY6AWW?B2!+9_XC[LYWE^W6$@'WE%DZ8YEB,Q!E9'-Y4RYJE$8!:ADG+(E"&.^:5SF)3!=!2EU*V.4BJCP50F, NV MDRJCE)2E5'5+J5<=I:0L)64I*4OI%5A*IEX=I:0L)64I*4NI]I;2W23>I#JJ MJ93V4B7Z!Q^W.V#>YK)+F$*W>9I]32VQ,JVO%3$#7B#!MDQG904FV.;0M#LE ML'YV3[ ]B$FD$FS+A,B5K_TW\;/\VK;(_!J1)%4>S6+8L^2' M7)+32FO+G6_K)FFQM=B'Z\KG41CC-\\)9_S'&(P[]\;_!PD9,M(MB:BQM#%7 M9]*8"W^:?R9!U5E,]=D3XTW,OKGI)S>^B4C4/V^)/Z#BYK\F[@ MNX%_A4'UF-ART^]C:C+>%BD%R6OY3F57UU^FK"W'%! MPO"9^8.S)$4GCS.;]"ZT]&6(IFFBL_BNP*LM;6UHM!*;18;:+)#[H+/QO*W" MHR-OT7@H/*[25">,-!1J*229IH7 M:750&9GE_3OUMI0YNGIOCC>6?7-7N'1K-5Q2IC4LP]X9KCOR="8RN+Z"NL'9 M891?TVAG^K6Z72F<[:ZY%,[5,!P*[M7T;75[*^!>/N\[PIU_.O"=G3G5D%*Z M98K>MTLA7OKU_6%=P[V&E+HMPY1RQ4:PPH+I,$S8\^&W1_''F>^"A@XC]F]Q M?:\6PQU3VF*X9>J=.=#7 W,(\+?H1]PQI8LV:ME]P9^X3Z#*@]&8^EP\=4L] M6$U<[&_,?PQ)2,\Q7?U[FGR\;Y M 882I0OR[+*)WUZ1/8W:;,XD)B[70",$ Q]$QLV* 8#0NC!S(M/9%Z<7*.M: MG_G$%U4Z> 07DC(#8:((1,$OP3])W0HG-_DKTV@;&GURZ#C2QC34.&H2+%5 MWKY_1<4"TMU+L5%[\.;'K87TVE;AV;4O'0P'K@?D:U@/<12RKMJF=^14%X\HCH 1M9T&SRR9H8CIK)V5J M45.RIA8UM:BI14TM:B5P1H^4:).>7MG=#?-%ZYP!?1=@MR0GX*(^N_24-:EQ M[6ID0)C/HU7;5P<'D?D "M7N:3\0];/%7Q%YHOP8,E6?9*A29CKI!>=PV[96 M(;)7K:FF8O-RL+G9/G:JGN+R\M*[+ER.?<8,I=T3N==H6H7J.Z,WMZ M@Y4K/7,VZ=0U=;/ \?)IGT5SL;R4A-BVBZ].FRZ5.E-%:HK4T>> ML!>N4*.D1DG-WE+3,Y70**%10K-E/31+28V2&B4U6TF-V;%?E]24ZF3SM9]F M9G5?9D\K-9]&F4-;'6^UC)MO5:V?N(-:/'#]1--J'7NG^H6K)RH)4A)T2 DR MVETE0$J E #M*D#MEA(@)4!*@'86H)9>MGW4%RZ KXJLB;(O\5V9H%6SU@TUQH()-<6 ]**E@4QQ8 MN_.KS!-*C/S>N+9'6MC7P5''5BIF?$L<]%.]4R&RJYT]Q>8[LGFK0F17;*[8 M?#*/8O+STKA&;'SM\4)VF',C3JMP!RR7S8NPV41U?JY3QTB4"LPAM ME4,&;,]*Y.6J;(!:@ED\=U?"LU+"&U:0'X0U9+DC[A;ZHQCE%L7NPF!46R&I1ATG=8 MC.4!*(.&1GQ7&U"?AL03OXD[8C[C44BPV_1TP*3#(''P<\3'5MNR=H.Y)H.3 M8B>G%2=X;3CG#B:Q3UBH/1 OICA!E#C#I#BI%HP%$PU"XD?(0I1';"3F-$BF M'R<8WTF>B#ER 5X_]PCPXP]G&'CP_628YCADV&I0&P4N];0W@H1_>S)UP_DP M\_STAOOA[:GV!X6!J38$'@Q@!&!+["N)?2HS<,0GD3$=! T_0[6'P .&Q1[F MC=G;,YAYK$\%ET]N]X.P3UD4AU0#CJ>G&A(H9/QGLX_]W5C:@EW<1)(D,I>2 MXW>?X1@_D.&Y=A=2PN/P67MFU .9B,,'(3=4M&[72"3> 11R)(3/)^!.*"U MA/MX-0][ [email protected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email protected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email protected]=VY=2TU=M.CP70YJ-?DU(N%/*FS@?NP[4[,2Q! [CPGH//7W@ M<;$KGAA6HLU1SM#WW4:^@_JL#AUD79C@HP"73P4&(*= CPATL@;(^YPX4_F: MOL$U/XA2&B>H@&Y,>ZPC)&)U)4^('MB#*;E@S7E$:#AG S]Y"^7I G7&A= 9 MG Y0%$^E*5L5X;_:"-+=C'V7,X=0OT8L2AAYSE0"]B1SZA^F'?ENX+-_(U]& M.6X^U2Z3%2=9:805X8O3FXS/6"9_T, M__HDZ3>72/=TVR^D?73;>6+-Y$#(47JR@9!;9QM:SA-T8*$'KH*WYJ=KXA-R M8 _>74E?Z*YDZH5W5\HP6%.PL:#4 MY>ZRW&714N*U%)F\0 TQ([C5*855QGH%I2Q&T"ZV)%^WT;&/7=#JI4ORK=!; M^4IX11?NV4=75:YBW]_G-YLG>P75T5FE+$A6(C"+4%4Y9-I6IPJ*ZH"EN8]D M8+UNHTJV]UA!A55&(VNG"HI'0V252BNN@N),7ZN6;1QYRG8OH:B,MDH;;6># M04@'N(]>42^SE!;;@:KBY7 [NB-:8%6\')I&M]$SJUM9LA2&X8$65S6,6K#* MN& E@1KBD(JR!]QF;^#QJEJQ7LKM+<5R=("UIF>V*M%-MA2+2FD45N5V&[*Z MA@PO5TI1E7)OH41@%GQN8QG'+@^M-@#J;T]]%SG6T7-#@W'3J& ,!1\GT>&5 M4EAEM*S*!&;!!M7K:ZRJ[*ECV%,1\0<8NJKLJ7J!6; ]U6ITV\=N5:4LJOI; M5+^EH??544S*;CJJW628C999"2J#Z2AJ*8SI3*)5=313*6VG2K4P/DX 7@[=-YWVL<..C]G"6%EB M1TC6Q1IO\N38ZJB_4AIF%6U*>Z3PNWQ3VFJ'W[U 4]KI$ZIPXL'+%V!^N:@I MEQ2LV;@L3E;1;5D%G*4E$42!I_E:"&Y:6BA?["\M&Q6*,C[TQ/#M*%:OF)OU\YB=NAX&^)86J7]GNFJ>L]-K@+B :C:V(2BQY;:$759/ +K$Q%9XM%77D]5'@&E:'>; MO&NX>0 I+J&J5II::>IC:.KE6[%*D;\6! I8B\GK6_I M_;A*(:!EC($J98"37FR4NM%K] RK$C5==HI44IRN.'T2I]?JF8K3%:?7G=/; M1J/=[2A.5YQ>=TYOM1IZJ\:AX!7S347 +)R][9ZEV+M^?%,1, MF[W:C8RKM74.^J0B8 M!;-WI]$V6K5E[U*=4KWJDRGTFZZ2A%-,LX0?H\!/LBVE>98O?[9>@AV>:@&V MR&NE!54!5AO %-N[8''.>',46<=+^7? M5OI$-H>#?MJN<8>*SS,^[QB*SQ6?UYW/C=.*1)(I/E=\OL]I]JE18SZO MXGG(KIY6Y8Y(+ID71VNJZI1*9Y4Q^K5,8!8<] HN5B7B;E1L=RW!+)Z[NXJ[ MZ\2VK%!F$TU,[)\VLCQ3+6VHI'*D*,&U\[BP9:6!#M/N;P)<[QXCWSB6AV\0:[7PB"_.T)WG*FC))OS3%]P/WP5GL M/^/XHF]&B U XGL>$3]BQ/.>L6?2I!D'YS3BVIL _@CA"O$UAX818;[69T\( MF'C@K6BID=W)]9S+QG&IC\V9> 08>^S?.!;E$;8DF> %3TZA/V<6GWC:R)J$:B019 M I]JSY3 D+[/'FC(2?B=PI3)IQMA 9RB>UL^$0D4?Y& MHOU/G[!0>R!>3+-[/F:SHLRR/DOX-=$#$X4!,#80-Y+VYA'J*J0.]F8!(J3= MNO&C )=/!0;:(P.THR'C6A02GQ-Q-1';Z1L\)7""QCVJ#C>&)Q$*%+Z(/"%J M(&(IJ5BD/2(DG+.!G[P5Q"%J$"\8, >TSI7OPK](-)C) 4KBJ59Q/JR-0-W- MR$.^GQ1VJ(I8E##T?%^H?GY%1"Y %D#^&_BPNKBH7Z=EH MR[B?:W&B<1D7/9VQ31;A0ZWO!8_P$>(]9SR7OU[27\KX$HR:4KP_B:W<4N5D;Q;:R.6T^O:[[V>GH7J!9F)%>= MSM6N-DVKX*U>O6&99H4(KTK35#-2^^_SSFKFGZ_>32J5TBIC&%2U.L*OTF8O MTA'>:,"8Y9JR=2V+5,C5:S#FS@;@(@UPBJC.54F, NVHJJAG90156DCZGN(@6'1'<6D M[*:CVDV=1J]][$-893G5WW(ZJM, MIK)JIM]]2D),EPKI _7C*NFE4MI.*EIX&QEY8S3:QK'+F!42$KR_RE/&6%') MJ $6*9C/MIRD;%9' 9;2,%,1P2HB^)574ZI3UCZFG8_&Q'_&)'A[!/TFB>M!/^Z-G=55$GGI2/6)2DV)Y)8!^&(P62@#@!_"UV;(Y M2?+]. RP5L2(:,!X2>Y]?[&&@#\/0;X:!]?8XBM#XFKWE/JYPCQP]0S6"4\S M$@#$62W\L!L:";%N1EH)@,^FWS=$,8YQ))H>BFZ'B!!16?F'462]Q:S\XI/R M7\H>VZ>0V(KY>;F.4)5'8%L?R $-2,/%Y1*X*D"F\C^>M->;R;.CE+]VV^+D MW0U#2A=*[^PPT#>X/.3:YP,,Y6/!HI66?::KZCTWE]2AHWM8C2SC %1M;$+1 M8TOMNO3?RNNIRB.@%.UNDW<--P\@Q254U4I3*TU]#$V]?)-6*?+7@D !*]'_ MW]ZW]C:N*]E^'V#^@Y"9 ;H!.:WW(_L!Y-4]N;<[W3?)/@?S:4.1:)NS9&[RC0*G\I%&SAIX+^XZ[\% 6 MHZ.8#'UJN]BA+=JRVM^L5(!T0'J.=(L@G?>[&LP@"(#.+- -650T&50Z(+WO M2-<-49+L_B*]LK$%%_%:,K!N:3&^-'2:'Q.+R1MX#(G9AG):S?HDJH;,@VJJ ME;U@P+CA1,S6X:WK7=\-!7@/5\R6X6V(9N=7GP'>PQ6S97B;HFGW%]Y,'5(- M^F"*VDTWV953>LN2_#$+@^RR9>$UR^,?K3/@X>%+L/=88U94$*PW@@'J0#! M'8]C"((!ZGIQNK&,N%TZ,73CK.)9]R_6)[$H?I%.#B^(\X#4# MF!\$<[/K7' *5V%=<'-M"8'1.;X M\6\G(_5$P-YO)ZZJ*JIIDL\6 -04V1SM(B]D]]E1;4D27KK5P69&NR, M]M89;6]GE*+.C#19:[TMF#SLV6811U4)$LQRG2PI)SM M]KG*I!I6(4)E2;:/W>>;X G%2I:(N&[)92H?5[7(6H/PUC./S M)P?[=%%_""_34.7[A*S!T]#WR,J=AD0<-JU*X4ID:.]U5A6Y&NY4E8E3U*). MF:JF,=0I,CU2R9FRU4(T*JHA,]0I[:U3^V;*5@MW=8HFO=,JAW3JY[GKA@O* MO0EA:4#^=+,:5#]"'[LOV7]?-[GE2+7LAZ;*VLGO^SSS:9:SL3/#/GDS26V+ M@-@6$;4M\D]C_"^4F2+E\Z9!B]VWR.913JENIQ^2]Q*'$."70]+UW2&:G=%_ M$6[BF!8O?R.'OM_?(QK7YW0Q-W!NE^9W=;JTU] MN'G7%L[ Y0C_&^(4;413/U%'1EI7,&WIK8B?&TZ"O*[?>%FQ.BL<2/5[Y- B M@#]Q,A7<19R0I26*LU*!^4,F"^R1SJ/79\1INVZ$25^P0ZL)DE;G891V9%D1 M6Z3U_7XBWZ?_1NCO!8[HQ]Z;+T6(%^,Q=C$A@Y"$9'&,29./6>U#,D3D*Z2- M&1T@D:HC^FLZA)1 4>*0;K^L]"=./W/)[E,8IR4%G0C']"?+ HDQ>NOMJ7"9 MEF]TD4\)FL\CA5Z2E@HEK D29ZDZ/#1&441^ MD3C/!-DQRN?A &[H)\G]# ]/CI^JIGB*4)*KK;6^Y.Q;XUG*@K:(9J5$\T+2_41 SU1E9,QZ5:-$Q4P= MJB:$F9-J4/^5A!GGMI==#:,5UBU]TZ=U=A%5_EZU/*H9#QNFQRL8SK-Y7C4M M\(H]\>?]4J%\0>$DWG%=M#,0H],X9F;GC@-F1I M7M++\QV2FH4FK&Q8JEU)U 3%=\A;N"FM#O(66-H.&W1=I-6';@BTH'KF^_C5 MXW./)AD/MUF2*AW$[4;_^I#):U;_\V/DX]&<+#$GOVLKUW$UX^O"3>) M0MDJ6FE_A&$4.EDLU337!N[=DRL+5L&G8!B%\_G.^W.X8!5\;8:A%P)-M]7F MAZPT!0RCT(VO2.3/6I*].6L.Q%FAMUVU5&6[:&_/KB%<):P5GOF0^;1:$*X2 MW@H7!EE*#QE;&+KRF-NQ&,A$N524+IH0H^9?Z8;A\G6;1%Y07V#\??QC94-W ML2#F$8KCJ]3L2DV2\\!;6>'I:HY73KS+.P-C69$ER3B"+Y#-+7=-SQ%=6 59 M&*W,"-T"+BA3[Y(#.(PR"UEQ1 %V;:4S%PG)O L7O-W_D3B MJK=S[;-%7/P9L9W7/Z1RK'XA\_J]K'V'F-6K7Z&]7ON<.@L6U.^0FOXXSEV= MU(J/J/N"%F[R7_V"N?MP[F1NC^QYJ>9.O8J+QQA[V*&C2=Z(PL5D*OPD9N,T MM?N?R ?A(A8>ZF(@!E"\H%Z$.*'S,$D7A7'H M+E*WYSPBVXT(4U=E(/Q-?H^3E\P!&OKDPY VE"TI9,:?L$NG-Y.$/I+L'%+_ M1R@$Y"TDD*;^HJ9PZON@7_ BTM] >'PA@S"A'M P>EESO&0B9B.T]NO4]>'C M&4Y27\YLCI+,\_ISBDC#/U'JD44QC>'#\93Z6$.RYF6>ELPCY:)4<,>=8D0: MFQ)J"I.(;L7(DR8XB%]]G6&V(4)Y9\9TE EG<)QZ5!PW_5%*;6$^?8FI_2Z0 MO4[F<3D5OI.OWP1D?!>9$7N5_Y3ZJLGJ2X:,"+88TPF*<@_TLJ^;0XY7FLG] MI/,PIF>W;[.Q2+"?"TM_%Z#,K$]=\Q0^4^3XR=1UJ&-\/G6BF>,B\ALBM$BZ M%GIIPX]D2")G0KY""T/3#GF(SJ](6O461 CJ/IJ^3# *R'LH>,)1&%"YR-L. MCH28@-]?^MIC-,,YZ@A/E@V@?&@N,*'V)'W&34"?1;ZT,DCS+ R$S'L6X[." M-,O7CKV-XO+!V3#25P34CV_/P6_/R4>1R/.X6"YQ!*NSS>^EY"633_V+ M<79T\>K\2_=5Y'&$0)_LQ<-G MTCTRALF4:." H(V^3N4B^@ZG;8F9VB!S%\9SNNJ(9#J"]-_UZ4E_MCZI[\8[ M#YJA*N);2&R&,!VN]Z D+2(_G*\#,GXA/2"*]HWDRX&996V]JI]U3!!5YLP0 M&1]Z7D-_2>=SEEHBZ0G-=#$C*BUYR>>#C"Q5?:F/DG""'@309Q 3.?V+:@!Z M<)3V+R9/)4C-NIZ-.>T0!5P6>)N*.:-'/>3_&2^6XQAO4B#K[/J8KK S(C]X M]"E)'IW@K[=?XYRWCA"D_J/4Z9H>^?C+I2_KV@I[5@;H=6:(OKR<$BFWP/]U M!)?JDP?IX[DM^9(=QSW+V>2GK!E MLY\=/Q'!GYRE%4C7NIDSG^?/3T^]TK4LI7H^&51AT=&F Y:O6V2<_)4'O,K] M)E+H9P,DB=-#,?+$I8<[7N([1B/2R6"RHO8(/)9:<@59@I=I@UBY[NN7N#$;JQ=]Q\_[M4ZOO.[_+3\K7C-)VL,.3M M1X3H D=WG5YVI.^093DI:5?(PN $P8*N366%S9>:5-PH.RY,=TG.FX.'[.S)K^8^F0&R#R': MDIH&Y',T3Y96"A+^"-+GI498O!Z8\N7\_,=Z,,DXW=ME _$F% [(^[-,C2\- MF&CAY^MEONW/3B9SBP^YBR@[M*7?N'[.%3T-3<1QNB:N"7)_?5E&CM69O,EZ M%Y(E+-_Q$?B158M^+&;KT>KW*R2Z$>N/0,6QC3+?/F.7EJ)BX[LB(%V2LL/;BO M9[P;42NK0[ \=Z:;('J8O'PV->KR_2T]OTYC8++&LNT5,9\>47[T3&&6G^;3 M71EIB9YZO%O"&6RGU+:361!8S =CH"3;Z$I#+RW#W!3<0E M!N1"4VUI0 M+B=:H$_J# )SAQV8NQ+:TV;DSD:0$-6=5-5&:$HFCHST6SC1!2*#CLB.:0T6 M\2U*OH\?"!1*A+"]1<5>D]E.7NB3PH!.>1H92\3,M#/R'JB"SWP(YZ_*^5M* MB-5X*6GUIJ1>&&DVDBUM(T2O?D>/.F+%G2V,7..EL^^#"-N%1W%LZ4C1)2X' MK+BO.Y).<-'7]^&#[8)C1[H969$-+D>LN+.%<>F\=/9]%&W+\"C6MGSP:7?8 M\5I?K<*HXV[Z^IDT@R?!9;HK=5_2Z7/S=3+K+K#KEU[D'2RILL+6E[^; M,:H0W&_*A1=)*F&%MR&JDCY&+MYV5%*VO(U1E?MEXZ5.L M1U59JRWR#^_1TGBH\)+EZLHENB>ZBM.\"3S.S@QRC9203(- M@Y?SF9.$U+,P(^W>IRYANL9?YD=TY!?9CNK/^\5CC/Y>T'W9$_G/P\L\:V?C M_??[KXV+L4KA"*FRL8[#';TN')X?-,00>?'G*)S]R(+/B&K9OZ_0L$- MQ9:+!-\E3T.=J)3GK?A>IB(KS77B^YB&2'HH\ [-KEFH V1SX\[REF?7$*Y2 M&LQ"2,B&;-43[B%,D]1&Z.+U@L"7J.A^I#F2C-4_E[]9R7.;DO0F&.,D?\]43>NBA?>1;5,;7O?BD1OH*/66T>M71V]#:-D>N&\E.^H5;QGD255V6NI(**&6U+&YO$QN1.]X"?61H=HZ"'V\BT!6:73/4.F=R^7ASL%B2L*)T"WB@&OV!LJ=;\ C4B< M9HG8(7&A+I)5]6")W]8V&CQ"#XF^C[^&P>0!1;,K])@4:5[Y[4^ENN;]\Y), M-TX^.RX]:WM)OTR?^#5TMJBL#?@57W=/[[JO#\B^_A6/QU?:)0+05-+C#0-] M[/*I>X=BQ]WZ74.QUK4=(Y"/T_Z1**^W"^I:MG8([email protected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email protected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email protected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email protected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email protected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email protected]=%#CD MX>GWER\^AQ%RG9CSQ8X!?_S685XI$[YUO#O@K7%PP-WR'?I?\O+_ U!+ P04 M " "<0$1(*#"'-D[5U; M<]NX%7[O3/\#JX=.^L#(LG.S&Z!%%&1+,9\LDSCWCX<'AR#X\5^/4\_Z3H5D/C]O=5X?M2S*'=]E?'S> M^M:WN_W+7J_UKT\?_V;;GRFG@@34M89S:S )N4O%E3^EUF\7#[>6;1T=GW7> MW7^QO@TNK>.CSCO[Z-@^ZMCVIX^/TCV3SH1.B07RN#QS_) '8G[>F@3![*S= M?AP*[[6DSNNQ_[T=GVP#CQ-D<-)I)62A$*!>'EU\%@G?K!*ZE.EIX(1F.'UT M)OKQ>$9#P/AW*@,]271.8XW'^!\+DA\_?KQ69+X8P]BCDS:>'A))D^%3CPQ7 MAD^I)'!,OG;\*;)_VSE>,N>$.5*OD#J%!)U5?;C/>3C5:^0&HAW,9[0-@VP8 M105S%G3E1*L$DCEZS>"$1B\9S$3.>#BC(0BE/29DMJ 9$3E4"L4GE+/62(3O M4:FE46?T1&B>GDB=T1"A 6X&*G',W[:CD^FAK AC,N <&>!D,G;75V,52ZNH' MM/^[T1$)/5 ]Y'^&Q&,C M1EU(%QZ=4AZL#$B=#H@8T^ K ;#.B$,K /C37_]B62IEL.G,%X'%UXB+_1QE MFEO?(8'*:FE/:Z'0IEX@%[SL):_7H$6KO:%"ZVBIKY#B54>ADNLP1Z-"*E#C MZ-3N'-N==Y75*,_/1;[1$B[^LY=LZNFSELNKZ+(@4K_JZ)"]CD_;&.4VIV.\ MMU:+C2?$"E6=V%3([YO!Q.=?32%%4P%4 DJ*+OG'7C*IITSVIE1%D80&?]A+ MXMH82>?Z*D%1)/B?G=!A3$XP)G7=H"ECJG@B11;_WCH@V9JMBAH)#?[8.G&L ME1V5()$0J5]U0%%8QM2_Q^"1.K>8DIJRBD^65-'/.E[1%U 5+Y*$ *^.MUF1 MA',_4/3J6')T-F-\Y,>'X""656=)L?Y 1Y8JM,Z(<#!#%Y=C[9GP9U0$#"J& M5+VO&$P$'9VWL.JWD]KH=_CG-11PR9 U :L)0-TA@(1ZMTOU$EK,V>@R54/7!L*6@DWAI /@Z"=*P>_+1"W\M5#+NHC4LOI*+>O5 M9:27=:_TLKXE>OVC05*]@-HS@L:: =%(-2(LATO)'<*M#;:Q739ZJ&#YP%Z@P@7'L M.WUR\)1(-P6E-W6@=)G6K0'6QL B9*,IQ.B9CC<.NV,(WI\ADTJU*,@NDS,_/K MG,K8FT+)>RU*L.[N MIN0K:%REY+_PX)_8^*R ![XPD#E6F9D*[ =M8+$.[BVEO? POK$]GX\#*J:0 MO(?!MH',LC,5RE-M*+$.O05Y-@J$G#X,7G@TWT(!YSO*:ZZ:#$!!M6WCM82Q MH0AWCK01CHI$D&PKT6H2D8A^X;%^9W,:)'.\&16VG!!!MPUT#E=34>YHHXQU MVE<:))/">RJL/HI]X1%^CU?:E 71? SK'YBK80%*N8ERO8R]J9@?:V/^7DWY M%O)5>769EO_"@_]!V\S9-N8Y7$V%^F3UX9D*](WU-;TK'ZU\SS MT0*FIJ+[1GLA8VG6CZ0V3T:7O9"CY"8:D$<#K94,.U,A?:OOD!RI.9*Z&0]0 MWDL/9L>6X5#2/T,\1''NN'5 -2Q-!36G[:6>6"]D6ML.O>VS>$4IIN"@[W^5-C:M5P.EQTO'Q$I3 MTA "M#Q-Q5O?),OT.YOH:CN5AN*;P]50A(_U3;+U-F@3Y)*VI:%PE_(W%7A] MWZRH.]I H*BA:2C^QHJ MTMP:1)J_=*26=0$, W!3<:9PI>]"5N@^-'#9*'ZS4#@3\+D]$\RA-O&\^)7: M)+*[!E"Y J8@]3ZS9+@BHFSK/E;1ND<5K>Y"Q07:&I25!%GXMJHY;#H:42>0 M3X:N7,&F4/6A-JJ$;^&F.L2ZCE1KT*1M_-$=.\TETJ9BT%)-$6SUXG.Z_-#N#CN;J6$*6=DWO3/ NE@'EIUNT6"+63U6U0QL M\E)9R%,38C]Z!@%9GGW'[;-V#K<*LDUA[%T-C*5FYW?14XYNK%Z#JTUB&ZI- M0V% %&1CG9WMA)M"EK;I7!U9WV+]8H@US9^2M3.&ZZB*4DR!1;_D-G^I3E- M58D67OMAL*A;M&,@ LRQ7>:%F P,92#C^IC"F;;_G NS:+U0K#$FI=2H66K4 M!>IL_9U,9_\$%"O-FW15[6U9TWEK4W&&@/5&W\LN?5FWR635%@@Z$P(ND_ O MKO$)IV@SUB[!!!*'EL)0)C.NCRG :1OFN4LJB;$%'CT*Z-S5THV.:I"K'#7<:*6'A9$Q-P2-G.XCL'A]->52^18=Q"%0080H&^FU.M;N"O"@H M?&QGOQD5'UG]MI3ZLE3\)4T+@JM62YRW A'2ED(/?H[G]^X(LND7(IS)20<_ ML/N%3H=4M-1'L9Y^%+7 D[Q$3 @A"%?Q9^.#MOJ0^-GC$ 3\N*/LP3 M?0OVS/6GA/$>G$";6E8T,/HZQ4 -=$,1[0/5WL20*1V3OL-@$+[;<^F+F1^Q MR9A4/FX/C>/!Q.?S+MP2_2YW*]NZ,=G^F7[!?,\?XS*Q'G?A3^ +N6IEX8AG M,VAI0/P66FIQ?G6&@=-T='$A_NPL_71/"[,+'0 M%W"3H&+*N&)V-UHTA /_&WU Z;SF@)PMT3H^^@AI4\OFE M/QW&*%G1?2 (ER.*EU:.=;>,#&$2'T#$512FM_M6E,Z#O,1<.]Z%&H'U&6!;<@Q9_^#NXT;U;VHNVI11G+SW!H9^*+_XG.&+JGRL,RQGQ/-/#/$]%;RE"K7[ M."YEDOV9H,2]X[\0H3+( TS$ODGJ#OS+N$-%<54+W#@8\2X(_^/&\]7#%QR8 MF+T#OL]\BUNUZ-*'6020W+!'BGE&C"D>$F2,=C%?[X<*5/7S[BP4U# >$GV5 MCFY"[U,4A$+/4Y^:N+WJ#JVZQR559/(_]N1?XJC%IZ.(2YLN+FX=O<",> MWW$*EWU=W#VL)H"M..Q?QDL^5 "5Q+7ZL'-, 9$]^/RY^C/ED"H\;**Z4\896H.=L@= M$2:BN46/0\H?LZ1$7KC($+.]FZ#DHA_L$+C,PYO_RH()]B# S.X4=R1;O2*J M#-R_A 6YA\&9/U(-O8Q9!0/VT1S0D'CX,O*M3]9,T9_<1S.2.Z+,FK!^XOE3 M[RU,MN]&E^K"NR&.:LY%#7CFQ-V*KR%J>S?Z3TA$@!=)?'PQ9=^2Q^X*HRK5 M[RT :QPUH&@01&&5AJ[=QER::R/C95DH?X<4[X#-6H/ M)B? %BJWKN-0CXCXB8MZI2UZ4>TSV!BD/&& D7DW;7WQ@EE!M ,"/HL"XR3< M#N]#3#[XW&X*TYG,5;T1Q?-?[E]]CE_QOA/W+HO9LNH>92I[I,VY8[XH#LZ<8DY7:E1CZ7?4M[XBKB?C*7N"+E-MX30O;X MKQ/F3.(YN;P38Z*>%RS,JT&XTP=P&YFK@B&O0MHG'D2)/&;-T@UXEJHJ%XEJ MQAT_CHDGFID;:>&(_4N)]Y=7J_JG#SS_?5Z]PJOV(DAO1= 5 M^64XWK>7^Q MW4MR>$F['S8/Z\/[QA3W-7@!>?WSYC45RV-;1P>N6$G MG/>N,J]O9?GV_MOZL8*$G\>?R7> MG3:@LWA>&:S3=E+_+,ALT/U4D6TY! = MCM5;;IE;XIYMN1^N'W-V--_07WE%8;FPG MW1)7F9/S,_BVREZQM1U:B?E/YL7\G5%-N+& ^\_@QXK9K@*#P_&&^0TP2[RW M X$'[^V*P"NC/AP_F-^LL,1U.Q!X\-ZNB+HRZL/Q@YFMPDK<94C(S^=5[:9^ MAIRIYWWH/JR^JU@M-V[ _M ]63'5E1 ?A!?*ONJ=_"ARQ@8\GLPGT1Y)TIG0 M*8%__P]02P,$% @ G$!$2(_6+_'<# N<$ !4 !M;&%B+3(P,34Q M,C,Q7V-A;"YX;6SM75MSV[H1?N],_X.J/C.R[).DR<0Y(]]2S]B1QW9Z3I\Z M$ E::$A !R!].;^^"Y*R9)L@00HB0-T@#S M(Q;CP>\'EV<#;["S^WG\\>)\\./Z<+"[,_[@[>QZ.V//^_HE(O3G9_ECA@0> MP)!49/_N#^=)LO@\&MW=W;V[G_'H'>,WH]V=G;W1DGI8D,MO@^2QP3KQ^U'^ MY2/IBZ[O]C+:\:=/GT;9MX^D@I010J?CT>_G9U?^',?((U0DB/J2%T$^B^S# M,^:C)!-:+82!DD+^YRW)//F1-][U]L;O[D4P_/K7OPP&N>@XB_ E#@?R]X_+ MTR=CQEB@",W$.Y_%T.OX_7AW;SR2E"/@.L$QIHE'60+]>\C_(R6"2+Z%AVC@ M!40LV/*#1LL!)<=_W]9X MR<,"[P\%B1<1'H[6Y.*CR$^CK,T9_%^02^RV192SC.\3#+NDF,LEU]"F1I#R MD_\$9J,< @\DD)L0_KGFB(H0 MEEQ!MSC*!]Q&]SGH3"2,%Q.U/=#_9%$P0_Y/4RB5_6T'UB7VV0TE?^+@- #) MDA"&C?!$")R(B5R$P-*$!DMN"!;P71K#A[[/4[S^A2;P+8S81#3KFCM$8I:I MP51X-P@MLETYPE$BEI]D0I3FHQ!C\7&3"1T_D\LF73@!M/4$'B(QAR^.@>06 M1=#T^9+I=M">"S.%E4&3G!)ZP0 /6G8BTIJA7X5@U[_P?9;"PKE #[*/[B1< MS\-K$_41SC7>);[%-+4C:@4/_1;U*86SPPUY))XF<\ROYXA^8RRX(U'4@:BU M>>B[J&'= .///<%.QNJWZ"XX6V">/%Q$".Q+;K47\ES4@2AKQ^Z-:)?;J13F M=VQ8F+JC=2^^&M5F7^N ,9<+3%RS0IC+*<#B&V="YUA8] M<*:%?.PP\NT&2G0EM/N*)%039-$5B:7M8E0K,YMG1,=W9Q\$W="I=GRW;TOB MFPEC[W4)HX,#B*YD?WF3[(;G$5U)OU])VGL3]4;A-EV1?W@E(N\\DZ,KX(]O MVJ-MVD-7Q/]X)6O8@=#Q2N1?1F5U R8K+7Q& 8O @?Q+L(@$LF+&FT%+ZF-/ MS#& \_P<@ =VAK# 2RE* YBE0+_"PLPXG516F&15KZ+"3)#HF2DJ%ITB-%1- MW'V$:\G/Z@0(^U(/0E43*T"DR3JEL,3P-;K'HA9%-;TU"&OJ2@N"FMX*A#26 M"@$'V3D7M/B"XSEL:W*++,#-;) *Q9,O;3%7LX3* M:)S(HS2L53/04R]@5T_GYAUV+X3"$9:_UISA27*(.'\ SO^%(F6=0:.V%J"Q M."9)E@R17"YGPG]9B]>@A1T8C%XES/]9.1D*LNX9?N;E5^^9:F)[S(-AR[7S MFGVO]70-21M(]H^JB\@H*JVR"- Z,X.$:<@ND1:Q$/\'6(3U1P]!MV M#TI;P;93J?9*?,I7/VL3$G6IH*865HOCM4OE*[7XVIR67"I)J06H]A9=JO^H MA='8)KE4'_@L#&RLYJD[#5$^);IFU3V-4+Y3FAX,W5,$I9:I'YNDXKSRU,SJ MY.QU4$7]80 M-8TSN;2I]!!6IZM=VE5Z>#8JFG)I@6JG7YY-IE;=A$OKM W0C4OR.S8#VL#J M8L)=%F=GSWC;\T@1/0,87@:;/W@L?/)QNR?>M>FZNX?;M>>NRZKKQ]#F":%$ MS//+!JIL=#7Q6Z*_GM%+='<.JX03%-4*N8S6(NO2NA?W2 3FM\J2A?H&%D'\ MQOC/4WK!F8^5CYVH)MXHM;:]JT6EZ[PLA5$S*RX9=FU,%>K()7NNC:=BX;ET MFM/&H]9DG;LCOW@1HS? 2PRV=Y9X89JD',NK4@E'?I*BR /<*<^\+FFM,ZIV M_HF1L;IS6 RRVZ4'LQ[<46CT,A*[E5#GCX*\Q(OB03_3\((3.&LM4#0)81K^ [email protected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email protected]&%]C>I?&^'J)*#X6 MTV=Z,'LF6;9[QO[P+OH22S=>5_W+ _VC8<;.Y@

;.]C

8. M-G>PN5^3S=VIP@ENL&UZQHU.9=@%[T%V06LUVS>!\6.4XV+_@!X_D",F!K$9 M>V'4EC?JPD*:P%L$WN(4T3S-%XSOT?M]+(TG>7*29F5A':?7J+5@4P:;,MB4 MP:8,-F6P*8--^:ILRN;J@F^#X>?J&I#BI5B?=_CQ[>T&!H-16]X,!@MI@L$0 M#(9)')>K,N-3*)D52TRGAY-G^R+6!6',TG!HU6HP(((!$0R(8$ $ R(8$,& M>$T&A .UP;;3Y@L*%HOTQAE$XJ1K875U0=[=9/<+KHKO"94 M)- ]2%]TO-FO2'/?R":M!=LSV)[!]@RV9[ ]@^T9;,_79'NV4!? #:4>MQO+ M9]!.CMUJT+YYB"-^9+"8II6':D3FT>TN+6CUU $K5RM$-^+WNA<.$UR@-&.1 MV#]+]+#]&7(878OAC?_P \2,.WG9Z^(W?WXIQ4*8S2^7&R;FY,7.5YN=YW_P M2;H\Y9(4FW,VHPN4"\?M9_ICNT;\*\-[46=H_!] [6;+!F@S4;K-D&D Q5!'!VCAJ="\7.M_VB>Y^MG5G2L'5OUD8K M^5H9$<9X1>H)%ZM,TWU$%4U)9.%QVP1"D2;5RR'/UKYO& M;706#> I6=WN/BOYZ"7:B!$ZS_E@95F=I>&N0:_ KK,T$7L=WQ7P;/Z)DF_% MLATR58L.H$F^^B^,Z-'G)]ODH?CFM;H5\7TC$=\[%_$\GZ<%15\/5J-<,FUA M_^9#S6ZR>^<'*RU0XWHC@M2_<5TGHMQ2U93N3WS]WC>A%/'?5MOYE?B)JY-E M(7S5V.\H*_$_T\7SW;7;CPRYLR[(M\[[ZN ;D+MJ_W#9IG6'O&C)/VR)9,>; M&RZ*8E\PK@<&DA!,N7<;UQL1I/Z/H\_H/EV5JUJ%1UFF!U&Y::D5M:Z,?U%W M%@V[(3OU8[\I8?8%%]R<0VRY?XM1@J1)$_Z!5N>(8I]Z\?>>1%1.FIH2P,7L M?]_8$[UGA.(8L4(IN;KP@._J1@ !P%0*UXWANM';=:.110W.8\^CH";#IA]K'5D!SL-!M_/(R0QP4)Q.W]J+,T/('\#M3/"\ MQ@R\4[1F9(TGEBJV\XAS\E=]Q0S(NS]!XGTR6B M"RQ^1=%"")@2/3C3%CH3O?K*;'Y6BLE9O>C\)&7"Z?'YS^>RYF.?[,]\SEQ?GQ[$J^>MJW-F@'=ZE O%V4B2>_+PA2"J,H MZ$ 0<49RU9^K_&EQAN+J?-\:1VF\._OV\6+_72+*=\)LLSS\KB@Y.\/YG MNZ$.>R0!95N];X!31.F&JT:3E4@=9 2JODK?0,11:R3^84'_0E_@HA!ZR7;R M*]UY545[$+Q&Y]I=\A\32LDW/B.F:,W_(@T9:M($#*#/E,M+FN9QNGZD"@R MZIJ ?2WO!0O#^\&05CF:2'$/<.8 XCY3]S M4!MU5Z_7:!>B]*"/0A-\H3D MYSG?'&Y1_G4VGV,NESA5Y%9RH[HA3$HEZH#"I"B),4ZJ5)/GC)4HC_ED%@DF MQ5DH3D>)_.85^P4E5B?;+T\#++7E0U17B.KR)2Y>[]@HHV6H*]X'@#N2W0EU M[:DRIQP!DSH#CO : 83^5T8(4AM%D%I'PI:W#/^[Y(*W>4(N"@0 MY;4(,6=V0 9_*$9#.F: @C[P\%P&NA0!+<:0*\72JH"/Y)7E2FE,6\/'ULRJ@(_+Q>[I M]I (V6RZ3=:@"Y< =Y%B!NNB$ND9*E M[[4A3&B980S=L@W1041TY#2*B3/4( MC[R!?D+486^6H\$4/C0]RJ ')%& IHBAJ%AN\\J8HH>B;[7.#O0(N)_L7O79 ML-:(\AI+7(CGNQ\ -TSY9?.)WO* V0O9*CF8C_0Q(85&2*'1JY[ '"!BV$./D0V6<)H?]-(43VC2*R M+X2KA'"5$*X2P@[email protected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email protected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email protected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end



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings